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Somatostatin and ghrelin: background 
 
Somatostatin (SST) and ghrelin are two peptides that exhibit a clear difference from 
structural, evolutive and functional points of view. However, these peptides also display a 
number of relevant similarities and overlaps. Thus, both peptides are processed from 
prepro-hormones that generate several biologically active peptides (for review, see 
(Tostivint et al., 2006; Garg, 2007)), which exert their physiological functions through 
binding to G-protein coupled receptor (GPCRs) (Kojima et al., 1999; Moller et al., 2003). In 
addition, although both peptides were primarily hypothesized by their hypophysotropic 
action at the hypothalamus, they are in fact mainly produced in the gastrointestinal tract 
(GIT), and have been shown to be tightly linked to a regulatory interplay between 
endocrine and metabolic processes (Patel, 1999; Cordido et al., 2009). Interestingly, 
although both peptides were isolated while searching a positive regulator of pituitary 
somatotropes (Brazeau et al., 1973; Kojima et al., 1999), their actual roles in the regulation 
of growth hormone (GH) secretion are opposite. Specifically, SST is the most potent and 
the only evolutively conserved inhibitor of GH release in the vertebrate lineage, whereas 
ghrelin is, together with GH-releasing hormone (GHRH), the most important stimulus for 
GH secretion in mammals (for review, see (Gahete et al., 2009)). 
Another similarity between SST and ghrelin systems is that despite being thoroughly 
studied, some of their actions are still uncertain or controversial and, as will be discussed 
later, cannot be explained by the interaction with their known receptors. Accordingly, 
there are still a number of questions that remains to be solved in order to fully understand 
the (patho)physiological functions that have been associated to SST and/or ghrelin 
systems. 
There are three potential, non-excluding causes which could help to explain, at least 
in part, the uncertain or controversial issues related to the functional features of SST and 
ghrelin systems: 1) the wide, growing diversity of SST- and ghrelin-related peptides and 
their receptors with new components being frequently added to each system; 2) the lack 
of complete, integrative studies focusing in the multiple components of these systems at 
different levels (central and peripheral), or 3) the molecular and functional interactions 
between the SST- and ghrelin-family members, which are still poorly studied and can 
increase not only the complexity but also the versatility of these systems, likely including 
novel undiscovered functions.  
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Somatostatin, cortistatin, and ghrelin peptidic family 
SST and ghrelin are the leading members of two families of peptides, each 
comprising several components, which are generated through different mechanism, from 
the existence of orthologous genes, to alternative transcriptional splicing and/or post-
translational processing and modifications. Specifically, SST is a 14-aminoacid 
hypothalamic peptide (SST-14) containing a disulfide bridge that allows its cyclic 
structure, which was originally discovered in 1973 by its ability to inhibit GH secretion 
(Brazeau et al., 1973). However, rather than generating SST-14 alone, human SST 
precursor (prepro-SST) can also generate an amino-terminally extended isoform of 28 
residues, named SST-28, which shares similar but not identical functions or tissular 
distribution with SST-14 (Pierotti and Harmar, 1985). Moreover, recent data suggest that 
processing of the N-terminal part of prepro-SST gives also rise to neuronostatin, a totally 
new peptide distinct from SST (Samson et al., 2008). Furthermore, SST shares its evolutive 
history with a closely related gene, cortistatin (CST), which encodes a peptide originally 
discovered in 1996 in rats as a 14-aminoacid cortical peptide (CST-14) (de Lecea et al., 
1996) and subsequently found in humans, as a 17-residue peptide that shares 11 of 14 
amino acids of SST-14 including the disulfide bridge and the FWK motif, which are crucial 
to exert their biological effects (Fukusumi et al., 1997) (Fig. 1). Both peptides, SST and CST, 
are encoded by orthologous genes derived from a hypothetical common SST/CST ancestor 
gene (Tostivint et al., 2004). Similar to SST, CST precursor (prepro-CST) can originate also 
several peptides (CST-14 and CST-28 in rodents and CST-17 and CST-29 in humans) which 
are analogous to somatostatin peptides (SST14 and SST28, respectively).         
Ancestral SST/CST gene5´UTR 3´UTR
SST gene5´UTR 3´UTR CST gene5´UTR 3´UTR
prepro-SST prepro-hormonesSP
pro-SST pro-hormones
prepro-CSTSP
pro-CST
gene duplication
transcription/translation
Gly Cys LysAsnPhe Phe
Trp
Lys
ThrPheThrCys Ser
SST14
S
S
Gly CysLysAsnPhePhe
Trp
Lys
ThrPheThrCysSerSST28
S
AlaLysArgGluArgProAlaMetAlaProAsnSerAsnAlaSer
S
Pro Cys LysAsnPhe Phe
Trp
Lys
ThrPheCys Ser
CST17
S
Lys Ser
MetArgAsp
S
Pro CysLysAsnPhePhe
Trp
Lys
ThrPheSerCysSerCST29
S
MetArgAspGluLysLysAlaSerGlnGlnProProAlaGlyGluGln
Lys
S
Figure 1. Schematic representation of SST/CST gene evolution and processing. 
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The relationship between SST and CST has remained unclear during years because the 
precursors of SST and CST peptides exhibit low similarities (nucleotide and amino-acid 
level), except for the C-terminal regions, which are highly conserved and codify the mature 
peptides (Tostivint et al., 2004). 
Ghrelin identification represented a bright example of reverse pharmacology, where 
the use of an orphan receptor enabled the discovery of an endogenous ligands (Kojima et 
al., 1999). In fact, the endogenous ghrelin-receptor (GHS-R) was initially discovered by its 
ability to bind to artificial compounds with GH-releasing activity (the so-called GH 
secretagogues or GHSs) such as GHRP‐6 or hexarelin (Howard et al., 1996). Then, almost 
25 years after the synthesis of the first GHS, the endogenous ligand for the orphan 
receptor was found. Specifically, ghrelin is a 28 amino acid peptide that was originally 
identified by Kangawa’s group from a gastric extract (Kojima et al., 1999). The mature 
peptide is cleaved from its precursor, prepro-ghrelin, by prohormone convertases (PC1/3) 
and is characterized by a very specific and unique structural modification, as the hydroxyl 
group of serine in position 3 is covalently acylated by an n‐octanoic acid residue, which is 
crucial for the biologic activity of the peptide, including GH release and orexigenic effects 
(for review, see (Zhu et al., 2006)). Of note, no other naturally occurring peptide has been 
previously shown to have this acyl-group as a posttranslational modification. The enzyme 
responsible for the acylation of ghrelin has been recently identified as the fourth member 
of the membrane-bound O-acyltransferases superfamily (MBOAT4) and was named 
accordingly as ghrelin O-acyltransferase (GOAT) (Gutierrez et al., 2008; Yang et al., 2008). 
Although acylated-ghrelin is the major active product of the ghrelin gene, it is now well-
established that its prepro-hormone can generate various bioactive molecules besides 
acylated-ghrelin, which are generated by several mechanism, including alternative 
splicing, extensive post-translational modifications or intron retaining processes (i.e. 
exon3-deleted-ghrelin, des-Gln14-ghrelin, non-acylated ghrelin, and mouse In2-ghrelin 
variant, respectively), and whose precise roles have not been fully elucidated (for review, 
see (Seim et al., 2009)). Interestingly, non-acylated ghrelin (UAG) is present in serum in far 
greater concentrations than acylated-ghrelin, yet it is unable to exert any recognizable 
endocrine activity (Broglio et al., 2004).  In addition, it has been recently demonstrated 
that ghrelin precursor can be processed to yield a completely different, 25-aa mature 
peptide, named obestatin, which was originally postulated as a natural antagonist of 
ghrelin (Zhang et al., 2005), yet this idea could not be confirmed by other groups and is 
currently under debate (Qader et al., 2008). 
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Figure 2. Schematic representation of alternative human ghrelin gene transcription. 
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SST/CST, and ghrelin receptors 
The complexity and versatility of the SST/CST and ghrelin systems are also 
influenced by their receptors. To date, five different intronless genes which encode for 5 
SST/CST receptors (sst1-5), as well as a carboxy-terminal spliced variant of the sst2, 
named sst2B, have been identified and are currently classified as Class A GPCRs (Moller et 
al., 2003). Like SST and CST, ssts are widely expressed throughout the body (Patel, 1999). 
All ssts show a comparable subnanomolar binding affinity to SST and CST, and display the 
typical molecular architecture shared by GPCRs comprising seven putative 
transmembrane domains (7TMD), the conserved DRY motif at the cytoplasmic face of 
TMD3 and N-linked glycosilation sites in the N-terminal domain (Moller et al., 2003). 
According to their sequence identity and pharmacological properties, ssts can be 
subdivided into two groups, namely SST1, which comprises sst2, sst3 and sst5, and SST2, 
which includes sst1 and sst4. In spite of their branched evolutive process, sequences of 
ssts are highly conserved among species as well as among the sst-subtypes, being more 
divergent in their N- and C-terminal domains (Moaeen-ud-Din and Yang, 2009). 
Interestingly, the most conserved sst-subtype across species seems to be the sst1, whereas 
the most divergent one is the sst5, this suggesting the existence of a unique evolutionary 
relevance for sst5, which is supported by its involvement in certain atypical processes, 
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such as the ability of sst5 to mediate stimulatory actions of SST and CST on GH secretion in 
various species (primate, pig and/or rodent) (Baranowska et al., 2006; Luque et al., 2006; 
Luque et al., 2008). 
The complexity and versatility of the sst family is further enhanced by the fact that 
several of these receptors are often present simultaneously in the same cells, where they 
are able to functionally interact with each other or with other GPCR family members 
forming homo- and/or hetero-dimers complexes that can couple to different signaling 
cascades to mediate multiple actions (Duran-Prado et al., 2008). In addition, our 
laboratory has recently identified and characterized new functional truncated variants of 
the sst5, with less than 7TMD, in various mammalian species (human, mouse, rat and pig) 
(Duran-Prado et al., 2009; Cordoba-Chacon et al., 2010; Durán-Prado et al., In 
preparation). These truncated sst5 variants have unique ligand-selective signaling 
properties, distinct distribution in normal tissues and pituitary tumors and different 
cellular localization to that of the originally identified, long sst5 isoform. Study of these 
novel variants could contribute to further our understanding of the already complex and 
highly versatile functional system comprised by SST, CST, and their receptor-subtypes.  
 
 
Figure 3. Schematic representation of SST/CST and ghrelin receptors signaling. 
AC: Adenilate ciclase; AMPc: Cyclic adenosine monophosphate; ATP: Adenosine triphosphate; G: G-protein; IP3: inositol
triphosphate; PIP2: phosphatidylinositol bisphosphate; PKA: Protein kinase A; PKC: Protein kinase C; PKcaM: Ca
2+/
calmodulin dependent protein kinase; PLA: Phospholipase A; PLC: Phospholipase C; PTP: Protein tyrosine phosphatase.  
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On the other hand, to date, only one gene encoding for ghrelin receptors (GHS-R) has 
been identified. Specifically, transcription of this gene can lead to the generation of a full-
length GPCR with 7TMD (GHS-R1a) (Howard et al., 1996) that is widely expressed 
throughout the organism of several species, or alternatively, to a truncated version with 
5TMD (GHS-R1b), which hitherto has only been found to date in human and bovine 
species (Colinet et al., 2009). Interestingly, GHS-R1a has been reported to specifically bind 
acylated-ghrelin but not des-acyl-ghrelin, while the endogenous ligand of GHS-R1b is still 
undiscovered and its precise role is as yet unclear. It is also worth noting that ghrelin 
receptors share a high evolutive identity with neurotensin receptors (NTSR1-3) (McKee et 
al., 1997) and, together with neuromedin U receptors (NMUR1-2), comprise a unique 
phylogenetic family, the so-called ghrelin receptor family (Holst et al., 2004). Interestingly, 
some members of this family (GHS-R1b and NTSR1) are able to physically and functionally 
interact  as it has recently been shown in cancer cells, thereby further increasing the 
complexity and versatility of the ghrelin system (Takahashi et al., 2006). 
 
Actions of SST, CST and ghrelin systems 
Over the last years, a number of detailed and extensive studies on the physiologic 
regulatory systems integrated by SST, CST and their receptors, sst1-sst5, and by ghrelin 
and its receptors, GHS-R1a/1b, has revealed the existence of common and strikingly 
parallel phenomena in their functionality. Thus, contrary to the earlier “one hormone-one 
receptor-one function” simplistic and unidirectional notion, it is now well established that 
each of these systems is in fact composed of multiple peptides and various receptors 
which can act in concert to exert a number of actions. Indeed, SST and CST, as well as 
ghrelin, have been found to oppositely regulate the physiology of various 
adenohypophysial cell types by acting directly at the pituitary level or indirectly at the 
central (hypothalamic) level. Specifically, besides the well-known effect of SST, CST, 
ghrelin or their synthetic analogs in regulating oppositely GH release from pituitary 
somatotropes, both systems also act on prolactin (PRL)- or ACTH-producing cells to 
influence their secretory capacity (inhibition by SST/CST and stimulation by ghrelin) 
(Enjalbert et al., 1982; Shimon et al., 1997; Rubinfeld et al., 2004; Schmid et al., 2005; 
Rubinfeld et al., 2006). 
In addition to the well-known functions of SST, CST, ghrelin and their receptors at the 
pituitary-hypothalamus interface, both systems have been reported to influence common 
endocrine and non-endocrine relevant processes at multiple levels, from central nervous 
system (CNS) to peripheral tissues in normal and pathological conditions. As an example, 
both systems play important regulatory actions (and interactions) on beta cell function 
1.- INTRODUCTION 
 
 
7 
 
and survival, as well as in glucose homeostasis (Efendic et al., 1974; Gerich et al., 1975; 
Brown et al., 1976; Gauna and van der Lely, 2005; Grottoli et al., 2006; Dezaki et al., 2008; 
Qader et al., 2008; Volante et al., 2009), although the molecular mechanisms underlying 
those effects are not fully elucidated. In a reciprocal loop, changes in the metabolic 
environment as those seen in severe metabolic dysregulation (i.e., obesity, fasting) tightly 
regulate multiple components of both systems at various levels (e.g. hypothalamus, 
pituitary, pancreas, etc). In addition to these metabolic actions, SST/CST and ghrelin have 
also been involved in the regulation of cortical functions. Indeed, both peptides, SST and 
CST, are widely expressed at CNS, where they act as neurotransmitters and 
neuromodulators (Viollet et al., 2008). However, at this level, SST and CST seem to exert 
different, and even opposite, actions. Specifically, CST causes hypo-motility, depresses 
cortical excitability and increases slow wave sleep without affecting REM sleep, whereas 
SST causes hyper-motility and enhances cortical excitability and REM sleep (de Lecea et 
al., 1996). In contrast, SST and CST, together with ghrelin, which has also been found to 
acts as a neuromodulator (Martin et al., 2005; Miao et al., 2007; Xu et al., 2009), seem to 
possess similar roles in cognitive processes, where they act as positive stimulus in 
memory and learning processes (Epelbaum et al., 2009; Toth et al., 2009a; Toth et al., 
2009b). 
CST and ghrelin (and to a lesser extent SST) have also been reported to exert potent 
anti-inflammatory actions in therapeutically relevant models of arthritis or inflammatory 
bowel disease (Gonzalez-Rey et al., 2006; Gonzalez-Rey et al., 2007; Bulgarelli et al., 2009) 
and can also influence atherogenesis (Liu et al., ; Kellokoski et al., 2009). In this context, it 
is noteworthy that both neuropeptide-receptor systems are highly expressed in a number 
of different tumors, where they can exert relevant and unique pathophysiological actions 
(Waseem et al., 2008; Watt et al., 2008; Nikolopoulos et al., 2009; Volante et al., 2009). For 
example, SST and its long-acting synthetic analogs (octreotide, lanreotide) can inhibit 
abnormal hormone or peptide secretion in different types of tumors of endocrine and non-
endocrine nature (i.e. pituitary, gastro-entero-pancreatic, etc) (Hofland et al., 2005; 
Grottoli et al., 2006; Giordano et al., 2007a) wherein they can also counteract cell growth 
and/or promote apoptosis via the sst expressed in tumoral cells (Reubi et al., 1990; 
Cameron Smith et al., 2003; Watt et al., 2008). In fact, these properties of SST analogs have 
served as the basis for their use in the treatment of a number of pituitary and 
neuroendocrine tumor pathologies (Vallette and Serri, 2008; Oberg, 2009). On the other 
hand, the pathophysiological role and therapeutic potential of the presence of ghrelin and 
its receptors in tumors is less understand, as is the case, for example, for ghrelin presence 
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in corticotropinomas causing Cushing’s disease where it can stimulate hormone secretion 
via GHS-R (Martinez-Fuentes et al., 2006).  
Nevertheless, expression of these neuropeptide systems is not restricted to 
neuroendocrine tumors, but also extends to different types of cancers. Indeed, it has long 
been known that SST and sst1-5, and more recently CST, ghrelin and GHS-Rs are 
functionally present in different cancers, such as breast, lung, ovary, prostate, or colon 
(Reubi et al., 1990; Cassoni et al., 2001; Cameron Smith et al., 2003; Jeffery et al., 2005; 
Watt et al., 2008). However, their function and potential clinical application in these 
contexts is still to be elucidated. 
 
Cross-regulation and interaction of SST/CST and ghrelin systems 
The remarkable overlap in the functional targets of SST/CST and ghrelin systems is 
accompanied by a tight and intrincated functional cross-regulation across the mammalian 
lineage. For example, it has been found that SST infusion reduce plasma ghrelin levels in 
rats (Shimada et al., 2003), and humans (Norrelund et al., 2002). On the other hand, 
ghrelin seems to exert a divergent action on SST release at systemic and local levels since 
ghrelin infusion seems to elevate plasma SST levels in humans (Arosio et al., 2003) while it 
reduces SST secretion in pancreas explants (Egido et al., 2002). The close relationship 
between SST/CST and ghrelin system is also patent at the molecular level. In fact, albeit 
SST and CST peptides exhibit similar subnanomolar binding affinities to all the ssts, their 
biological actions are not absolutely overlapping, indicating that other receptors should 
mediate SST and CST divergent actions. In this scenario, CST but not SST has been found to 
activate the human proadenomedulin receptor MgrX2 (Robas et al., 2003). Moreover, CST 
but not SST has also been found to specifically activate the human GHS-R1a (Deghenghi et 
al., 2001) which suggests that CST could represent a natural link between ghrelin and 
SST/CST systems. Furthermore, our group has recently identified new functional 
truncated variants of sst5, with less than 7TMD, in humans (Duran-Prado et al., 2009), pigs 
(Durán-Prado et al., In preparation), mice and rats (Cordoba-Chacon et al., 2010) which 
exhibit different signaling capacities in response to SST or CST. Finally, an additional line 
of evidences supporting the profound relation between SST/CST and ghrelin systems, 
which also increases the complexity of these systems comes from the recent 
demonstration that sst5 can physically interact with GHS-R1a forming heterodimers, 
which could modify the signaling elicited by ghrelin and/or SST. However, the functional 
consequences of this interaction are still unknown.  
 
1.- INTRODUCTION 
 
 
9 
 
In sum, there is emerging evidences to support the notion that, rather than being 
isolated neuropeptide-receptor systems with distinct, separate functions, SST, CST, ghrelin 
and their related peptides and receptors comprise a network of physiologically 
interrelated components able to functionally interact at the molecular, cellular and 
organismal level to regulate multiple functions in health and disease. In this scenario, the 
next challenge will be to identify, characterize and place in a physiological context and in a 
position of potential therapeutic application the elements comprising the SS/CST/ghrelin-
receptor supra-system, their interactions and new components. 
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The general aim of this study was to further our knowledge of the role of the 
SST/CST and ghrelin systems in (patho)physiological conditions that extend outside the 
most classical neuroendocrine hypothalamus-pituitary actions, and incorporate new 
functions and interactions at the interface of cancer, and metabolic and neurodegenerative 
disorders. 
 
This general aim was developed into the following specific objectives: 
 
Objective 1. To investigate the reciprocal crosstalk between SST and ghrelin systems in 
conditions of metabolic stress in the mouse. Specifically, to explore regulation of 
SST/ghrelin expression by fasting at the hypothalamus-pituitary-stomach axis, and 
to explore the role of endogenous SST in the control of ghrelin plasma levels, as well 
as ghrelin expression in this axis, using SST knock-out mice. Additionally, we will 
analyze the possible involvement of the ghrelin-acylation enzyme (GOAT) in 
controlling acyl/desacyl-ghrelin levels under metabolic insults (fasting and diet-
induced obese mice models). 
 
Objective 2. To explore the putative relevance of SST/CST and ghrelin systems, especially 
their two novel members, sst5TMD4 and In2-ghrelin variant, in breast cancer. To 
this end, levels of expression of the individual components of the two systems will 
be measured in human breast cancer samples, and their putative functional 
relevance was addressed by using human breast cancer cell lines. 
 
Objective 3. To study the potential roles of the SST/CST and ghrelin systems in Alzheimer 
disease (AD). To this end, the absolute mRNA levels of individual components of the 
SST/CST and ghrelin systems were evaluated in three regions of the temporal lobe 
of AD patients and matched controls. 
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3.1.- Regulation of SST, ghrelin and GOAT in metabolic conditions (Articles I & II) 
It is now well-established that SST and ghrelin exert key regulatory roles in the 
hypothamalus (HPT)-Pituitary (Pit)-stomach axis in normal conditions and under extreme 
metabolic challenges (fasting and obesity), by acting via endocrine, paracrine or autocrine 
mechanism (Mounier et al., 1989; Ferraro et al., 1996; Horvath et al., 2001; Dimaraki and 
Jaffe, 2006). In order to determine whether a reciprocal regulatory loop also exists 
wherein catabolic (fasting) or obese states influence the production of HPT, Pit or stomach 
SST and/or ghrelin, we used mice model. These animals are widely employed to study the 
consequences that a patho-physiologic state can cause on specific tissues and cell 
functions because of their easy experimental manipulation (Hochgeschwender and 
Brennan, 1995; Luque and Kineman, 2006; Luque et al., 2007; Luque et al., 2009). 
Likewise, mice are ideally suited to study the pathophysiological importance of gene 
products because of the feasibility to generate genetically modified mice over- or under-
expressing the product of interest (i.e., knockout models) (Hochgeschwender and 
Brennan, 1995; Luque and Kineman, 2007; Luque et al., 2009). Accordingly, we used male 
mice under extreme metabolic conditions (fasting and obesity) to measure the expression 
levels of SST and/or ghrelin and compared with matched-controls. In addition, we also 
determined the potential role that endogenous SST plays in the regulation of ghrelin gene 
synthesis at the HPT, Pit and stomach levels, as well as in the secretion of circulating 
acylated- and total-ghrelin levels in male mice, with or without endogenous SST [SST-
intact controls and SST-knockout(KO)], and under normal or catabolic conditions (48h-
fasting). 
Our results indicated that SST was highly expressed in mouse HPT and stomach and, 
although fasting tends to decrease HPT and stomach SST mRNA levels, these differences 
did not reach statistical significance. Similarly, HPT and stomach ghrelin mRNA levels 
were not significantly altered in fasted mice compared to fed-control mice; conversely, Pit 
ghrelin expression was increased in fasting. On the other hand, ghrelin mRNA levels in Pit 
and stomach, but not in HPT, were decreased in obese mice. Furthermore, although 
circulating levels of total (acylated + desacylated) ghrelin were not altered in fasted mice 
compared with fed mice, plasma levels of active (acylated) ghrelin were drastically 
increased in fasted mice. Diet-induced obese mice tended (50% reduction, p=0.13) to 
suppress total-ghrelin levels in mice without altering acylated-ghrelin levels, which was 
consistent with a significant decline in stomach ghrelin expression (considered the major 
source of circulating ghrelin). 
The remarkable difference in the regulation of total and acylated ghrelin in plasma 
during fasting and obesity, together with the discovery of the GOAT enzyme as the acyl-
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transferase responsible for ghrelin acylation (Gutierrez et al., 2008; Yang et al., 2008), led 
us to investigate whether the expression of the GOAT enzyme could be one of the 
underlying mechanisms responsible for the divergent regulation of circulating total and 
acylated ghrelin observed in extreme metabolic conditions. Our results indicated, for the 
first time, that GOAT is expressed at high levels in stomach and its regulation correlates 
with circulating acylated-ghrelin levels in fasted and obese mice (up-regulation and down-
regulation, respectively). Interestingly, we found that GOAT was also present and 
regulated in HPT and Pit in response to metabolic extremes, since a significant increase in 
HPT and Pit GOAT mRNA levels under fasting conditions but a decline in Pit, but not HPT, 
in the obese state were observed. Nonetheless, our data clearly demonstrated that GOAT 
mRNA levels paralleled the expression levels of ghrelin in the mouse tissues analyzed 
(Stomach  pituitary = hypothalamus). This, coupled to the previous data showing that 
the precursor peptide processing enzymes PC1/3 are expressed in stomach, Pit and HPT 
(Macro et al., 1996; Dong and Day, 2002; Nillni, 2007), strongly support that in addition to 
the plasma acylated-ghrelin produced by the stomach, locally production of ghrelin could 
be an alternative source of acylated-ghrelin within the Pit and HPT. Intriguingly, our 
results suggest that the substrate of GOAT activity in the mouse Pit may not be limited to 
the native-ghrelin locally produced within this gland. In fact, our laboratory has previously 
identified a spliced mRNA ghrelin variant that retains the intron 2 (In2-ghrelin variant; 
(Kineman et al., 2007)), which may be of biological relevance because it is expressed at 
higher levels than the native ghrelin transcript in the Pit and is regulated under metabolic 
stress (fasting and diet-induced obesity (DIO)). Interestingly, we have found that GOAT 
expression levels closely paralleled those of In2-ghrelin variant, but not those of native-
ghrelin, in the mouse models analyzed (fasting, DIO and knockout models), thereby 
suggesting that In2-ghrelin variant could be a primary substrate for GOAT in the Pit. 
Finally, our data using a SST-KO mouse model (Zeyda et al., 2001) support previous 
indications suggesting the existence of a profound relation between SST/CST and ghrelin 
systems (Egido et al., 2002; Norrelund et al., 2002; Arosio et al., 2003; Shimada et al., 
2003). Specifically, SST-KO mice exhibited increased ghrelin mRNA expression in the 
stomach, as well as elevated circulating levels of total-ghrelin, but not acylated-ghrelin, as 
compared to SST-intact control mice. This suggests that endogenous SST can inhibit 
ghrelin mRNA expression and consequently circulating total ghrelin levels in mice. 
Interestingly, fasting did not alter neither stomach ghrelin mRNA expression nor plasma 
total-ghrelin levels; however, it did increase circulating acylated-ghrelin levels in both 
SST-KO and SST-intact mice, compared with their controls fed SST-KO and SST-intact mice, 
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suggesting the existence of a different player, independent of SST regulation, that regulate 
plasma acylated-ghrelin levels in fasting conditions. 
In all, our results indicate that the expression of the SST/ghrelin system in the HPT-
Pit-stomach axis is tightly regulated by metabolic conditions and is strongly influenced by 
the presence of SST. In addition, our data also show novel evidence for the coordinated 
regulation of GOAT and In2-ghrelin variant expression in this axis, which suggest a 
potential functional relevance of this system. 
 
3.2.- SST, ghrelin and breast cancer (Articles IV & V) 
SST/CST/ssts and ghrelin/GHS-Rs are two well-known endocrine regulatory 
systems composed of multiple peptides and receptors which are widely expressed and 
exert multiple actions in normal and pathological conditions (Patel, 1999; Cordido et al., 
2009). In this context, it is noteworthy that SST/CST-ghrelin systems are highly expressed 
in a number of different endocrine-related tumors, including breast cancer. Moreover, 
there is emerging evidence showing that specific components of these systems can play 
relevant and unique pathophysiological roles in these pathologies, likely by regulating cell 
proliferation and tumor progression (Waseem et al., 2008; Watt et al., 2008; Nikolopoulos 
et al., 2009). This may be of particular relevance in breast cancer, a multi-factorial 
pathology profoundly influenced by endocrine factors, such as circulating and/or locally-
produced GH, IGF-I and estrogen (Haslam, 1988; Laban et al., 2003). In fact, antihormonal 
treatments using therapeutic agents that block the effect of estrogens (e.g. tamoxifen) are 
widely used in the management of breast cancer patients, since these drugs are effective in 
blocking the in vivo and in vitro estrogen-mediated effects of GH/IGF-I axis on tumor 
progression and/or proliferation of breast cancer cells (Laban et al., 2003). 
As mentioned above, SST/CST and ghrelin systems are widely expressed in breast 
cancer tissues and derived cell lines (Cameron Smith et al., 2003; Jeffery et al., 2005), 
suggesting a possible autocrine and/or paracrine function. However, the precise role and 
the local regulation of SST/CST and ghrelin systems in breast cancer are still uncertain. 
Indeed, clinical trials using long-acting SST analogs have been unsatisfactory (Watt et al., 
2008), and in vitro assays have failed to demonstrate any relevant effect of ghrelin in 
breast cancer cell lines. Nevertheless, hope for a potential application of these agents still 
exist because, there is data indicatingº that SST-analogs can reduce plasma IGF-1 in breast 
cancer patients (Dolan et al., 2001), and this could be relevant in antihormonal therapies, 
as IGF-1r seems to be crucial in the development of endocrine therapy resistance (Casa et 
al., 2008).  
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In this context, the following two studies (Papers III & IV) were conducted to 
determine the putative relevance of SST/CST, ghrelin and their receptors in breast cancer, 
specially focusing in two novel components of these systems recently identified by our 
research group: 1) the truncated human sst5TMD4 (Duran-Prado et al., 2009; Durán-
Prado et al., 2010) and 2) a human In2-ghrelin variant (Papers IV of this work).  
 
3.2.1- The role of sst5TMD4 in breast cancer (Article IV)  
In this study, we report for the first time the presence of the new truncated isoform 
sst5TMD4 (Duran-Prado et al., 2009) in breast cancer. Specifically, expression of 
sst5TMD4 was found in 28% of the human breast cancer samples analyzed (n=12 out 40) 
and its expression was highly correlated with that of sst2. Interestingly, when sst2 and 
sst5TMD4 were coexpressed in the same cell lines (hamster ovarian CHO-K1 or human 
breast cancer MCF-7 cells), they show a preferential intracellular localization, which was 
comparable to that previously described for sst5TMD4 alone (Duran-Prado et al., 2009) 
and also parallel to that reported recently for the endogenous sst1-5 expressed in MCF-7 
(Watt and Kumar, 2006). In line with this, use of a Fluorescence resonance energy transfer 
(FRET) analysis demonstrated that sst5TMD4 is able to physically interact with sst2, and 
physically retain a high proportion of this receptor in the intracellular compartments, thus 
acting as a dominant negative for sst2. This is further supported by the fact that sst5TMD4 
is also capable to alter the normal ability of sst2 to signal in terms of intracellular calcium 
mobilization in response to its endogenous ligands (SST and CST). Interestingly, it has 
been previously reported that the alteration of the sst2 plasma membrane localization 
could lead to the elimination of an inhibitory sst2-mediated autocrine loop, which derives 
into an epithelium-mesenchymal transition (EMT), and enhanced proliferation and 
invasion (Benali et al., 2000; Leu et al., 2008). Interestingly, in addition to the dominant-
negative role observed for sst5TMD4 over sst2 in cell models, we have found that stable 
expression of sst5TMD4 in MCF-7 cells leads to a mesenchymal-like or fibroblastoid 
appearance instead of the usual epithelial morphology signature of this cell type, 
reinforcing the notion that sst5TMD4 could play a relevant role in the patho-physiology of 
breast cancer cells. In fact, compared with mock transfected cells, sst5TMD4-stably 
transfected cells showed higher migratory and proliferative abilities, two properties that 
could be determinant in tumoral progression and metastases. Taken together, our findings 
that sst5TMD4 expression is directly correlated with the most clinically aggressive 
samples obtained from patients with breast tumors, as well as with enhanced signs of 
malignancy in in vitro cells models, it is tempting to speculate that the presence and 
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actions of the truncated sst5TMD4 could contribute, at least in part, to the development 
and increase of malignancy observed in some breast cancer. 
In order to ascertain the molecular basis of the increased malignancy features of 
MCF-7 cells transfected with sst5TMD4, we studied two major signal transduction 
pathways known to be involved in proliferation, migration and phenotype transformation 
in cancer cells, Akt and extracellular signal-regulated kinases (ERKs) (Santen et al., 2002; 
Liu et al., 2007). Our results indicate that the basal phosphorylation levels of Akt and ERK 
are different in sst5TMD4-stably transfected cells compared with mock-transfected 
control cells. Specifically, sst5TMD4-expressing cells show a higher level of both, P-Akt and 
P-ERK levels than cells that do not express sst5TMD4. These elevations in P-Akt and P-
ERK levels observed in sst5TMD4-stably transfected cells compared with control cells 
could be linked to, and may perhaps underline, the malignant characteristics associated to 
breast cancer cells, because it has previously demonstrated that P-Akt levels are increased 
in 30-40% of the human breast cancer samples compared with controls, and that this 
elevation promotes epithelial-mesenchymal transition, which derives in tumor 
progression to an invasive and metastatic carcinoma (Liu et al., 2007). In addition, it has 
been shown that mitogen-activated protein kinases (MAPK) cascades are even more 
important than Akt in breast cancer. Specifically, ERK1 and ERK2 are the two most 
relevant MAP kinases isoforms in breast cancer and are usually over-expressed and over-
phosphorylated in certain type of mammary tumors, especially, node positive primary 
tumors (Santen et al., 2002). The increase in P-ERK levels has been associated to poor 
survival in triple negative cancers (estrogen receptors-, progesterone receptors-, and 
epithelial-growth factor receptors-lacking breast cancers) where such increase is 
considered a poor prognosis factor (Eralp et al., 2008). Inasmuch as several evidences 
pointing to a basal, constitutive inhibitory effect of endogenous SST, possibly via sst2, on 
P-ERK levels (Ben-Shlomo et al., 2007), our data showing that sst5TMD4 alters the 
localization and functionality of sst2, lends credence to the view that the elevated P-ERK 
levels observed in sst5TMD4-expressing breast cancer cells could be associated to a 
blockade of a constitutive inhibitory action of SST/sst2, and that this, in turn, is linked to 
the bad progression and features of cancer cells expressing this receptor variant. 
 
3.2.2- In2-ghrelin variant and breast cancer (Paper V) 
Similar to that previously found in the murine ghrelin gene (Kineman et al., 2007), we 
have demonstrated that the human ghrelin gene can also suffer processes of intron (In) 
retention to generate a new ghrelin-variant. Specifically, human In2-ghrelin transcript 
variant contains Exon(Ex)0, Ex1, In2 and Ex2 but lacks Ex3 and Ex4 compared with the 
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native-ghrelin transcript. Given the fact that the In2-variant and native-ghrelin transcripts 
share the Ex0 and 1, we speculate that the human In2-ghrelin variant share with the native 
form the start codon, located in the exon 1, originating a new transcript of 117 amino acids 
(prepro-In2-ghrelin) with similar 5´-sequence. In consequence, human In2-ghrelin variant 
mRNA could codify a new prepro-In2-ghrelin peptide, that would contain a similar signal 
peptide sequence, and, most importantly, would conserve the putative acylation site at 
Ser3 in the N-terminus present in the native prepro-ghrelin but, having a totally different 
C-terminal tail than that of native prepro-ghrelin.  
In2-ghrelin variant was found to be widely expressed in various human tissues (n=22) 
which might indicate that this novel variant could be physiologically relevant and exert 
specific biological actions. Interestingly, we observed a remarkably high correlation 
between the expression levels of In2-ghrelin variant, but not of native-ghrelin, and those 
of GOAT in human tissues (R2=0,921). Accordingly, it seems reasonable to propose that 
In2-ghrelin variant may be a primary substrate for GOAT in human tissues. On the other 
hand, expression levels of human native-ghrelin and In2-ghrelin variant were not 
correlated in the human tissues studied, suggesting that the expression of both transcripts 
is likely to be differentially regulated in humans in a tissue-dependent manner. 
Pathophysiologic relevance of human In2-ghrelin variant was supported by the fact 
that its expression levels were found to be highly up-regulated (8-fold) in ductal breast 
cancer samples (n=40) compared with breast tissue controls (n=4). Moreover, in this same 
context, we showed for first time that GOAT enzyme is present in normal mammary gland 
and breast cancer tissues in human. Similar to that found with the In2-ghrelin variant, the 
expression levels of GOAT were significantly higher in breast cancer samples compared 
with normal mammary gland samples. In fact, we found a strong, positive correlation 
between the expression levels of In2-ghrelin variant and GOAT in breast cancer samples 
analyzed, an observation that reinforces our notion that In2-ghrelin variant could be a 
primary substrate for GOAT in humans. In clear agreement with previous 
immunohistochemistry results showing very low levels of native-ghrelin in the normal 
breast epithelium, with moderately higher levels in the breast cancer samples (Jeffery et 
al., 2005), our current data show a slight but non-significant increase of native-ghrelin 
mRNA levels in breast cancer samples. In addition, we observed very low levels of 
expression of the acyl-ghrelin receptor GHS-R1a in both normal and tumoral breast 
tissues, whereas, in striking contrast, the truncated receptor variant GHS-R1b was 
strongly expressed in tumoral samples but undetectable in normal breast samples. These 
latter findings compare well with those previously reported by Jeffery et al (Jeffery et al., 
2005). Interestingly, in the present study, we observe a positive, albeit not significant, 
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correlation trend (R2=0,403; p=0.097) between the expression levels of GHS-R1b and In2-
ghrelin variant, but not with native-ghrelin.  
Intriguingly, in vitro experiments using a human model of breast cancer cells (MDA-
MB-231 cell line) further support and extend the potentially important physiologic role of 
the novel In2-ghrelin variant derived from the data obtained in human breast cancer 
samples. Indeed, as previously observed in breast cancer tissues, MDA-MB-231 cells also 
expressed high levels of In2-ghrelin variant, GOAT and GHS-R1b, whereas the expression 
of native-ghrelin and GHS-R1a were very low. Of note, overexpression of In2-ghrelin 
variant in MDA-MB-231 cells resulted in an increased rate of basal proliferation compared 
with mock-transfected control cells. Additionally, we have observed that treatment with 
acyl-ghrelin oppositely regulates the expression levels of native-ghrelin and In2-ghrelin 
variant. Specifically, treatment with both acylated- and non-acylated-ghrelin significantly 
up-regulate the expression levels of native-ghrelin while down-regulate the mRNA levels 
of In2-ghrelin variant suggesting that an auto-regulatory loop is in place in these cell type 
involving these two ghrelin variants. Furthermore, we also observed that treatment with 
tamoxifen significantly reduced the expression levels of In2-ghrelin mRNA levels, while it 
tends to up-regulate native-ghrelin mRNA levels. Accordingly, since tamoxifen is currently 
used as a primary therapeutic agent for the treatment of estrogen receptor (ER)-positive 
breast cancers (Jordan, 2007) and because the ghrelin axis has been reported to exert 
relevant actions in cancer cells (Jeffery et al., 2005), it is tempting to propose that our 
current findings may have important implications for this pathology, and therefore that 
they merit further, detailed investigation in future studies. 
 
3.3.- SST, ghrelin and Alzheimer Disease (Articles III and VI) 
There is increasing evidence that the SST/CST and ghrelin systems play relevant 
roles in the regulation of cognitive processes (Viollet et al., 2008). Indeed, SST and ghrelin 
are considered as positive stimuli in spatial and motor learning (Zeyda et al., 2001; Toth et 
al., 2009a; Toth et al., 2009b), and SST and CST have been reported to be involved in 
memory consolidation and evocation (Mendez-Diaz et al., 2005; Kluge et al., 2008). Of 
note, SST is one of the most severely reduced peptides in Alzheimer’s disease (AD) (Davis 
et al., 1988; Bissette and Nemeroff, 1992b; Nemeroff et al., 1992; Molchan et al., 1993; 
Nilsson et al., 2001), a neurodegenerative disorder characterized by cognitive deficits, 
such as impairment of episodic memory. Moreover, in addition to the extracellular 
accumulation of amyloid-β (Aβ) in senile plaques (SP) and the intracellular aggregation of 
hyperphosphorylated tau protein comprising neurofibrillar tangles (NFTs), the two major 
neuropathological hallmarks of AD (Selkoe, 2001), abnormalities in several neuropeptides 
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and neurotransmitters systems (such as SST) have also been found, and are suggested to 
play substantial roles in this pathology (Bissette and Nemeroff, 1992a; Proto et al., 2006; 
Epelbaum et al., 2009). As mentioned earlier, SST/CST and ghrelin systems are involved in 
the regulation of a wide variety of processes, such as inflammation, endocrine 
homeostasis, energy balance, or obesity. Interestingly, AD is currently considered a 
multifactorial disorder, whose origin and progression have been claimed to be influenced 
by inflammatory, energetic (obesity), and endocrine (GH-IGF1) signals (Giordano et al., 
2007b; Erol, 2008). Nevertheless, despite these clear overlaps, data reported hitherto on 
the regulation of SST/CST and ghrelin systems in the brain of AD patients are scarce 
and/or inconclusive. In the following two articles, we have explored by qrtRT-PCR the 
mRNA levels of SST, CST, and ghrelin, as well as, their receptors and other related 
components (i.e. neprilysin, a SST-regulated enzyme involved in Aβ degradation) in the 
three regions, inferior, medial, and superior, of the temporal lobe, one of the most affected 
cortical structures in AD (Braak and Braak, 1991). 
 
3.3.1- SST and ssts in Alzheimer Disease (Article III) 
It is nowadays widely accepted that SST is one of the most selectively reduced 
neuropeptides in the brain of AD patients (Davis et al., 1988; Nemeroff et al., 1992; 
Epelbaum et al., 2009). However, there is no precise quantitative data on the expression of 
SST and its receptors in the brain of AD patients and, surprisingly no data has been 
reported concerning its highly related peptide CST. In our study, use of qrtRT-PCR allowed 
to confirm that SST expression displays a remarkable reduction (83.9%) in the temporal 
lobe of AD patients as compared with controls. Additionally, it demonstrated for the first 
time that CST is expressed in the temporal lobe of AD patients. In fact, similar to that found 
for SST, we observed that CST mRNA levels were significantly decreased in the whole 
temporal region of AD patients as compared to control samples. However, since the extent 
of reduction (40%) for CST was lower than that observed for SST, CST expression levels 
were higher than those of SST in temporal region of AD patients. It is worth noting that the 
reduction in SST expression was observed in the three regions of the temporal lobe of AD 
patients (inferior, medial, and superior) that were analyzed, whereas CST mRNA levels 
were only significantly decreased in the inferior temporal region. The divergent mRNA 
alteration observed for SST and CST in AD patients compared to controls may imply that 
these peptides play a dissimilar role in AD, which could be region-dependent. Additionally, 
we observed that neprilysin is also present in the whole temporal lobe; however, its 
expression levels were considerably lower than those of SST and CST. Although there was 
a trend for neprilysin mRNA levels to be down-regulated in the whole temporal lobe of AD 
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compared with control subjects, this difference did not reach statistical significance. 
Hence, our data suggest that Aβ accumulation in the temporal lobe could be due to a lack 
of neprilysin activation by SST rather than to a reduction of its expression. 
Data regarding the presence and/or abundance of SST/CST receptors (ssts) in AD 
are even more limited and controversial than those reported for their ligands (Beal et al., 
1985; Krantic et al., 1992; Kumar, 2005). In this study, we used specific sets of primers to 
independently determine the mRNA copy number of each sst subtype, and found that all 
five ssts are expressed, at very different levels, in the temporal cortex of control brains 
(sst2 ≥ sst1 ≥ sst3 > sst4 >> sst5). Interestingly, an overall reduction of 53% in the number 
of ssts mRNA copies was observed in AD temporal cortex as compared with control 
samples. Specifically, analysis of the individual receptor subtypes revealed that while sst1, 
sst3, and sst4 mRNA levels were significantly reduced, expression of sst2 showed a 
numerical reduction that did not reach statistical significance. Interestingly, the reduction 
of sst1-4 expression in AD patients was mainly restricted to the inferior temporal gyrus 
and was not so apparent in the medial and superior lobe. On the other hand, expression 
levels of sst5 were not altered between AD and control patients in any of the whole 
temporal regions analyzed. Taken together, these and our previous results suggest that Aβ 
accumulation in the temporal lobe may not be only due to a lack of neprilysin activation by 
SST but also to a reduction of SST sensitivity caused by decreased levels of ssts. 
 
3.3.2- Ghrelin system in Alzheimer Disease (Article VI) 
Although ghrelin has been reported to act as a positive stimulus in memory and 
learning processes (Toth et al., 2009a; Toth et al., 2009b), to our knowledge this is the first 
study systematically analyzing expression of the ghrelin axis in brains of AD patients in 
comparison to control subjects. Absolute quantification of mRNA copy number in the 
temporal cortex demonstrated that ghrelin, In2-ghrelin variant, as well as GOAT mRNAs 
are abundantly expressed in the brain of both control and AD subjects. Yet, when 
comparing expression levels between control and AD samples, we observed a general 
reduction of native-ghrelin (50%) and In2-ghrelin variant (41%) in the whole temporal 
gyrus of AD patients, although this difference did not reach statistical significance for the 
In2-ghrelin variant, likely due to the limited number of samples measured and the 
intrinsic inter-individual and inter-region variability. Notwithstanding this, it is interesting 
to note that In2-ghrelin variant expression was detected in the medial and superior, but 
not in the inferior temporal lobe regions, whereas native-ghrelin expression was detected 
in all regions. In addition, we noticed that In2-ghrelin variant expression was severely 
decreased in the superior lobe, while the reduction in native-ghrelin mRNA levels 
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observed in AD patients was mainly detected in the inferior lobe. Along these same lines, 
GOAT mRNA levels did not change in whole brains of AD patients as compared with 
matched controls; however, when each region was considered separately, a significant 
reduction in GOAT expression was observed in the inferior, but not in the medial and 
superior lobes of AD patients.  
We also analyzed the expression levels of both ghrelin receptor (GHS-R) transcripts, 
GHS-R1a and GHS-R1b, in the temporal lobe of AD and control subjects. This showed that 
both receptors are expressed at similar levels in control subjects, whereas their 
abundance in the temporal region of AD patients was regulated in a strikingly opposite 
manner. Thus, while expression of GHS-R1a was markedly reduced in AD tissues, GHS-R1b 
mRNA levels were increased by 3-fold in the whole temporal lobe of AD patients as 
compared with controls. Although the pathophysiological relevance of these findings is 
still unknown, our results are reminiscent of previous data showing that GHS-R1b is more 
expressed than GHS-R1a in other pathological situations, such as colorectal cancer 
(Waseem et al., 2008), adrenocortical tumors (Barzon et al., 2005), and, as shown in the 
present Thesis, in breast cancer. Interestingly, it has been recently demonstrated that 
GHS-R1b can heterodimerize with GHS-R1a, acting as a dominant-negative receptor, 
partially blocking GHS-R1a functionality (Chu et al., 2007; Leung et al., 2007). In this 
context, our data may imply that the elevated expression of GHS-R1b observed in AD 
patients could block the positive memory and learning roles exerted by ghrelin via its full-
length GHS-R1a receptor (Toth et al., 2009a; Toth et al., 2009b), and therefore, this event 
could contribute, at least in part, to the cognitive deficit and impaired episodic memory 
processes observed in AD patients.  
Since ghrelin levels have been shown not to vary in the cerebrospinal fluid of AD 
patients (Proto et al., 2006), our findings could suggest that locally-produced acylated/ 
non-acylated native-ghrelin and/or In2-ghrelin variant may exert autocrine and/or 
paracrine functions in the human temporal lobe. This idea would be supported by a 
previous study on human astrocytoma cell lines (Dixit et al., 2006), which demonstrated 
that ghrelin/GHS-R1a-axis could constitute an autocrine regulatory pathway regulating 
astrocytoma cell migration and invasiveness of cancers in humans. Hence, in that ghrelin 
system has been demonstrated to directly influence memory processes (Carlini et al., 
2002; Carlini et al., 2004; Diano et al., 2006; Carlini et al., 2008; Carvajal et al., 2009), the 
breakdown of the ghrelin system in the temporal lobe of AD patients reported herein 
could help to explain, at least in part, the impairment of memory processes observed in 
AD. 
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1.- The SST and ghrelin systems are differentially and tissue-specifically regulated by 
metabolic insults at the hypothalamus-pituitary-stomach axis, where both systems appear 
to crosstalk. In particular: 
1.a.- Fasting profoundly alters SST and ghrelin expression in mouse hypothalamus-
pituitary-stomach axis as well as ghrelin levels in plasma. 
1.b.- Endogenous SST tone is a relevant regulator of ghrelin, since circulating ghrelin 
as well as its stomach mRNA levels are increased in SST knock-out mice. 
1.c.- Mouse GOAT mRNA regulation, together with GOAT activity and substrate 
availability, could act in concert to control acyl-ghrelin plasma levels under conditions 
of metabolic challenge. 
2.- The SST/CST and the ghrelin systems are dysregulated in human breast cancer, 
wherein some new components of these systems (sst5TMD4, In2-ghrelin, GHS-R1b, GOAT) 
may particularly contribute to this pathology, as supported by: 
2.a.- sst5TMD4 is present in aggressive breast cancers, where it is associated with 
bad prognosis markers, and its expression in breast cancer cell lines increases their 
malignancy, possibly by altering signaling and disrupting a protective feedback loop 
involving sst2/SST. 
2.b.- In2-ghrelin is a new human ghrelin variant that, together with GHS-R1b and 
GOAT, but not native ghrelin or GHS-R1a, is highly expressed in human breast cancer 
samples, and whose overexpression promotes augmented proliferation in breast 
cancer cell lines. 
3.- The SST/CST and ghrelin systems are profoundly impaired in one of the most 
important memory-related regions, the temporal gyrus, of the brain of Alzheimer disease 
patients as compared to matched controls. In particular: 
3.a.- A global, albeit peptide-specific and region-dependent reduction in SST, CST and 
sst1-4, is patent in temporal lobe of AD patients 
3.b.- Dysregulation of ghrelin system in AD includes a reduction of ghrelin, In2-ghrelin, 
GOAT, and GHS-R1a mRNA levels as well as a strong increase in the GHS-R1b expression. 
Since SST/CST and ghrelin systems directly influence memory processes potentially 
exerting “protective” roles, breakdown of these systems in the temporal lobe of AD 
patients may contribute the impairment of memory processes observed in this pathology. 
 
 
 
4.- GENERAL CONCLUSIONS 
30 
 
 
Global corollary: 
The SST/CST and ghrelin systems are present and their components differentially 
regulated in axes and pathological conditions markedly distinct and distant from their 
original neuroendoendocrine actions at the hypothalamus-pituitary unit. Accordingly, it 
seems reasonable to propose that SST/CST, ghrelin and their receptors and related 
peptides comprise two highly interrelated pleiotropic systems, with additional 
pathophysiological roles than those previously envisioned, which also unveil likely new 
targets for therapeutic intervention. 
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Corticosterone and total ghrelin levels are increased in somatostatin
(SST) knockout mice (Sst/) compared with SST-intact controls
(Sst/). Because exogenous ghrelin can increase glucocorticoids, the
question arises whether elevated levels of ghrelin contribute to ele-
vated corticosterone levels in Sst/ mice. We report that Sst/ mice
had elevated mRNA levels for pituitary proopiomelanocortin
(POMC), the precursor of adrenocorticotropic hormone (ACTH),
whereas mRNA levels for hypothalamic corticotropin-releasing hor-
mone (CRH) did not differ from Sst/ mice. Furthermore, SST
suppressed pituitary POMC mRNA levels and ACTH release in vitro
independently of CRH actions. In contrast, it has been reported that
ghrelin increases glucocorticoids via a central effect on CRH secretion
and that n-octanoyl ghrelin is the form of ghrelin that activates the
GHS-R1a and modulates CRH neuronal activity. Consistent with
elevations in total ghrelin levels, Sst/ mice displayed an increase in
stomach ghrelin mRNA levels, whereas hypothalamic and pituitary
expression of ghrelin was not altered. Despite the increase in total
ghrelin levels, circulating levels of n-octanoyl ghrelin were not altered
in Sst/ mice. Because glucocorticoids and ghrelin increase in
response to fasting, we examined the impact of fasting on the adrenal
axis and ghrelin in Sst/ and Sst/ mice and found that endogenous
SST does not significantly contribute to this adaptive response. We
conclude that endogenous SST inhibits basal ghrelin gene expression
in a tissue specific manner and independently and directly inhibits
pituitary ACTH synthesis and release. Thus endogenous SST exerts
an inhibitory effect on ghrelin synthesis and on the adrenal axis
through independent pathways.
somatostatin; adrenocorticotropic hormone; hypothalamic-pituitary-
adrenal axis; corticotropin-releasing hormone; pituitary; stomach
SOMATOSTATIN (SST), OR ITS SYNTHETIC ANALOGS, can reduce
circulating adrenocorticotropic hormone (ACTH) and glu-
cocorticoid levels in rats and humans in vivo (19, 43, 46). The
inhibitory actions of SST are believed to be due, at least in part,
to a direct effect on the pituitary. This hypothesis is supported
by the fact that SST can block corticotropin-releasing hormone
(CRH)-mediated ACTH release in cultures of primary rat
pituitary cells, mouse pituitary tumor cells (AtT-20), and cul-
tures of human corticotropinomas (20, 25, 44), where this
effect appears to be mediated by the SST receptors sst2 and/or
sst5 (20, 43, 44). Both the in vivo and in vitro inhibitory effects
of SST on ACTH release can be masked by glucocorticoids,
where glucocorticoids directly inhibit basal and CRH-mediated
ACTH release (19, 25). However, a recent study (20) demon-
strates that an sst5 selective agonist can inhibit ACTH release
in vitro in the presence of glucocorticoids. The inhibitory
action of exogenous SST on ACTH release has prompted
speculation regarding the role of endogenous SST as a corti-
cotropin release-inhibiting factor (14). More recent observa-
tions support such a role, where pituitaries of sst2 knockout
mice release more ACTH in vitro (47) and corticosterone
levels are elevated in SST knockout mice (Sst/) (50).
Preliminary data generated by our laboratory have confirmed
that basal corticosterone levels are elevated in both male and
female Sst/ mice (28). Interestingly, using an assay that
recognizes both the n-octanoyl and des-acyl forms of ghrelin,
we also found that total ghrelin levels of Sst/ mice were
2-fold that of Sst/ controls. The n-octanoyl modified form
of ghrelin, via activation of the GHS-R1a, has been shown to
enhance food intake and stimulate the release of growth hor-
mone and glucocorticoids, whereas the des-acyl form of ghre-
lin, via an unknown receptor pathway, has been shown to
decrease food intake, regulate cardiac and adipocyte function,
and mediate cell proliferation and apoptosis in a variety of
tissues (for review see Refs. 9, 11, 16, 23, and 24). Because
n-octanoyl ghrelin and its synthetic analogs [growth hormone
secretagogues (GHS)] have been shown to increase ACTH and
glucocorticoids in chickens, rats, mice, and humans (4, 5, 37,
45), where this action is thought to be mediated by an increase
in CRH neuronal activity and CRH gene expression (5, 17, 18,
21), we hypothesized that the elevated ghrelin levels may in
part be responsible for the increase in corticosterone levels in
the Sst/ mice. However, it should be noted that the role of
ghrelin in mediating the hypothalamic-pituitary-adrenal (HPA)
axis may represent a pharmacological response given that a
recent report (27) demonstrated that administration of ghrelin
in fed subjects, to achieve circulating concentration observed
just prior to anticipated food intake, did not affect circulating
ACTH or cortisol levels.
Therefore, to further explore the interrelationship between
endogenous SST, ghrelin, and adrenal function we compared
the HPA axis of fed Sst/ and Sst/ mice in relation to
circulating ghrelin levels (measured as total or n-octanoyl only)
and ghrelin gene expression in the stomach, pituitary, and
hypothalamus. Because a rise in glucocorticoids and ghrelin
represent a part of the adaptive response to fasting, we also
examined the role endogenous SST plays in mediating this
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response. Finally, we examined the direct effect of SST and
ghrelin on proopiomelanocortin (POMC) mRNA levels and
ACTH release in primary pituitary cell cultures.
MATERIALS AND METHODS
Animals. Development and initial characterization of SST knockout
(Sst/) mice have been previously reported (50). Male mice, het-
erozygous for the SST-null mutation, were bred in a C57BL/6J
background (Jackson Laboratory, Bar Harbor, ME) to generate Sst/
and Sst/ mice for this study. Genotypes were determined by PCR
of tail-snip DNA, using primers and genotyping protocol reported in
the Jackson Laboratory web site for the 129S-Ssttm1Ute/J background
(http://jaxmice.jax.org/pub-cgi/protocols/protocols.sh?objtypeprotocol
&protocol_id210). All experimental procedures were approved by
the Animal Care and Use Committees of the University of Illinois at
Chicago and the Jesse Brown Veteran’s Administration Medical
Center. Animals were housed under a 12:12-h light-dark cycle
(lights-on 0700). All mice were handled daily at least 1 wk prior to
euthanasia to acclimate them to personnel and handling procedures.
In vivo studies. For studies examining the impact of endogenous
SST on the adrenal axis and ghrelin, male mice 9–10 wk of age were
weighed and food was withdrawn (0800–0900) from a subset of
mice, whereas the remaining received food ad libitum (n  4–10
mice/genotype/treatment group). Forty-eight hours later mice were
weighed and killed by decapitation, without anesthesia. Trunk blood
was mixed with 15 l of MiniProtease inhibitor (Roche, Nutley, NJ)
and placed on ice until centrifugation at 13,000 rpm for 10 min.
Plasma was stored at80°C until evaluation of circulating hormones.
Hypothalami, pituitaries, and stomachs were collected and frozen in
liquid nitrogen and stored at80°C until analysis of mRNA levels by
quantitative real-time RT-PCR (qrtRT-PCR, see below).
Primary pituitary cell cultures. For studies examining the direct
effects of SST and ghrelin on pituitary POMC mRNA levels and
ACTH release, pituitaries were collected from 10- to 12-wk-old male
mice from a mixed background (C57BL/6J  FVB/N; n  3–5
pituitaries pooled/experiment, 3 separate experiments) or randomly
cycling female baboons ranging in age from 7 to 12 yr (n  1
pituitary/experiment, 2–5 separate experiments). Mouse pituitaries
were obtained after CO2 asphyxiation, whereas baboon pituitaries
were obtained after pentobarbital sodium overdose from control
animals under Institutional Animal Care and Use Committee-ap-
proved studies conducted by other University of Illinois at Chicago
investigators. Pituitaries were enzymatically dispersed into single
cells as previously described (2), with the exception that mouse
pituitaries were dispersed in 1.7-ml polypropylene microfuge tubes
(2–3 pituitaries/1 ml digestion medium/tube), and baboon pituitaries
were dispersed in spinner flasks (1 pituitary/30 ml digestion medium/
flask). All culture reagents were obtained from Sigma-Aldrich (St.
Louis, MO) unless otherwise specified. Cells were plated at 2 
105/well in -MEM (Invitrogen, Grand Island, NY) containing 10%
horse serum, 0.15% BSA, 6 mM HEPES, and penicillin-streptomycin
(Invitrogen). After a 24-h incubation cultures were rinsed in serum
free medium, and vehicle or SST (100 nM) and CRH (10 nM), alone
or in combination, were added or cultures were treated with ghrelin
(10 nM, 3–5 wells/treatment group). Cultures were incubated for an
additional 18 h, and medium was removed and frozen for subsequent
analysis of ACTH levels and total cellular RNA recovered for deter-
mination of POMC mRNA levels, as described below.
RNA isolation and reverse transcription. Total RNA was extracted
from whole hypothalami and pituitaries or from primary pituitary cell
cultures using the Absolutely RNA RT-PCR Miniprep kit (Stratagene,
La Jolla, CA) with DNAse treatment according to the manufacturer’s
instructions. For RNA extraction from whole stomachs, the protocol
was modified. Specifically, the stomach was placed in a 15-ml
polypropylene conical tube containing 2 ml of lysis buffer. The
sample was mechanically homogenized using a conical tephalon
pestle for 5 min. Homogenates (1.5 ml) were transferred to 1.7-ml
microfuge tubes and centrifuged at 13,000 rpm for 15 min, and 200 l
of the supernatant were mixed with 400 l of lysis buffer. The
solution was subjected to further homogenization for 1 min and
centrifuged for 5 min, and supernatants were then column purified
using the Absolutely RNA RT-PCR Miniprep kit as instructed. The
amount of recovered RNA from hypothalami, pituitaries, and stom-
achs, was determined by the Ribogreen RNA quantification kit (Mo-
lecular Probes, Eugene, OR). Total RNA (1 g for whole tissue
extracts and 0.25 g for primary pituitary cell cultures) was reversed
transcribed (RT) in a 20-l volume using random hexamer primers
and reagents supplied in the cDNA First Strand Synthesis kit (MRI
Fermentas, Hanover, MD). RT reactions were treated with Ribonu-
clease H (1 U, MRI Fermentas), and duplicate aliquots (1 l) of the
resulting cDNA were amplified by qrtRT-PCR, where samples are run
against synthetic standards to estimate mRNA copy number (see
below).
Primer selection. Specific primers for all mouse transcripts were
designed using published sequences as templates [GenBank, National
Center for Biotechnology Information (NCBI); Table 1]. To obtain
partial nucleotide sequences of the baboon POMC and cyclophilin A
coding region, we aligned published cDNA sequences from a variety
Table 1. Species-specific primers used for quantitative real-time RT-PCR
Gene
GenBank
Accession No. Primer Sequence
Nucleotide
Position Product Size
Mouse
CRH NM_205769 Sense: TCTGGATCTCACCTTCCACCT Sn 630 95
Antisense: CCATCAGTTTCCTGTTGCTGT As 724
POMC NM_008895 Sense: GAGGCCTTTCCCCTAGAGTT Sn 617 154
Antisense: CACCGTAACGCTTGTCCTT As 770
Ghrelin NM_021488 Sense: TCCAAGAAGCCACCAGCTAA Sn 164 126
Antisense: AACATCGAAGGGAGCATTGA As 289
SST NM_009215 Sense: TCTGCATCGTCCTGGCTTT Sn 138 113
Antisense: CTTGGCCAGTTCCTGTTTCC As 250
Cyclophilin A NM_008907 Sense: TGGTCTTTGGGAAGGTGAAAG Sn 421 109
Antisense: TGTCCACAGTCGGAAATGGT As 529
Baboon
POMC DQ315472 Sense: CCCTACAGGATGGAGCACTT Sn 7 127
Antisense: CGTTCTTGATGATGGCGTTT As 133
Cyclophilin A DQ315473 Sense: CAAGACGGAGTGGTTGGATG Sn 351 122
Antisense: TGGTGGTCTTCTTGCTGGTC As 472
CRH, corticotropin-releasing hormone; POMC, proopiomelanocortin; SST, somatostatin.
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of several primate species [human, Pan troglodytes (chimpanzee) and
Macaca nemestrina (pig-tailed macaque)] and selected primers cor-
responding to areas of 100% homology. Using these primers, we
amplified cDNA generated from baboon pituitary total RNA. The
product generated was sequenced and demonstrated close similarity to
POMC and cyclophilin A transcripts of other primates. This sequence
was submitted to GenBank, and the accession numbers, which are
shown in Table 1, were subsequently used to select primers appro-
priate for real-time PCR. Specifically, primers were selected using
Primer 3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_
www.cgi; Steve Rozen, Whitehead Institute for Biomedical Research)
with selection parameters set to 1) pick primers that span an intron
(when known) and that differ by no more than 0.2°C in annealing
temperature, 2) exclude primers that may form primer dimers, and 3)
amplify a product of 90–200 bp. Sequences of selected primers were
used in BLAST (NCBI) searches to check for potential homology to
sequences other than the designated target. Primers were then used in
a standard PCR reaction to amplify cDNA generated by reverse
transcription, and products were run on agarose gels and stained with
ethidium bromide to confirm that only one band, of the expected size,
was amplified and no primer dimers formed. These PCR products
were then column purified (Qiagen, Valencia, CA) and sequenced to
confirm target specificity. The primers, the expected product sizes,
annealing temperatures and Genbank accession numbers are provided
in Table 1.
Confirmation of primer efficiency, construction of standard curves,
and qrtRT-PCR. The initial screening of primer efficiency in a
real-time PCR reaction was performed amplifying twofold dilutions
of RT products, where optimal efficiency was demonstrated by a
difference of one cycle threshold between dilutions. At the end of the
amplification, the final products were subjected to graded tempera-
ture-dependent dissociation to verify that only one product was
amplified. For real-time PCR reaction, IQ SYBR Green Supermix
(Bio-Rad, Hercules, CA) was used, where thermocycling and fluores-
cence detection were performed using a Stratagene Mx3000p real-
time PCR machine. If preliminary primer efficiency tests were con-
firmed, the concentration of purified PCR products (generated by
standard PCR and purified for sequencing as described above) was
determined using Molecular Probe’s Picogreen DNA quantification
kit, and the PCR products were serial diluted to obtain standards
containing 101, 102, 103, 104, 105, and 106 copies of synthetic
template per 1 l. Standards were then amplified by real-time and
standard curves generated by the Stratagene Mx3000p Software. The
final volume of the PCR reaction was 25 l: 1 l of RT sample, 12.5
l of the IQ SYBR Green Supermix, 0.375 l of each primer (10 M
stock solution), 0.375 l of the reference dye (Bio-Rad), and 10.375
l of dH2O. Thermal cycling profile consisted of a preincubation step
at 95°C for 10 min followed by 40 cycles of denaturation (95°C, 30 s),
annealing (61°C, 1 min), and extension (72°C, 30 s). The efficiency of
amplification for all curves was between 97 and 103%, meaning all
templates in each cycle were copied. To estimate the starting copy
number of cDNA (as shown in Table 2), RT samples were PCR
amplified, and the signal compared with that of standard curve run on
the same plate. In addition, total RNA samples that were not RT and
a no-cDNA control were routinely run in each plate to control for
genomic DNA contamination and to monitor potential exogenous
contamination, respectively. Also, to control for variations in the
amount of RNA used in the RT reaction and the efficiency of the RT
reaction, mRNA copy number of the transcript of interest was ad-
justed by the mRNA copy number of cyclophilin A (a peptidyl
isomerase), where cyclophilin A mRNA level did not significantly
vary between experimental groups, within tissue type (Table 2).
Assessments of hormones levels. Commercial ELISA kits were
used for determination of circulating levels of corticosterone (Octeia
Rat/Mouse ELISA, cat. no. AC-14F1; IDS, Fountain Hills, AZ) and
total and n-octanoyl ghrelin (Rat/Mouse ELISA, cat. nos. EZGDAC-
87K and EZGAC-86K, respectively; Linco). Circulating ACTH levels
were not assessed in these mice due to the limited volume of plasma
collected (200–300 l/mouse). However, ACTH release from pri-
mary mouse and baboon pituitary cultures treated with SST and/or
CRH, or those treated with ghrelin, was measured using the ALPCO
ACTH ELISA kit (cat. no. 21-SDX018), where the amino acid
sequence of mouse and primate ACTH do not differ.
Statistical analysis. Samples from all groups within an experiment
were processed at the same time; therefore, the in vivo effects of
genotype/fasting and the in vitro effects of SST/CRH were assessed
by two-way ANOVA followed by a Newman-Keuls test for multiple
comparisons. Effects of fasting on SST mRNA levels in Sst/ or the
in vitro effects of ghrelin on POMC mRNA levels and ACTH release
were assessed by Student’s t-test. P 	 0.05 was considered signifi-
cant. All values are expressed as means 
 SE. All statistical analyses
were performed using the GB-STAT software package (Dynamic
Microsystems, Silver Spring, MD).
RESULTS
Somatostatin. Absolute hypothalamic and stomach SST and
cyclophilin A mRNA copy numbers, as determined by qrtRT-
PCR, are shown in Table 2, whereas Fig. 1 illustrates hypo-
thalamic and stomach SST mRNA copy number, adjusted by
cyclophilin A mRNA copy number, in Sst/ and Sst/ mice.
Table 2. Absolute cDNA copy number/0.05 g total RNA of gene transcripts in the hypothalamus, pituitary, and stomach
of fed and fasted (48 h) Sst/ and Sst/ mice, as determined by quantitative real-time RT-PCR
Sst/ Sst/
Fed Fasted Fed Fasted
Hypothalamus
Cyclophilin A 204,279
36,352 235,119
35,305 206,973
22,778 252,667
44,545
SST 37,878
3,614 36,490
7,383 ND ND
CRH 80
11 124
27 67
9 116
18
Ghrelin 17
2 18
2 17
3 23
6
Pituitary
Cyclophilin A 130,493
18,570 123,535
9,931 131,479
15,341 125,613
7,300
POMC 1,875,000
275,984 1,414,520
97,762 2,810,857
123,729 2,110,800
172,841
Ghrelin 30
4 67
9 40
6 70
7
Stomach
Cyclophilin A 157,686
18,046 178,200
9,342 155,513
10,126 149,350
6,674
SST 55,687
6,754 45,597
10,466 ND ND
Ghrelin 170,228
37,406 249,320
34,145 336,713
37,421 304,650
28,158
Values represent means 
 SE. ND, not detectable.
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SST mRNA levels were undetectable by qrtRT-PCR in Sst/
mice in both the hypothalamus (Fig. 1A) and stomach (Fig.
1B), thus confirming the PCR genotyping results. In Sst/
mice, fasting tended to suppress hypothalamic and stomach
SST mRNA levels; however, these effects did not reach sta-
tistical significance. A modest inhibitory effect of fasting on
hypothalamic SST expression has been previously reported in
mice (35). However, in the rat, fasting has been reported to
enhance SST mRNA levels in the pyloric antrum but not the
acid-secreting region of the stomach (38, 48), although others
report a regional increase or decrease in SST mRNA following
fasting, depending on the housekeeping gene used as the
internal control (49).
HPA axis of Sst/ vs. Sst/ mice. Circulating corticoste-
rone levels were significantly elevated in Sst/ mice com-
pared with wild-type controls (Fig. 2A). Forty-eight hours of
fasting increased corticosterone levels, where this rise did not
significantly differ between genotype. Elevated corticosterone
levels of fed Sst/ mice were associated with a significant
increase in pituitary POMC mRNA levels compared with
Sst/ mice (Fig. 2B). It should be noted that the differences in
pituitary POMC expression were maintained between geno-
types following the 48-h fast. Despite the elevated levels of
POMC mRNA, Sst/ mice tended to have lower levels of
hypothalamic CRH mRNA compared with Sst/ mice, con-
sistent with corticosterone negative feedback; however, this
did not reach statistical significance (P 	 0.17). However,
fasting did result in an overall increase in CRH mRNA levels,
independent of genotype (P 	 0.05; Fig. 2C).
Effect of SST on POMC mRNA levels and ACTH release in
primary pituitary cell cultures. The enhanced levels of pitu-
itary POMC mRNA of Sst/ mice occurred independently of
increases in hypothalamic CRH expression, suggesting SST
may directly mediate pituitary ACTH synthesis. To further
explore this possibility, we examined the effects of SST (100
nM, 18 h) on POMC mRNA levels and ACTH release in
primary mouse pituitary cell cultures in the presence and
absence of CRH (10 nM), and the results are presented in Fig.
3A. In the mouse, SST alone decreased POMC mRNA levels
Fig. 1. Somatostatin (SST) mRNA levels in the hypothalamus (A) and stom-
ach (B) of fed and fasted (48 h) Sst/ and Sst/ male mice (n  5
mice/group). SST mRNA copy number was determined by quantitative real-
time RT-PCR (qrtRT-PCR), and the values were adjusted by cyclophilin A
copy number as an internal control. Values represent means 
 SE. n.d., not
detectable by qrtRT-PCR.
Fig. 2. Circulating corticosterone levels (A), pituitary proopiomelanocortico-
tropin (POMC) mRNA levels (B), and hypothalamic corticotropin-releasing
hormone (CRH) mRNA levels (C) of fed and fasted (48 h) Sst/ and Sst/
male mice (n  5–8 mice/group). Pituitary POMC mRNA and hypothalamic
CRH mRNA copy numbers were determined by qrtRT-PCR, and the values
were adjusted by cyclophilin A copy number as an internal control. Values
represent means 
 SE. *Values that differ within genotype in response to
fasting; †values that differ between genotype within dietary group. P 	 0.05
was considered significant.
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and ACTH release. Although it has been previously reported
that CRH enhances POMC mRNA levels in primary rat pitu-
itary cell cultures (12, 15), CRH did not alter POMC expres-
sion in mouse pituitary cultures but did stimulate ACTH
release, where this action was blunted by coculture with SST.
A similar dissociation between the direct pituitary effects of
CRH on POMC mRNA levels and ACTH release has been
previously reported in the sheep (26). However, it should also
be noted that CRH has been shown to enhance POMC mRNA
levels in AtT20 cells, an ACTH-producing tumor cell line
derived from a mouse pituitary (1). Therefore, the effects of
CRH on POMC expression not only vary between species but
are also dependent on the pathophysiological state of the tissue
tested.
To determine whether the inhibitory action of SST on
POMC expression and ACTH release is confined to the mouse
model, or represents a regulatory control mechanism that can
be observed across species, we repeated the in vitro experiment
using primary pituitary cell cultures from a nonhuman primate
(Papio anubis, baboon), and the results are shown in Fig. 3B.
As in the mouse, SST alone decreased POMC mRNA levels
and ACTH release following an 18-h treatment. In contrast to
the mouse, CRH stimulated both pituitary POMC mRNA
levels and ACTH release. Also, SST effectively blocked CRH
stimulation of POMC mRNA levels and blunted CRH-induced
ACTH release. Taken together, these results confirm that the
effects of CRH on pituitary ACTH synthesis are species
dependent. Nonetheless, they clearly demonstrate that SST,
independently of CRH, can work directly at the level of the
pituitary to reduce ACTH synthesis and release in two diverse
species.
Circulating ghrelin and ghrelin mRNA levels in Sst/ vs.
Sst/ mice. Total circulating ghrelin levels were dramatically
elevated in Sst/ vs. Sst/ mice in both the fed and fasted
state (Fig. 4A). The elevation in circulating total ghrelin levels
of Sst/ mice was associated with a significant increase in
ghrelin mRNA levels in the stomach (Fig. 4C). Although
Sst/ mice displayed a clear increase in ghrelin expression,
circulating levels of n-octanoyl ghrelin did not differ between
genotype (Fig. 4B). Interestingly, fasting had an overall stim-
ulatory effect on n-octanoyl ghrelin levels, where the response
reached significance in the Sst/ mice (Fig. 4B). However,
total ghrelin levels (Fig. 4A) and stomach ghrelin mRNA levels
(Fig. 4C) were not significantly altered by fasting.
Although the stomach is the primary source of circulating
ghrelin (3), ghrelin has been detected in both the hypothalamus
(39) and pituitary (22). Therefore, we also examined whether
endogenous SST and fasting interact to regulate hypothalamic
and pituitary expression of ghrelin. The hypothalamus and
pituitary did express detectable levels of ghrelin (Table 2).
However, when hypothalamic and pituitary ghrelin mRNA
levels were compared with those expressed in the stomach, the
absolute mRNA copy number was 10,000- and 5,000-fold less,
respectively. Hypothalamic ghrelin mRNA levels did not differ
between genotype or in response to fasting (Fig. 5A), incon-
sistent with reports in the rat, where hypothalamic ghrelin
mRNA levels were reduced by 24- and 48-h fasting (39). At
the level of the pituitary, ghrelin mRNA levels did not differ
between genotype; however, fasting significantly increased
pituitary ghrelin expression in both groups (Fig. 5B).
Effect of ghrelin on POMC mRNA levels and ACTH release
in primary pituitary cell cultures. It has been previously shown
that ghrelin (n-octanoyl) or its synthetic analogs do not affect
Fig. 3. Effect of 18-h treatment of SST (100
nM) and/or CRH (10 nM) on POMC mRNA
levels and adrenocorticotropic hormone
(ACTH) release in primary pituitary cell cul-
tures from mice (A) and baboons (B). POMC
mRNA copy numbers were determined by
qrtRT-PCR, and the values were adjusted by
cyclophilin A copy number as an internal
control. Values are expressed as %vehicle-
treated controls (set at 100%) within experi-
ment and represent means 
 SE of 3 inde-
pendent experiments for mice (4–6 wells/
treatment/experiment) and 2 independent
experiments for baboons (4–6 replicates/
treatment/experiment). In this set of experi-
ments, the amount of ACTH released per 2
105 cells over the 18-h period in vehicle-
treated cultures was 179 
 35 pg/ml for
mouse and 12,548
 1,049 pg/ml for baboon.
*Values that differ from vehicle-treated con-
trols; †values that differ from cultures treated
with SST or CRH alone. P 	 0.05 was
considered significant.
E399EFFECTS OF ENDOGENOUS SST ON ADRENAL AXIS AND GHRELIN
AJP-Endocrinol Metab • VOL 291 • AUGUST 2006 • www.ajpendo.org
 on O
ctober 14, 2008 
ajpendo.physiology.org
D
ow
nloaded from
 
the release of ACTH from primary rat pituitary cell cultures or
primary cultures from human fetal pituitaries (13, 41). How-
ever, a synthetic ghrelin analog was effective in stimulating
ACTH release in cultures from human corticotropinomas (7).
Given that the direct pituitary effects of ghrelin on ACTH
release may be dependent on the species, age, and physiolog-
ical state of the tissue donor, we tested the direct effects of
ghrelin (10 nM) on POMC mRNA levels and ACTH release in
primary pituitary cell cultures from normal mice and baboons,
and the results are shown in Fig. 6. Ghrelin had no significant
effect on POMC mRNA levels in pituitary cell cultures pre-
pared from mice or baboons. Likewise, ghrelin did not affect
ACTH release from mouse pituitary cells. However, ghrelin
did have a modest but significant stimulatory effect on ACTH
release in baboon pituitary cell cultures, where the values
shown are the means of five separate experiments, performed
on cultures from different baboons. In three experiments
ghrelin had no effect on ACTH release, whereas in two
experiments ghrelin showed a clear 60% increase in ACTH
released into the medium over the 18-h culture period (data not
shown). Given that these pituitary cell cultures were prepared
from randomly cycling female baboons of different ages, we
cannot exclude the possibility that reproductive environment
may alter the corticotrope response to ghrelin.
DISCUSSION
In Sst/ mice, corticosterone levels were more than dou-
bled compared with their respective Sst/ control values, as
previously reported (50). In this study, we demonstrate that
elevation in glucocorticoid levels in the Sst/ mouse are
associated with a significant increase in pituitary POMC ex-
pression, without a concomitant rise in hypothalamic CRH
expression. These in vivo results, coupled with our present in
vitro findings showing that SST can directly suppress POMC
mRNA levels and ACTH release in primary mouse pituitary
cell cultures and with the fact that pituitaries of sst2 knockout
mice release more ACTH in vitro (47), strongly support the
hypothesis that, at least in the mouse, endogenous SST can act
as a corticotropin synthesis/release-inhibiting factor (14). The
Fig. 4. Circulating total ghrelin (A), n-octanoyl ghrelin (B), and stomach
ghrelin mRNA levels (C) of fed and fasted (48 h) Sst/ and Sst/ male mice
(n  5–8 mice/group). Stomach ghrelin mRNA levels were determined by
qrtRT-PCR, and the values were adjusted by cyclophilin A copy number as an
internal control. Values represent means 
 SE. *Values that differ within
genotype in response to fasting; †values that differ between genotype within
dietary group. P 	 0.05 was considered significant.
Fig. 5. Hypothalamic (A) and pituitary (B) ghrelin mRNA levels of fed and
fasted (48 h) Sst/ and Sst/ male mice (n  5–8 mice/group). Ghrelin
mRNA copy numbers in the hypothalamus and the pituitary were determined
by qrtRT-PCR, and the values were adjusted by cyclophilin A copy number as
an internal control. Values represent means 
 SE. *Values that differ within
genotype in response to fasting. P 	 0.05 was considered significant.
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fact that the direct inhibitory actions of SST on POMC mRNA
levels and ACTH release were also observed in primary pitu-
itary cell cultures from a nonhuman primate suggests that
endogenous SST may also play an important role in regulating
corticotroph function in higher-order mammalian species, such
as humans.
We also observed that total circulating ghrelin and stomach
ghrelin mRNA levels [the primary source of circulating ghrelin
(3)] were increased in Sst/ mice, indicating that endogenous
SST tone is a critical regulator of ghrelin synthesis. This is
consistent with reports demonstrating that treatment with SST
or its synthetic analog (octreotide) suppresses circulating
ghrelin in rats and humans (6, 34, 42), where this effect is
thought to be primarily mediated via sst2 (42). The inhibitory
effect of SST on ghrelin release can also be observed following
perfusion of SST into the gastric artery, suggesting a direct
effect on gastric ghrelin production (40). In fact, SST produced
locally in the stomach may play a major role in mediating
ghrelin synthesis and release, given that SST-producing gastric
cells directly contact ghrelin-producing cells (40). In contrast
to the role of endogenous SST in regulating gastric ghrelin
expression, hypothalamic and pituitary ghrelin mRNA levels
were not altered in the Sst/ mice compared with Sst/
controls, demonstrating that the regulatory action of SST on
ghrelin expression is tissue specific.
Despite the rise in total ghrelin output, n-octanoyl ghrelin
levels were unaltered in Sst/ mice. Also, fasting resulted in
a rise in n-octanoyl ghrelin in both Sst/ and Sst/ mice
without significant changes in total circulating ghrelin levels or
stomach ghrelin gene expression, consistent with reports of
others showing no effect of fasting on total circulating ghrelin
levels in the mouse (29, 36). This is in contrast to the effects of
fasting in rats, where increases in circulating levels of n-
octanoyl ghrelin are clearly reflected by increases in total
ghrelin levels, where 90% represents the des-acyl form (31).
Our present results demonstrate that regulation of ghrelin gene
expression and posttranslational modification of ghrelin, via its
acylation, are not always linked. This disconnection has also
been observed in adult mice following feeding of C:8 medium-
chain fatty acids, where n-octanoyl ghrelin levels rose, in the
absence of changes in total ghrelin levels (32). Also, n-
octanoyl ghrelin levels, but not total ghrelin levels, are reported
to fall during the transition from suckling to weaning in mice
and rats, where milk is rich in medium-chain fatty acids (33).
Taken together, these results indicate that dietary medium-
chain fatty acids can be used as direct substrates for acylation
of existing ghrelin. Although the specific enzymatic pathway
mediating acylation of ghrelin remains to be defined, we can
conclude from our present results that endogenous SST tone
has no major impact on this process in fed or fasted mice.
We originally hypothesized that the elevated ghrelin levels
observed in the Sst/ mouse may contribute to the elevated
glucocorticoids observed in this mutant model. Previous stud-
ies indicate that the stimulatory effect of ghrelin on the adrenal
axis of the rat is not mediated by direct pituitary effects on
ACTH secretion (13), consistent with our present in vitro
results where primary mouse pituitary cell cultures were used.
Also, ghrelin does not appear to have a direct effect on adrenal
steroidogenesis (8). However, the major impact of ghrelin on
glucocorticoid production is likely mediated centrally by en-
hancing CRH neuronal activity via neuropeptide Y-mediated
suppression of GABA inhibitory tone (10). Given that the
stimulatory effect of ghrelin on CRH release requires its acyl
modification (30), we might conclude that SST-mediated al-
teration in total circulating ghrelin levels is not responsible for
alterations in the adrenal axis of the Sst/ mice. We cannot
ignore the possibility that centrally produced n-octanoyl ghre-
lin may be regulated by SST (39). If hypothalamic n-octanoyl
Fig. 6. Effect of 18-h treatment of n-octanoyl
ghrelin (10 nM) on POMC mRNA levels and
ACTH release in primary pituitary cell cultures
from mice (A) and baboons (B). POMC mRNA
copy numbers were determined by qrtRT-PCR,
and the values were adjusted by cyclophilin A
copy number as an internal control. Values are
expressed as %vehicle-treated controls (set at
100%) within experiment and represent means 

SE of 3 independent experiments for mice (4–5
wells/treatment/experiment) and 5 independent ex-
periments for baboons (4–6 replicates/treatment/
experiment). In this set of experiments, the amount
of ACTH released per 2  105 cells over the 18-h
period in vehicle-treated cultures was 1,792 
 68
pg/ml for mouse and 4,476 
 1,050 pg/ml for
baboon. *Values that differ from vehicle-treated
controls. P 	 0.05 was considered significant.
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ghrelin levels were modulated by endogenous SST, we might
have anticipated a change in CRH expression in the Sst/ on
the basis of previous observations (5, 21) showing that intra-
cerebroventricular delivery of ghrelin or GH-releasing pep-
tide-6 increases CRH mRNA levels in mice. However, the lack
of endogenous SST had no stimulatory effect on hypothalamic
CRH expression.
Taken together, these findings do not support our original
hypothesis that elevated levels of ghrelin contribute to elevated
corticosterone levels in the Sst/ mouse. However, our find-
ings do support a role for endogenous SST as a true cortico-
tropin release-inhibiting factor under basal (fed) conditions,
although endogenous SST does not play a major role in
regulating the HPA axis in the fasted state. Our results also
reveal that endogenous SST suppresses gastrointestinal ghrelin
production; however, SST does not play a role in regulating
posttranslational acylation of ghrelin in the fed or fasted state.
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a b s t r a c t
Ghrelin acts as an endocrine link connecting physiological processes regulating food intake, body com-
position, growth, and energy balance. Ghrelin is the only peptide known to undergo octanoylation. The
enzyme mediating this process, ghrelin O-acyltransferase (GOAT), is expressed in the gastrointestinal
tract (GI; primary source of circulating ghrelin) as well as other tissues. The present study demonstrates
that stomach GOAT mRNA levels correlate with circulating acylated-ghrelin levels in fasted and diet-
induced obesemice. In addition, GOATwas found to be expressed in both the pituitary and hypothalamus
(two target tissues of ghrelin’s actions), and regulated in response to metabolic status. Using primary
pituitary cell cultures as a model system to study the regulation of GOAT expression, we found that
acylated-ghrelin, but not desacyl-ghrelin, increased GOAT expression. In addition, growth-hormone-
releasing hormone (GHRH) and leptin increased, while somatostatin (SST) decreased GOAT expression.
The physiologic relevance of these later results is supported by the observation that pituitary GOAT
expression inmice lackingGHRH, SST and leptin showed opposite changes to those observed after in vitro
treatment with the corresponding peptides. Therefore, it seems plausible that these hormones directly
contribute to the regulation of pituitary GOAT. Interestingly, in all the models studied, pituitary GOAT
expressionparalleled changes in the expressionof a dominant spliced-variant of ghrelin (In2-ghrelin) and
therefore this transcript may be a primary substrate for pituitary GOAT. Collectively, these observations
support the notion that the GI tract is not the only source of acylated-ghrelin, but in fact locally produced
des-acylated-ghrelin could be converted to acylated-ghrelin within target tissues by locally active GOAT,
to mediate its tissue-speciﬁc effects.
© 2010 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
The primary source of circulating ghrelin is the stomach, where
proghrelin can be modiﬁed by the addition of an O-linked octanoyl
side group added to its serine-3 residue, via the actions of ghrelin
O-acyltransferase (GOAT) to produce acylated-proghrelin (Kojima
et al., 1999; Ariyasu et al., 2001; Garg, 2007; Gonzalez et al., 2008;
Gutierrez et al., 2008; Yang et al., 2008; Gomez et al., 2009; Sakata
et al., 2009). Then, prohormone convertase 1/3 (PC1/3) can fur-
ther process proghrelin (acylated or des-acylated) to generate the
∗ Corresponding author at: Department of Cell Biology, Physiology and Immunol-
ogy, Campus Universitario de Rabanales, Ediﬁcio Severo Ochoa (C6), Planta
3, University of Córdoba, E-14014 Córdoba, Spain. Tel.: +34 957 21 85 94;
fax: +34 957 21 86 34.
E-mail address: raul.luque@uco.es (R.M. Luque).
mature 28-amino acid peptide ghrelin (Garg, 2007). Only a small
proportion of circulating ghrelin is acylated, while the remaining is
in theunmodiﬁedordes-acylated form,whereboth formshavebio-
logical effects (vander Lely et al., 2004;KojimaandKangawa, 2005).
Acylated-ghrelin is the primary endogenous ligand for the growth
hormone secretagogue receptor (GHS-R), and it is now recognized
that the acyl-ghrelin/GHS-R system exerts actions on multiple tis-
sues, many of them related to regulation of metabolic functions
(for review, van der Lely et al., 2004). In particular, acylated-ghrelin
works at the level of the hypothalamus as a potent orexigenic sig-
nal (Kojima and Kangawa, 2005), and at the level of the pituitary
to modulate hormone release including augmentation of growth
hormone (GH), adrenocorticotropin (ACTH) and prolactin release
(Kojima and Kangawa, 2005; Gahete et al., 2009). In addition,
acylated-ghrelin acts systemically to regulate glucose homeosta-
sis and adiposity, where the deletion of the genes encoding ghrelin
or its receptor prevents diet-induced obesity, improves insulin sen-
0303-7207/$ – see front matter © 2010 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.mce.2009.12.023
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sitivity and enhances glucose-stimulated insulin secretion (Yada et
al., 2008).
Although theGI track is considered themajor sourceof acylated-
ghrelin, other tissues express ghrelin, PC1/3 and GOAT (Gonzalez
et al., 2008; Gutierrez et al., 2008; Yang et al., 2008) (for review,
van der Lely et al., 2004). Therefore, it is possible that locally
producednon-acylated-proghrelinmight be converted to acylated-
proghrelin within target tissues by locally active GOAT, to mediate
tissue-speciﬁc effects. Local production of acyl-ghrelin is supported
by a recent report demonstrating that acylated-ghrelin can be
produced by a thyroid and a pituitary cell line that express ghre-
lin, PC1/3 and GOAT if n-octanoic acid is available as a substrate
(Takahashi et al., 2009). Given the fact that hypothalamus and pitu-
itary are targets for acylated-ghrelin, coupled with the fact that
these tissues also express ghrelin (for review, van der Lely et al.,
2004), GOAT (Gonzalez et al., 2008; Gutierrez et al., 2008; Yang
et al., 2008) and PC1/3 (Dong and Day, 2002; Nillni, 2007), it is
possible that local production of acylated-ghrelin, as well as that
produced by the GI tract, may play an important role in regu-
lating this neuroendocrine axis in response to metabolic signals.
Therefore, the goals of the current study were (1) to determine
whether GOAT expression in the stomach correlates with circulat-
ing acylated-ghrelin levels in mice under conditions of metabolic
stress (i.e., fasting, and obese mouse models), (2) to conﬁrm if
GOAT is expressed within the hypothalamus and pituitary and
if expression levels are mediated by metabolic stress and (3) to
determine whether primary regulatory factors for the pituitary-
metabolic interface candirectly regulateGOATexpression, byusing
primary mouse pituitary cell cultures as a model system.
2. Material and methods
2.1. Animals and cell culture
All experimental procedures were approved by the Animal Care and Use Com-
mittees of the University of Cordoba, University of Illinois at Chicago and the Jesse
Brown VA Medical Center. Mice were housed under standard conditions of light
(12-h light, 12-h dark cycle; lights on at 07:00h) and temperature (22–24 ◦C),
with free access to tap water and food (standard rodent chow; LabDiet, St. Louis,
MO, USA; Catalog no. 5008; fat, 17kcal%, carbohydrate, 56kcal%; protein, 27kcal%).
Leptin-deﬁcient ob/ob mice and their corresponding controls were purchased from
Jackson Laboratories, while growth-hormone-releasing hormone (GHRH), somato-
statin (SST) and neuropeptide Y (NPY) knockout mice were bred in house. Original
breeders were obtained from Dr. Ute Hochgeschwender (SST-KO), Dr. Richard D.
Palmiter (NPY-KO) and Dr. Roberto Salvatori (GHRH-KO) as previously reported
(Alba and Salvatori, 2004; Park et al., 2005; Luque et al., 2006, 2007b,c; Luque and
Kineman, 2006, 2007).Micewerehandleddaily at least 1weekprior to euthanasia to
acclimate them to personnel and handling procedures andwere sacriﬁced by decap-
itation, without anesthesia, under fed conditions unless otherwise speciﬁed. Trunk
blood was immediately mixed with MiniProtease inhibitor (Roche, Nutley, NJ) and
placed on ice, centrifuged and plasma was stored at −80 ◦C until analysis of total-
and acylated-ghrelin by ELISA (Linco, St. Charles, MO) following the manufacturer’s
instructions, including the addition of hydrochloric acid at a ﬁnal concentration of
0.05N in order to prevent rapid des-acylation of ghrelin after the plasma collection.
Tissues (stomachs, pituitaries and hypothalami) were immediately frozen in liquid
nitrogen and stored at −80 ◦C until further analysis of mRNA levels by quantitative
real-time RT-PCR (qrtRT-PCR; see below).
2.2. Inﬂuence of metabolic stress on circulating total and acylated-ghrelin and
stomach, pituitary and hypothalamic GOAT mRNA levels
For these studies, serumand tissues previously processed and analyzed for other
endpoints were used, where each study is listed below followed by a brief summary
of the experimental design. Fasting – Ten-week-old male C57Bl/6J mice were either
fed ad libitumor fasted for 12h (food removedat 19:00h), 24hor 48h (food removed
at 07:00h) (Luque et al., 2007c). An additional group of 8–9-week-old male C57Bl/6
x FVBN mice (n=5/group) were also fed ad libitum or fasted for 24h (Kineman et
al., 2007). For these and subsequent studies all tissues and blood were collected
between07:00and09:00h.Diet-inducedobesity (DIO) –MaleC57Bl/6Jmice (n=6–7)
were fed a low-fat (LFD; 10kcal% from fat) or a high-fat (HFD; 60kcal% from fat) diet
starting at 4 weeks of age and killed at 20 weeks (Luque and Kineman, 2006). Leptin-
deﬁcient mice (ob/ob) – Blood and tissues were analyzed from 10-week-old ob/ob
mice and their littermates-controls (ob/?), as well as from ob/ob mice treated with
vehicle (control 1), leptin (7d via osmotic mini-pumps released at a rate of 0.5l/h,
delivering a total of 15.6g of leptin each day) or from a group of ob/ob mice pair-
fed along with the leptin-treated animals that was used as an additional control
(control 2) to match the food intake of leptin-treated mice (Luque and Kineman,
2006; Luque et al., 2007a) in order to differentiate between direct effects of leptin
and thosemediated indirectly by leptin-induced reduction in food intake andweight
loss.
2.3. Direct regulation of GOAT mRNA levels by acylated-ghrelin, desacyl-ghrelin,
GHRH, SST, leptin, NPY, insulin and IGF-I in mouse primary pituitary cell cultures
To examine whether primary regulatory hormones for the pituitary-metabolic
interface can directly control pituitary GOAT expression, pituitaries of 8–12-
week-old male C57Bl6 mice obtained from “Centro de Instrumentación Cientíﬁca”
(University of Granada, Spain) or from Jackson Laboratories (Bar Harbor, ME, USA)
were enzymatically dispersed (n=3–5 pituitaries pooled/experiment, 6–7 sepa-
rate experiments) into single cells and cultured (250,000 cells/well, 24-well plates)
in serum containing -MEM, as previously described (Luque et al., 2006; Luque
and Kineman, 2006). After 24–48h of culture, media was removed and wells were
washed in serum-freemediaandsubsequently treatedwithmouseacylated-ghrelin,
desacyl-ghrelin, GHRH,NPY, insulin, IGF-I (10nMeach), SST-14 (100nM) andmouse
leptin (10ng/ml), for 24h (Sigma, Saint Louis, MO or Phoenix, Burlingame, CA, USA),
and then total cellular RNA was extracted for determination of GOAT mRNA lev-
els by qrtRT-PCR (see below). In order to determine if the direct actions of GHRH,
SST, NPY or leptin could be important in maintaining in vivo expression of pitu-
itary GOAT, total RNA obtained from pituitaries of 9–11-week-old GHRH-knockout
(KO) (B6129PF1/J), SST-KOmice (C57Bl/6J),NPY-KOmice (129/sv), leptin-KO(ob/ob;
C57Bl/6J) and their respective littermate controls used in other studies (Alba and
Salvatori, 2004; Park et al., 2005; Luque et al., 2006, 2007b,c; Luque and Kineman,
2006, 2007), were also evaluated from GOAT mRNA levels by qrtRT-PCR.
2.4. RNA isolation and reverse transcription (RT)
Tissues and cell cultures were processed for recovery of total RNA using the
Absolutely RNA RT-PCR Miniprep Kit with Deoxyribonuclease treatment (Strata-
gene, La Jolla, CA) as previously described (Luque et al., 2006, 2007c; Luque and
Kineman, 2006, 2007). The amount of RNA recovered was determined using the
Ribogreen RNA quantiﬁcation kit (Molecular Probes, Eugene, OR). Total RNA (1g
for whole tissue extract and 0.25g for primary cell cultures) was reversed tran-
scribed with enzyme and buffers supplied in the cDNA First Strand Synthesis kit
(MRI Fermentas, Hanover, MD). cDNA was treated with ribonuclease H (1U; MRI
Fermentas) and duplicate aliquots (1l) were ampliﬁed by qrtRT-PCR, in which
samples were run against synthetic standards to estimate mRNA copy number, as
described below.
2.5. Quantiﬁcation of GOAT and ghrelin mRNA levels by qrtRT-PCR
Details regarding the development, validation, and application of a qrtRT-PCR to
measure expression levels ofmouse transcripts, includingghrelinmRNA levels, have
been reported previously (Luque et al., 2006, 2007a,c; Luque and Kineman, 2006,
2007; Kineman et al., 2007). Speciﬁc primer sequences, GenBank accession numbers
and product sizes for mouse GOAT, ghrelin and cyclophilin used in this study were
as follows: GOAT (Mboat4; forward 5′-ATTTGTGAAGGGAAGGTGGAG-3′ and reverse
5′-CAGGAGAGCAGGGAAAAAGAG-3′ , NM 001126314, 120bp); ghrelin (forward
5′-TCCAAGAAGCCACCAGCTAA-3′ and reverse 5′-AACATCGAAGGGAGCATTGA-3′ ,
NM 021488, 126bp) and cyclophilin (forward 5′-TGGTCTTTGGGAAGGTGAAAG-3′
and reverse 5′-TGTCCACAGTCGGAAATGGT-3′ , NM 008907, 109bp). Primers were
selected using Primer 3 software (Rozen and Skaletsky, 2000)with selection param-
eters set to identify primer sets that: (1) span an intron (when possible), (2) differ
by no more that 1 ◦C in annealing temperature, (3) are at least 20bp in length, (4)
have a GC content between 45 and 55%, but (5) exclude primers that may form
primer-dimers. Sequences of selected primers were used in BLAST (NCBI) searches
to check forpotential homology to sequencesother than thedesignated target. Initial
screening of primer efﬁciency using real-time detection was performed by ampli-
fying 2-fold dilutions of RT products, where optimal efﬁciency was demonstrated
by a difference of one cycle threshold between dilutions and a clear melting peak
followed by a graded temperature-dependent dissociation to verify that only one
product was ampliﬁed. The thermocycling proﬁle consisted of one cycle of 95 ◦C for
10min, 40 cycles of 95 ◦C for 30 s, 61 ◦C for 1min, and 72 ◦C for 30 s. PCR products
were then column-puriﬁed (QIAGEN, Valencia, CA) and sequenced to conﬁrm target
speciﬁcity. After conﬁrmation of primer efﬁciency and speciﬁcity, the concentration
of puriﬁed products was determined using Molecular Probe’s Picogreen DNA quan-
tiﬁcation kit, and PCR products were serial diluted to obtain standards containing
1, 101,102, 103, 104, 105, and 106 copies of synthetic template. Standards were then
ampliﬁed by real-time PCR, and standard curves were generated using Stratagene
Mx3000p software. The slope of a standard curve for each template examined was
approximately −3.33 (R2 ≈1), indicating that the efﬁciency of ampliﬁcation of our
primers was 100%, meaning that all templates in each cycle were copied. To deter-
mine the starting copy number of cDNA, RT samples were PCR ampliﬁed and the
signal was compared with that of a speciﬁc standard curve of each transcript run on
thesameplate. Inaddition, totalRNAsamples thatwerenot reversed transcribedand
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a no DNA control were run on each plate to control for genomic DNA contamination
and tomonitor potential exogenous contamination, respectively. Also, to control for
variations in the amount of RNA used in the RT reaction and the efﬁciency of the
RT reaction, mRNA copy number of the transcript of interest was adjusted by the
mRNAcopynumber of cyclophilinA (used ashousekeeping gene),where cyclophilin
AmRNA levels didnot signiﬁcantly varybetweenexperimental groups,within tissue
type or treatment group (data not shown).
2.6. Data presentation and statistical analysis
Samples fromall groupswithin an experimentwere processed at the same time.
The effects of fasting and leptin replacement were assessed by one-way ANOVA
followed by a Newman–Keuls test for multiple comparisons, while the effects of
obesity, genotype and the in vitro effects of acylated-ghrelin, desacyl-ghrelin, GHRH,
SST, NPY, leptin, insulin and IGF-I were assessed by Student’s t-test. p<0.05 was
considered signiﬁcant. All data are expressed as means± SEM. The in vivo effects of
fasting/obesity/genotype were obtained from a minimum of 5 animals per group.
Results from in vitro studieswere obtained from3 to 7 separate, independent exper-
iments (3–5 wells/treatment) carried out in different days and with different cells
preparation. Endpoints displaying heterogeneity of variance were log transformed
prior to analysis. All statistical analyseswere performedusing theGB-STAT software
package (Dynamic Microsystems, Inc., Silver Spring, MD, USA).
3. Results and discussion
3.1. Quantiﬁcation of GOAT mRNA levels in mouse stomachs,
pituitaries and hypothalami
Using qrtRT-PCR, we found that GOAT mRNA levels were 5-
fold greater in the stomach as compared to the pituitary and
hypothalamus (Table 1). These results are consistent with other
reports showing relative expression levels of GOAT in both human
(Gutierrez et al., 2008) and rodent (Gonzalez et al., 2008; Yang et
al., 2008; Sakata et al., 2009) tissues. Interestingly, the expression
level of GOAT transcripts in the mouse tissues analyzed in the cur-
rent study (Table 1) paralleled the mRNA levels of ghrelin in the
same tissues (stomachpituitary =hypothalamus), as previously
reported (Kineman et al., 2007).
Since it has been previously reported that the enzyme PC1/3
which is required for the conversion of preprohormones, including
pre-proghrelin to its 28 amino acid form, is also expressed in the
pituitary and hypothalamus (Dong and Day, 2002; Nillni, 2007),
as well as the GI tract (Macro et al., 1996), it is possible that the
source of acylated-ghrelin within the pituitary and hypothalamus
may include locally produced ghrelin, in addition to that found in
the circulation. Therefore, the current study compared the impact
ofmetabolic stress (fasting and obesity) on circulating ghrelin (acy-
lated and total) levels, as well as GOAT and ghrelin mRNA levels in
the stomach, pituitary and hypothalamus. Speciﬁcally, Fig. 1 illus-
trates the impact of fasting, diet-induced obesity (DIO) and obesity
caused by leptin deﬁciency (ob/ob mice) on circulating acylated-
and total-ghrelin levels and stomach GOAT mRNA levels (panels A,
B and C, respectively), as well as pituitary and hypothalamic GOAT
mRNA levels (panels D, E and F, respectively). It should be noted
that, in some cases we have previously published the regulation of
stomach, pituitary and hypothalamic ghrelin mRNA levels in these
Table 1
Absolute cDNA copy number/0.05g total RNA of GOAT gene transcripts in the
stomach, pituitary and hypothalamus ofmale C57Bl/6mice, as determined by quan-
titative real-time RT-PCR.
GOAT mRNA copy #
Whole tissue:
Stomach 357 ± 46
Pituitary 67 ± 8
Hypothalamus 73 ± 5
Primary pituitary cell culture: 63 ± 2
Values represent means± SEM (n=27–43 control tissues or control culture-
wells/experimental or treatment group).
model systems (Kineman et al., 2007; Luque et al., 2007a,c). These
results are summarized in Fig. 1 as the relative changes in ghrelin
mRNA levels (=,↑,↓), as compared to controls, as shownbeloweach
graph of tissue-speciﬁc GOAT expression.
3.2. Effects of nutrient deprivation on GOAT/ghrelin axis
As shown in Fig. 1, panel A, fasting did not alter circulat-
ing levels of total-ghrelin or stomach ghrelin expression, but did
increase circulating acylated-ghrelin (12 and 24h) and stomach
GOAT mRNA levels (24h). The impact of 24h fasting on stomach
GOAT mRNA levels was conﬁrmed in tissues taken from an inde-
pendent set ofmalemice fromanother study (Kinemanet al., 2007),
using two different primer sets for ampliﬁcation of the GOAT tran-
scripts (supplemental Fig. 1). These results differ from those of a
recent report by Kirchner et al. (2009) showing that fasting (12,
24 and 36h) signiﬁcantly increased total-ghrelin levels and tended
to increase acylated-ghrelin levels, but unexpectedly suppressed
stomach GOAT mRNA in C57Bl/6 male mice. It is possible that such
differences may be related to the time of food withdrawal, time of
sample collection, type of standard rodent chow provided and/or
the method of euthanasia which were not clearly deﬁned in that
study. In fact, Kirchner et al. (2009) observed a diurnal pattern of
circulating ghrelin and stomach ghrelin/GOATmRNA levels, aswell
as an association between stomach GOAT expression and the type
of dietary lipids supplied. It is also possible that the differences
observed are related to the analytical techniques applied, where
circulating ghrelin levels were assessed by commercial assays in
the current study, but in the case of Kirchner et al. (2009), were
assessed byMALDI-TOFmass spectrometry of immunoprecipitated
ghrelin. Finally, with respect to GOAT mRNA levels, although both
the current study and that of Kirchner et al. (2009) used real-time
RT-PCR, the primer sets used and the characteristics and prop-
erties of the primers were not the same (length of primers, GC
content, etc.). Nonetheless, our current observations are consis-
tent with other reports showing a clear rise in acylated-ghrelin
levels in fasted humans and other species (for review: Casanueva
and Dieguez, 2002; Gottero et al., 2004; Kojima and Kangawa,
2005; Williams and Cummings, 2005; Cummings, 2006), includ-
ing mice (Perreault et al., 2004; Luque et al., 2006, 2007c; Zizzari
et al., 2007), as well as an increase in stomach GOAT mRNA lev-
els in rats subjected to 21 days of caloric-restriction (Gonzalez et
al., 2008). However, it should be noted that like Kirchner et al.,
Liu et al. failed to detect a rise in circulating acylated-ghrelin in
fasted humans (Liu et al., 2008). It should also be emphasized that
in the current study the fasting-induced rise in acylated-ghrelin
was observed at 12 and 24h, but began to fall after 48h, while
the fasting-induced rise in GOAT mRNA was only observed at 24h.
These results suggest that an increase in GOAT expression levels
in the stomach may only in part contribute to the rise in circulat-
ing acyl-ghrelin, where enhanced GOAT activity and/or substrate
availability may precede that process. However, after 48h of fast-
ing circulating acylated-ghrelin levels and GOAT mRNA levels did
not differ from controls (Fig. 1, panel A), where 48h of fasting in
a mouse represent a severe catabolic state (Luque et al., 2007c).
This observation is consistent with reports showing that the pro-
portion of circulating acylated-ghrelin falls after long-term fasting
in humans (61.5h-fasting) (Liu et al., 2008) and rats (48h-fasting)
(Toshinai et al., 2001; Gonzalez et al., 2008) and with the recent
observation indicating that 48h of fasting did not signiﬁcantly alter
stomach GOAT mRNA expression in rats (Gonzalez et al., 2008;
Takahashi et al., 2009). Taken together our current results sug-
gest that changes in stomach GOAT expression may contribute
in part to fasting-induced changes in circulating acylated-ghrelin
levels, a hypothesis previously put forth by other laboratories
(Gonzalez et al., 2008; Gualillo et al., 2008). However, given the
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Fig. 1. Circulating total- and acylated-ghrelin and stomach, hypothalamus and pituitary GOAT mRNA levels in: mice fed ad libitum or fasted for 12-, 24-, and 48-h (panels A
and D), mice fed a low-fat diet (LFD control group) or high-fat diet (HFD obese group) (panels B and E) and lean controls (/?) and obese (ob/ob) mice (panels C and F). Values
are shown as mean± SEM (n=5–8 mice/group) and expressed as percent of the respective control group (set at 100%). Group means that do not share a common letter (a and
b) signiﬁcantly differ (p<0.05; panels A and D). Asterisks (*p<0.05, **p<0.01) indicate values that signiﬁcantly differ from lean control LFD or /? values. The tissue-speciﬁc
regulation of ghrelin mRNA levels in these mice models as previously reported (Kineman et al., 2007; Luque et al., 2007a,c) are shown below each graph of tissue-speciﬁc
GOAT expression and are provided as the relative changes (=, ↑, ↓) as compared to controls.
only other report examining this relationship in mice gave dif-
ferent results (Kirchner et al., 2009), and the fact that there are
many potential levels of GOAT regulation (transcriptional, trans-
lational, enzyme activity level, substrate availability), it will be
important for other laboratories to validate and conﬁrm these ﬁnd-
ings.
3.3. Effects of obesity on GOAT/ghrelin axis
As shown in Fig. 1, panel B, diet-induced obesity tended (50%
reduction, p=0.13) to suppress total-ghrelin levels in mice with-
out altering acylated-ghrelin levels, consistent with a signiﬁcant
decline in stomach ghrelin expression, while GOAT mRNA levels
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remained unchanged. In contrast, obesity as a result of leptin deﬁ-
ciency (ob/ob mice; Fig. 1, panel C) led to a signiﬁcant decline
in circulating acylated-ghrelin levels (and a downward trend in
total-ghrelin levels), changes which were accompanied by a sig-
niﬁcant decrease in stomach ghrelin but not GOAT mRNA levels,
similar to DIO mice. This is the ﬁrst report to explore the impact
of DIO on stomach GOAT and ghrelin expression, while a previ-
ous study showed similar results for stomach GOAT and ghrelin
mRNA levels in ob/ob mice (Kirchner et al., 2009). In addition,
others have reported a signiﬁcant decline in total- or desacyl-
ghrelin in DIO (Ueno et al., 2007) and obese Ay (Nonogaki et al.,
2006) mice and a reduction in total- and acylated-ghrelin lev-
els in obese humans (Casanueva and Dieguez, 2002; Gottero et
al., 2004; Ghigo et al., 2005; Kojima and Kangawa, 2005), where
DIO-induced alterations in acylated-ghrelin levels may be depen-
dent on the time of day sampled (Perreault et al., 2004). Taken
together these results indicate that the decline in circulating total-
ghrelin levels in the obese state could be in part due to a decline
in stomach ghrelin gene expression, however alterations in cir-
culating acylated-ghrelin may be related to factors independent
of GOAT expression, such as the rate of degradation of acylated-
ghrelin, GOAT enzyme activity levels or substrate (ghrelin or fatty
acid) availability.
3.4. Impact of metabolic stress (fasting and obesity) on
hypothalamic and pituitary GOAT expression
As shown in Fig. 1, panel D, fasting also enhanced expression of
GOAT at both the hypothalamic [at 48h (p=0.0016)] and pituitary
[24h (p=0.017) and 12h (p=0.051)] level. Interestingly, it should
be noted that the timing of the GOAT mRNA rise was different
from that observed in the stomach (Fig. 1, panel A). Conversely, DIO
(Fig. 1, panel E) andobesity caused by leptin deﬁciency (Fig. 1, panel
F) did not alter hypothalamic GOAT expression, but did result in a
signiﬁcant decline in pituitary GOAT mRNA levels. As in the stom-
ach, hypothalamic and pituitary GOAT expression did not always
parallel local changes in ghrelin expression. Taken together, these
results suggest that local production (ghrelin gene expression)
and/or modiﬁcation (via GOAT gene expression) of ghrelin may
contribute to the regulation of hypothalamic and pituitary function
independent of circulating ghrelin levels produced by the stomach
which would be supported by a recent study indicating that var-
ious cell lines, including the mouse pituitary cell line AtT20, can
produce acylated-ghrelin when both ghrelin and GOAT are present
in the cells andwhen substrate (fatty acid) is available in the culture
medium (Takahashi et al., 2009).
3.5. Direct regulation of GOAT mRNA levels by ghrelin,
desacyl-ghrelin, GHRH, SST, leptin, NPY, insulin and IGF-I in
mouse primary pituitary cell cultures
Given the dynamic changes in pituitary GOAT expression in
both fasting (up-regulation; Fig. 1, panel D) and obesity (down-
regulation; Fig. 1, panels E and F), we used primarymouse pituitary
cell cultures as a model system to explore which central or sys-
temic factors might mediate these changes. First, to conﬁrm that
mouse primary pituitary cells maintain differentiated function (i.e.
GOAT expression) after dispersion and culture, the absolute mRNA
levels (copy numbers/0.05g total RNA) of GOAT were compared
between whole tissue extracts and extracts prepared from pitu-
itary cultures 24h after incubation in serum-free media, and the
results are shown in Table 1. Transcript levels did not signiﬁcantly
vary between in vivo and in vitro samples, indicating that the cell
preparation and culture conditions were appropriate to maintain
GOAT expression. Based on reports from our laboratory and others
showing that the levels and/or actionsof ghrelin,GHRHandNPYare
Fig. 2. Top panel: Effect of 24-h treatment with acylated-ghrelin, growth-hormone-
releasinghormone (GHRH), somatostatin (SST), neuropeptideY (NPY), leptin, insulin
and IGF-I onGOATmRNA levels inmouse primary pituitary cell cultures. Data repre-
sent the mean± SEM (n=3–7 experiment performed in different cell preparations;
3–4 wells/treatment). Bottom panel: GOAT mRNA expression levels in pituitaries of
growth-hormone-releasing hormone knockout (GHRH-KO), somatostatin knockout
(SST-KO), neuropeptide Y knockout (NPY-KO) and ob/ob (leptin deﬁcient)mice. Val-
ues are shown as mean± SEM and expressed as percent of intact control mice (set
at 100%; n=5–9 mice/group). Asterisks (*p<0.05, **p<0.01, ***p<0.001) indicate
values that signiﬁcantly differ from respective controls (shown by the dotted line
set at 100%).
up-regulated in fasting (Henry et al., 2001; Park et al., 2005; Luque
et al., 2006, 2007c; Kirchner et al., 2009) and down-regulated in
obesity (Tannenbaum et al., 1990; Ahmad et al., 1993; Maccario et
al., 1999; Lin et al., 2000; Perreault et al., 2004; Luque andKineman,
2006; Nonogaki et al., 2006; Luque et al., 2007a) while those for
SST, leptin, insulin and IGF-I are down-regulated in fasting (Henry
et al., 2001; Frystyk, 2004; Park et al., 2005; Luque et al., 2006;
Gonzalez et al., 2008) and up-regulated in obesity (Zhou et al.,
1997; Frystyk, 2004; Luque andKineman, 2006; Luque et al., 2007b,
2008), we incubated primary pituitary cell cultures with these hor-
mones for 24h and measured the impact on GOAT mRNA levels. As
shown inFig. 2, toppanel, acylated-ghrelin clearly stimulatedGOAT
expression compared to vehicle-treated controls (set at 100%). In
order to conﬁrm that this effect on GOAT mRNA levels was directly
exerted by acylated-ghrelin and not by desacyl-ghrelin (as result of
a des-octanoylationof acylated-ghrelin in thepituitary cell cultures
after 24h of incubation), pituitary cell cultures were treated with
desacyl-ghrelin for 24h. The results clearly indicate that treatment
with desacyl-ghrelin did not alter GOAT mRNA levels. In addition,
as shown in Fig. 2 (top panel), GHRH and leptin stimulated and
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Table 2
Relative effect of metabolic condition (fasting, obesity) or inactivating mutations in
growth-hormone-releasing hormone (GHRH), somatostatin (SST) or leptin genes
on pituitary GOAT, ghrelin and In2-ghrelin variant mRNA levels, as determined
by quantitative real-time RT-PCR. This summary represents data presented in the
current report, combined with previously published reports (Kineman et al., 2007;
Luque et al., 2007a,c).
GOAT mRNA Native ghrelin In2-ghrelin
Fasting 24h ↑ ↑ ↑
Diet-induced obese ↓ No change ↓
GHRH-KO ↓ No change ↓
SST-KO ↑ ↑ ↑a
Leptin-KO (ob/ob) ↓ ↓ ↓
a Differences observed only in females.
SST inhibited pituitary GOAT expression, while NPY, insulin and
IGF-I had no effect, compared to vehicle-treated controls (set at
100%). In order to determine if these direct actions might also be
important in maintaining pituitary GOAT expression in vivo, we
examined pituitary expression of GOAT in available mouse mod-
els that lack GHRH, SST, NPY and leptin. Accordingly, we found
an opposite effect of GHRH-KO, SST-KO and leptin-KO on pituitary
GOAT expression, as compared to that observed after in vitro treat-
ment with the corresponding hormone (Fig. 2, bottom panel). It is
also interesting to note that when the impact of leptin replacement
wasexamined in theob/obmodel (Luqueet al., 2007a),weobserved
that pituitary and stomach GOAT mRNA levels were greater than
that observed in pair-fed controls (supplemental Fig. 2), which is
consistent with the report of Gonzalez et al. (2008) showing that
administration of exogenous leptin markedly increased expression
levels of GOAT in the stomach of fasted rats. Taken together these
results indicate that acylated-ghrelin may in fact regulate its own
production at the level of the pituitary by increasing the expression
of GOAT. In addition, these results clearly demonstrate that GHRH,
SST and leptin are key regulators of pituitary GOAT expression, an
observation which may in part explain changes in pituitary GOAT
expression observed in response to metabolic extremes. Intrigu-
ingly, the substrate of GOAT activity in themouse pituitarymay not
be limited to native ghrelin being locally produced within the pitu-
itary, because our laboratory has identiﬁed a spliced mRNA ghrelin
variant containing exon2, intron2 and exon3, but lacking exon1, 4
and5 (In2-ghrelin variant; Kinemanet al., 2007)which is expressed
at higher levels than the native ghrelin transcript in the pituitary
(139±24 copies for In2-ghrelin variant versus 18±3 copies for
native ghrelin/0.05g RNA). If this variant is translated, it would
encode a protein that would include the ﬁrst 36 amino acid of the
pre-proghrelin,where residues24–28 represent theﬁrstﬁveamino
acidsofmatureghrelin and thus contain theSer-3acylation site. It is
interesting to note thatwhenwe compared the impact ofmetabolic
stress (fasting and DIO) or GHRH, SST and leptin deﬁciency on pitu-
itary expression of GOAT, native ghrelin and In2-ghrelin, the levels
of GOAT expression paralleled those of In2-ghrelin variant but not
native ghrelin, in all cases (summarized in Table 2, and details
presented in supplemental Fig. 3). Based on these observations it
seems reasonable to propose that the In2-ghrelin variant could be
a primary substrate for GOAT in the anterior pituitary gland.
Although more experiments are required to fully elucidate
the physiologic signiﬁcance of our ﬁndings in the pituitary, our
data give credence to the possibility that local production and/or
modiﬁcation of ghrelin (des-acylated to acylated via GOAT gene
expression) may contribute to the ﬁne regulation of pituitary func-
tion in response to metabolic stress. For example, circulating GH
levels are known to rise in response to fasting in the mouse, and
this is associated with an increase in pituitary expression of GH,
GHRH-R and GHS-R and a decline in SST receptor expression (rat
and mouse; Luque et al., 2007a, 2008). The acute rise in systemic
acylated-ghrelin, in combination with an increased sensitivity of
the pituitary to ghrelin and GHRH actions, might initiate local pro-
duction of acylated-ghrelin by augmentation of ghrelin and GOAT
expression, thereby acting as a positive ultrashort feedback loop
to enhance or facilitate GH release. In contrast, GH output is sup-
pressed in obesity, an effect which is believed to be due in part to
enhanced SST tone (for review see Luque et al., 2008) and a decline
in pituitary of GHRH-R, GHS-R and GH (Luque and Kineman, 2006;
Luque et al., 2008). In this context, our data would support the idea
that part of the negative effects of SST on somatotrope function
could include direct suppression of GOAT expression and a decline
of locally produced acylated-ghrelin, further contributing to the
decline in GH release observed with weight gain.
In summary, we report herein a series of novel analyses
on the regulation of the mouse GOAT/ghrelin system at the
circulating-stomach–pituitary-hypothalamic levels by energy sta-
tus and relevant metabolic cues in the mouse. By applying a
combination of studies involving in vivo models (fasting, obesity
and knockout mice) and primary pituitary cell cultures, our results
further characterize the impact of changes in body energy stores on
the expression of GOAT in different tissues and deﬁne the role of
key regulators, such as acylated-ghrelin itself, GHRH, SST and lep-
tin on the control of GOAT expression in the mouse. The fact that
GOAT mRNA levels are oppositely regulated in extreme metabolic
states (fasting, DIO) and its regulation is tissue-dependent suggests
that this enzyme may be of biological relevance in coordinating
the neuroendocrine response to metabolic stress. Although much
work remains to be done to fully understand howGOATﬁts into the
control of energy homeostasis, our results reinforce the contention
thatGOAT/acylated-ghrelin systemcould operate as a novelmolec-
ular conduit for the integration of energy balance, metabolism and
pituitary function.
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Abstract 
Alzheimer disease (AD) is a progressive neurodegenerative disorder characterized by 
severe cognitive deficit, wherein the impairment of episodic memory is the major 
hallmark. AD patients exhibit augmented accumulation of amyloid-β (Aβ) and 
hyperphosphorylated tau protein in specific brain regions. In addition, several 
neuropeptides/neurotransmitter axes clearly associated with cognitive processes, Aβ 
turnover, and tau phosphorylation have also been found to be impaired in AD, such as 
somatostatin(SST)/cortistatin(CST) and dopamine(DA) systems. However, to date there is 
no precise quantitative data on the expression of these systems in the human brain of AD 
and normal patients. Here we measured by quantitative real-time PCR the mRNA levels of 
SST/CST, DA and their receptors (sst1-5 and drd1-5, respectively) in addition to neprilysin 
(a SST-regulated enzyme involved in Aβ degradation) in three regions of the temporal 
lobe, one of the cortical regions most severely affected by AD. Our results reveal that some 
components of SST/CST- and DA-axes are divergently altered in the three areas of AD 
patients. Despite this region-specific regulation, an overall, common reduction of these 
systems was observed in the temporal lobe of AD patients. Conversely, neprilysin 
expression was not altered in AD, suggesting that Aβ accumulation observed in AD is due 
to a lack of neprilysin activation by SST rather than to a reduction of its expression. 
Collectively, our results define a comprehensive scenario wherein reduction of ssts, drds, 
and sst ligands SST and CST, could be involved, at least in part, in some of the more 
important defects observed in AD. 
 
 
Keywords:  Somatostatin, cortistatin, dopamine, somatostatin receptors (ssts), dopamine 
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Introduction 
Alzheimer disease (AD) is a progressive neurodegenerative disorder diagnosed to more 
than 50% of people above the age of 85 [1] and represents the predominant cause of 
senile dementia. Since the first and most severe cognitive deficit in AD is the impairment 
of episodic memory and the temporal lobe is essential for episodic memory functions, the 
major AD pathology is located in this structure [2]. Neuropathologically, AD is 
characterized by the intracellular aggregation of hyperphosphorylated tau protein 
comprising neurofibrillar tangles (NFTs) [3] and the extracellular accumulation of 
amyloid-β (Aβ) in senile plaques (SP), mainly located in the temporal lobe of the brain [2]. 
The steady-state level on Aβ is determined by its synthesis/clearance balance. In contrast 
to familial AD, the underlying pathogenic mechanism of sporadic cases of AD is still 
unclear. However, some authors have suggested that the impaired clearance of Aβ could 
be responsible for these cases of AD [4, 5]. Aβ catabolism is mediated by a group of 
proteolytic enzymes (i.e. neprilysin) which exhibit different subcellular localization and 
act on distinct forms of Aβ [6, 7]. Indeed, neprilysin seems to play a key role in decreasing 
the levels of Aβ deposition in brain [8-10]. However, data concerning its mRNA expression, 
protein levels and activity in AD brains are still controversial [11-16]. 
Although NTFs and SP are the major hallmarks of this disease, abnormalities in several 
neuropeptides and neurotransmitters have also been suggested to play an important role 
in AD. Specifically, somatostatin (SST) is one of the most selectively reduced 
neuropeptides in the brain of AD patients and, to date, is the only tested peptide capable to 
upregulate neprilysin activity in primary cortical neurons [17, 18]. Moreover, we have 
recently shown that SST and its highly related peptide cortistatin (CST) act as potent 
inhibitors of tau phosphorylation [19].  
Dopamine (DA) is a well-known neurotransmitter involved in cognitive functions. 
Although some studies suggest that DA can be involved in AD, the precise role of the 
dopaminergic system in this pathology remains still unclear. Interestingly, some studies 
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have functionally linked these systems by showing that somatostatin (ssts) and dopamine 
receptors (drds) can interact in the presence of their ligands to generate new receptors 
with altered pharmacological and functional properties [20, 21]. Thus, available 
information supports the notion that both the somatostatinergic and dopaminergic 
systems and perhaps their interactions can play relevant roles in AD. However, elucidation 
of those potential roles would require a precise assessment of the presence of each of 
these components in relevant areas of the human brain. Unfortunately, there is a lack of 
quantitative consistent data concerning expression of the molecular components of these 
systems in temporal lobe of AD patients. Accordingly, in the present study, we carried out 
a detailed quantification of mRNA expression levels of these systems (SST, CST, sst1-5, 
neprilysin and drd1-5) in both, control subjects and AD patients, by quantitative real-time 
PCR (qrt-PCR) in three different regions (inferior, medial and superior) of the temporal 
lobe, the most affected cortical structure in AD [2].  
 
Material and methods 
Tissue samples.  
Human brain tissues were obtained from the Netherlands Brain Bank (Netherlands 
Institute for Neuroscience, Amsterdam) which supplies post-mortem specimens from 
clinically well documented and neuropathologically confirmed cases and controls. The 
Netherlands Brain Bank abides to all local ethical legislation. All material has been 
collected from donors for or from whom a written informed consent for a brain autopsy 
and the use of the material and clinical information for research purposes had been 
obtained by the Netherlands Brain Bank. Frozen samples used in this study were from 
three different regions of the temporal lobe (inferior, medial and superior) of six patients 
(four males and two females, 68-91 years) with the clinical diagnosis of AD and six non-
demented controls (four males and two females, 73-93 years). Tissue samples were taken 
at death and during 3-5h post-mortem intervals. Available clinicopathological details of 
each patient are shown in Table 1.  
Nucleic acids isolation and reverse transcription (RT).  
Total RNA from frozen samples was isolated with the RNA Miniprep Kit (Stratagene, 
Texas, USA) following manufacturer’s instructions and the amount was quantified using 
the Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, DE, USA). For RT-
PCR studies, 1 µg of total RNA were reverse transcribed using the AMV kit (Roche 
diagnostics, Mannheim, Germany).  
Quantitative real-time PCR (qrt-PCR) measurements.  
Expression of sst1-5, their ligands (SST and CST) as well as neprilysin and the dopamine 
receptors (drd1, drd2total, drd2long, drd3, drd4, and drd5) was screened by qrt-PCR 
using specific primers for each transcript (Table 2). Since it was not possible to design a 
specific and efficient set of primers to selectively amplify drd2short, we designed two 
separate set of primers to amplify drd2total and drd2long [22]. Details of primer selection, 
verification of primer specificity, and confirmation of efficiency as well as construction of 
standard curves have been previously reported in detail [22, 23]. Amplifications were 
performed using the iCycler IQ™ system (Biorad, CA, USA). The final volume of the PCR 
reaction was 25 µl including 100 ng of sample, 12.5µl of IQ™ SYBR Green Supermix 
(Biorad), 1µl of each primer (10 µM stock solution) and 9.5µl of dH2O. The thermocycling 
profile consisted of 40 cycles at 94º C for 30s, 61º C for 30s, and 72º C for 30s. In addition, 
a non-DNA control was run on each plate to monitor potential exogenous contamination. 
To control for variations in the amount of RNA used in the RT reaction and the efficiency 
of the RT reaction, the expression level (copy number) of one housekeeping gene 
(cyclophilin-A) was determined for each sample where cyclophilin A copy number was not 
altered between experimental groups. At the end of the amplification, the final product 
was subjected to graded temperature dependent dissociation to verify that only one 
product was amplified. In addition, PCR products were run on 2% agarose gel containing 
ethidium bromide to confirm that only one band, of the expected size, was amplified and 
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all PCR products were then column-purified (Bioneer Inc., CA, USA) and sequenced to 
confirm target specificity. To determine the starting copy number of cDNA, RT samples 
were PCR amplified, and the signal was compared with that of a specific standard curve for 
each transcript run on the same plate (1, 101, 102, 103, 104, 105 , 106 copies). It should be 
noted that the slope of a standard curve for each template examined was between -3,31 
and -3,35 (R2 of the standard curve between 0,997 and 1,002) indicating that the efficiency 
of amplification was close to a 100%, meaning that all templates in each cycle were copied.  
Statistical analysis.  
Kolmogorov-Smirnov test was used to assess the normality of the distribution of all 
variables. Student's t-test analysis was used for normally distributed variables, while 
Mann-Whitney U-test was used for nonparametric variables. P values less than 0.05 were 
considered significant. All statistical analyses were performed using the GraphPad Prism 
and SPSS 13.0 software packages. 
 
Results 
 
Expression of SST, CST and neprilysin in the brain of control subjects and AD 
patients. 
It is widely accepted that SST is one of the most selectively reduced neuropeptides in the 
brain of AD patients [18]; however, no data has been reported concerning its highly 
related peptide CST. Additionally, data concerning neprilysin mRNA expression, protein 
level and activity are still controversial [11-16]. In the present study, absolute 
quantification of mRNA copy number in the temporal cortex by qrt-PCR confirmed a 
remarkable 83.9% reduction of SST expression in AD patients as compared with controls 
(Table 3). This difference is highly significant (p≤0.0001) when comparing the whole 
temporal gyrus (Figure 1, left panel), and was also significant when each lobe was 
considered separately (Figure 1, left panel). Likewise, SST mRNA level difference between 
AD and control subjects is consistent in both, female and male genders (data not shown). 
CST expression has not been analyzed in detail hitherto in brains of AD patients. In fact, 
this is the first report demonstrating that CST is expressed in temporal lobe from AD 
patients, wherein CST mRNA levels are higher than those of SST (136,216 ± 15,561 vs. 
58,709 ± 13,490 copies/100ng of total RNA, respectively; Table 3). Nevertheless, and 
similar to that found for its highly related peptide SST, we observed that CST mRNA levels 
are decreased in the whole temporal region of AD patients as compared to control samples 
(p=0.016), although the extent of reduction (40%) is lower than that observed for SST 
(Table 3 and Figure 1, middle panel). In contrast, when each lobe was analyzed separately, 
we observed that CST mRNA levels were significantly decreased only in the inferior 
temporal region (p=0.0014) and not in the medial and superior gyrus (Figure 1, middle 
panel). Similar to SST, no differences were observed between genders (data not shown). 
Quantification of neprilysin mRNA copy number revealed that the absolute expression 
level of this gene is, by and large, considerably lower than that of SST and CST (Table 3). In 
whole temporal lobe, neprilysin mRNA levels are slightly lower in AD patients compared 
to control subjects, although this difference does not reach statistical significance (Table 3 
and Figure 1, right panel). Similarly, no significant differences are found between temporal 
regions (Figure 1) or between genders (data not shown). As mentioned before, we used 
cyclophilin as internal control whose mean mRNA copy number in non-demented control 
was 3,412 ± 1,080 copies/100ng of RNA and, in AD patients was 3,158 ± 1,227 (p=0.72). 
These results are consistent with previous data reporting that the mRNA expression levels 
of cyclophilin remain consistently unaltered in brains from AD patients [12, 24, 25]. 
 
Expression of SST/CST receptors (ssts) in brain of control subjects and AD patients. 
The data reported on the presence and/or abundance of SST/CST receptors (ssts) in AD 
are limited and controversial [26-28]. Using a set of specific primers to determine the 
mRNA copy number of each sst subtype (Table 2), we found that all five ssts are expressed 
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in temporal cortex of control brains, although at very different levels (sst2 ≥ sst1 ≥ sst3 > 
sst4 >> sst5) (Table 3). Interestingly, an overall reduction of 53% in the number of ssts 
mRNA copies was observed in AD temporal cortex. Specifically, sst1, sst3 and sst4 were 
significantly reduced (p=0.015; p=0.016 and p=0.025; respectively), while reduction of 
sst2 copy number was not significant and expression level of sst5 did not change (Figure 
2) in the whole temporal region of AD patients compared with controls samples. Gender 
comparison did not reveal differences in the expression of ssts between female and male 
patients (data not shown), except for sst4, whose mRNA expression was drastically 
reduced only in AD females compared to controls (females: 1,174±230 vs. 210±55 
copies/100ng total RNA, respectively [p=0.019]; males: 800±178 vs. 1,037±390 
copies/100ng total RNA, respectively [p=0.628]). Interestingly, the reduction of ssts 
expression in AD patients is mainly restricted to the inferior temporal gyrus, where mRNA 
level of sst1, sst2 and sst3 are significantly reduced and where sst4 shows also a similar 
trend (p=0.07) (Figure 2). Additionally, expression of sst3 and sst4 shows a trend to be 
reduced in the superior temporal lobe of AD brains compared to controls (p=0.08 and 
p=0.06, respectively). 
 
Expression of dopamine receptors (drds) in brain of control subjects and AD 
patients. 
Although dopamine has been associated with cognitive functions, attenuation of learning 
impairment and neuroprotection [29-32], only drd2 has been studied in detail to date in 
brains of AD patients [33-35]. Here, we used a set of specific primers to determine the 
mRNA copy number of each drd subtype (Table 2). Our results indicate that all five drds 
are expressed in whole temporal cortex of control brains, although at very different levels 
(drd1 > drd5 ≥ drd4 > drd2 >> drd3) (Table 3). Of note, in AD whole temporal cortex, we 
quantified an overall reduction of 50% in the mRNA copy number of drds compared to 
controls. Specifically, drd1, drd2T, drd2L, drd3 and drd4, were significantly reduced, while 
the reduction of drd5 copy number in the whole temporal lobe did not reach statistical 
significance (Figure 3). Gender comparisons did not detect differences in the expression of 
drds between female and male patients (data not shown), except for drd3, whose mRNA 
expression, despite its low (but detectable) levels, was found to be reduced only in female 
AD patients compared to controls (females: 9±2 vs. 2±1 copies/100ng total RNA, 
respectively [p=0.014]; males: 6±2 vs. 8±2 copies/100ng total RNA, respectively [p=679]). 
The reduction of drds expression, similar to that of ssts, is mainly circumscribed to the 
inferior temporal gyrus, where mRNA level of all the drds were markedly reduced, 
including drd5 (Figure 3). Additionally, expression of drd2T and drd2L were also 
statistically reduced in the superior temporal lobe of AD brains compared to controls 
(p=0.046 and p=0.011, respectively). 
 
Discussion 
Somatostatin (SST) is a cyclic, 14 amino acid neuropeptide originally identified in 
hypothalamus as a potent inhibitor of pituitary growth hormone release [36]. However, 
SST was soon found to be widely expressed throughout different tissues and to be 
especially abundant in the central nervous system (CNS), where it exerts important 
functions as neurotransmitter and neuromodulator [37]. More than 20 years later, a 
neuropeptide with strong structural and functional homology to SST was identified and 
was named cortistatin (CST) after its predominant expression in cortex [38], although it is 
also present in peripheral tissues [39, 40]. It is widely accepted that SST is one of the most 
selectively reduced neuropeptides in the brain and cerebrospinal fluid (CSF) of AD 
patients [18, 41-45]. In contrast, and despite the close relationship between the two 
peptides, no data has been reported hitherto concerning CST levels in AD. Here, we have 
quantified by qrtPCR the mRNA copy number of both transcripts in the temporal gyrus, 
the most affected region by Aβ accumulation [2] of control and AD patients. Consistent 
with data reported previously for this and other CNS regions [18, 41-45], we observed a 
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remarkable reduction (83,9%) of SST mRNA levels in AD patients compared to controls. 
Since SST produced in the neurons of the temporal lobe can be released locally or distantly 
in other cortical structures through the terminal-axons of the somatostatinergic neurons 
[37], it could be argued that the decrease of SST levels observed in this and other CNS 
regions [18, 41-45] can be, in part, due to the des-regulation of SST mRNA in the temporal 
lobe. Interestingly, our results indicate, for the first time, that CST is also significantly 
reduced in this cortical region, although the magnitude of the decrease was considerably 
lower (below 40%) as compared with SST (reduction of 83,9%). A detailed analysis of this 
decrease in the different regions (inferior, medial and superior) of the temporal lobe 
revealed the possible origin of the SST-CST differences. Indeed, whereas SST mRNA levels 
were drastically reduced in all these regions, CST mRNA expression was only decreased in 
the inferior gyrus region of the temporal lobe but not in the superior and medial regions. 
The divergent mRNA alteration observed for SST and CST in AD patients compared to 
controls suggest that these peptides may play a dissimilar role in the disease and that this 
role could be region-dependent. 
Indeed, in spite of the high homology exhibited by SST and CST, it has been already 
reported that these peptides can exert different and, even, opposite actions. Specifically, 
although SST and CST basically act as two siblings in regulating endocrine secretions (for 
review, see [46]), SST causes hyper-motility and enhances cortical excitability and REM 
sleep, whereas CST causes hypo-motility, depresses cortical excitability and increases slow 
wave sleep without affecting REM sleep [38]. Furthermore, CST (but not SST) has been 
reported to be a potent endogenous anti-inflammatory peptide [47].  
It has also been reported that SST and CST exert direct actions in processes involved in AD 
generation and/or progression. Thus, treatment of primary cortical neurons with either 
SST or CST similarly induced, albeit with different kinetics, phosphorylation of tau at 
Ser262 [19], a parameter that has been reported to be modified in the brain of patients 
with AD [48]. In addition, SST exerts a positive role in the catabolism of Aβ. Specifically, 
SST increases the activity of neprilysin [17] and insulin-degrading enzyme (IDE) [49], two 
of the best known Aβ-degrading enzymes. Conversely, the role of CST on the regulation of 
neprilysin or IDE activity has not yet been investigated. In fact, SST is the only tested 
peptide capable to up-regulate neprilysin activity in primary cortical neurons [17].  
Neprilysin plays a key role in decreasing the levels of Aβ deposition in brain [8-10]. 
However, data concerning mRNA expression, protein level, and activity of this enzyme in 
the brains of AD patients are still controversial, although most studies report a lack of 
change or a reduction of neprilysin mRNA or protein in AD [11-16]. In agreement with 
these data, our results indicate that neprilysin mRNA copy number did not significantly 
vary in AD temporal lobe, despite a slight numerical reduction compared with control 
subjects. Since such a small decrease of neprilysin in AD could not satisfactorily explain 
the high level of Aβ accumulation in the whole temporal lobe, some authors have 
suggested that this accumulation is due to a lack of neprilysin activation by SST rather 
than to a reduction of its expression [50] which would be supported by the data presented 
in this report. 
The potential contribution of SST and CST to the pathogenesis of AD could be elicited not 
only through changes in their expression but also through variations in the levels of their 
receptors. SST and CST exert their biological actions by binding to five members of the so-
called family of somatostatin receptors, which belong to the superfamily of G protein 
coupled receptors (GPCRs) (sst1-5) [51]. Both peptides exhibit a comparable 
subnanomolar binding affinity to the five ssts, which could help to explain why both 
peptides share many actions at different targets [51]. On the other hand, CST, unlike SST, 
has been suggested to bind to the ghrelin receptor 1A (GHSR-1A) [52] and also to bind to 
the Mrgx2 receptor [53, 54]. It has been hypothesized that activation of these non-SST 
receptors by CST might be involved in the dissimilar or, in some instances, opposite 
actions of both peptides. All five ssts are present in the brain [55] and several reports [26-
28], but not all [56], have shown that their expression patterns are altered in AD in a 
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region-dependent manner. Thus, in earlier studies, measurements of ssts concentration in 
the temporal cortex of AD patients and controls by selective and non-selective radioligand 
assays showed that total receptor levels were reduced approximately by half in AD 
patients [26, 27]. Moreover, Scatchard analysis indicated a reduction in receptor number 
rather than a change in affinity [26, 27]. More recently, immunocytochemical studies 
revealed that the expression patterns of the five ssts are not uniformly altered in frontal 
cortex of AD patients, since sst2, sst4 and sst5 levels were decreased in AD, while sst1 was 
not altered and sst3 was increased [28]. Our recent results are in agreement with Beal´s 
data, as they show an overall 53% decrease in ssts mRNA copy number in the whole 
temporal lobe of AD patients compared with controls. On the other hand, the pattern of 
individual receptors whose changes in expression would contribute to this overall 
decrease is not identical to that described in frontal cortex in previous studies [28]. 
Indeed, our results indicate a reduction of more than 50% in the mRNA copy number of 
sst1, sst3 and sst4 (in this latter case, only in females) in whole temporal lobe of AD 
patients, whereas sst2 expression showed a small non- significant decrease and sst5 levels 
did not vary. Of note, we observed that the major changes in ssts expression pattern were 
restricted to the inferior gyrus of the temporal region, while data reported previously [28] 
specifically focused the analysis to the frontal cortex of AD patients. Consequently, the lack 
of parallelism with previous results may be related to differences in both, the brain 
regions analyzed and the different end points (mRNA vs. protein) measured in each study. 
The frequent pattern of coexpression of different ssts in this and other tissues has 
important implications, since these receptors have the capacity to interact with each other 
and thereby modify their functional properties of individual ssts [57-59]. Indeed, studies 
with SST agonists suggest that the coexpression of specific ssts can be critical to promote 
precise biological actions. Thus, for example, infusions of octreotide, a SST agonist 
selective for sst2, 3 and 5, in AD patients caused a significant degree of memory 
improvement in story recall as compared with placebo conditions [60]. In contrast, this 
analog was not able to mimic SST and CST actions on tau phosphorylation, probably 
because the activation of sst2, sst3 and sst5 is not enough to increase the phosphorylation 
of this protein, and others receptors, specifically sst4, could be crucial in this process as 
previously demonstrated by our laboratory [19]. 
Interestingly, ssts are also able to interact with other GPCRs, including opioid [61] and 
dopamine receptors [20, 21], thereby originating new receptors with altered 
pharmacological and/or functional properties. Specifically, sst2 and sst5 have been 
reported to interact with drd2. Dopamine is a well-known major neurotransmitter in the 
CNS, involved in neuronal functions as important as emotion and cognition. Accordingly, 
the possible impact of the dopamine system in AD has been extensively studied, and, 
although several studies point out an important role of this system in this pathology [29-
32], a comprehensive, definite conclusion on its impact in AD has not been reached. Thus, 
whereas previous studies have shown that the dopaminergic system does not seem to be 
drastically affected in AD as compared to other neuromodulatory systems, some reports 
have suggested that this system could be impaired in this disease [34, 35, 62, 63]. In line 
with this, the levels of expression of drds in different brain regions and their role in AD are 
still unclear and controversial. Immunocytochemical studies of some drd subtypes in 
various brain regions of AD patients indicate that drd subtypes could be regulated in AD in 
a region-specific manner [32-35, 64]. More recently, a drds screening in frontal cortex of 
AD patients showed that protein levels of drd1, drd2, drd3 and drd4 are reduced whereas 
drd5 is increased in AD patients as compared with controls [65]. In the present study, the 
use of a precise quantitative approach (qrt-PCR) to measure drds expression in temporal 
lobe indicates similar although not identical tendencies to those observed by Kumar and 
Patel in frontal cortex. Indeed, we observed an overall reduction of drds mRNA levels in 
AD, as compared with controls. Specifically, the expression of all five drds is clearly 
reduced in the inferior region of temporal lobe in AD and mRNA levels of drd2 are also 
decreased in the superior region. These findings differ from those reported in frontal 
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cortex [65] likely due to differences in both brain regions analyzed and the end point 
(mRNA vs. protein) measured. Notwithstanding, it is most noteworthy that the balance of 
Gs and Gi/0 coupled receptors (drd1/drd5 and drd2/drd3/drd4, respectively), which 
shows an equilibrate expression in control subjects, was found to be clearly altered in AD 
patients, thus reinforcing the contention that there is a clear impairment of the 
dopaminergic axis in the temporal lobe of AD patients. 
In summary, the results presented herein provide for the first time a precise quantitative 
measure of changes in mRNA copy number of important molecular components of the 
SST/CST/ssts and drds systems in a key brain region in AD. Our data indicate that, in AD, 
mRNA levels of SST and CST but not neprilysin are markedly decreased in the temporal 
lobe, one of the most important cortical structures in memory and cognition, and the most 
affected region by SP accumulation and, consequently, by AD. Since accumulation of Aβ in 
non-familial AD has been suggested to be related with Aβ catabolism impairment, and 
neprilysin expression is not significantly affected in these patients, we and other suggest 
that formation of SN in temporal lobe of AD patients could be originated by the lack of 
neprilysin stimulation, due to the loss of SST and, possibly, also of CST. The reduction of 
the stimulatory effect elicited by SST would be potentiated by the overall decrease of ssts 
mRNA levels in the temporal lobe, shown in this work. Furthermore, the previously 
reported impairment of the dopaminergic system in AD would also be potentiated by the 
marked reduction of drds transcripts in temporal lobe reported herein. Taken together, 
our results indicate a general decrease of potentially “protective” neuropeptide/ 
neurotransmitter/receptor systems (i.e., somatostatinergic and dopaminergic systems) in 
the whole temporal lobe of AD patients, being the inferior gyrus the most sensitive region 
for these reductions in the temporal lobe. Future works should aim at dissecting the 
precise role of individual receptors in this pathology and on their potential value as 
specific therapeutic target in AD. 
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Table 1 
Case details of control subjects and AD patients 
Case (NBB number) Age Gender Tangles Senile plaques PM time (h) ApoE Genotype 
Controls       
S00/183 73 F 0 B 4:00 3/2 
S00/318 83 F 1 B 5:30 3/2 
S94/068 85 F 1 B 5:00  
S96/204 93 F 1 A 4:25  
S95/181 74 M 3 C 5:00 4/3 
S01/206 85 M 1 B 4:15 4/4 
AD patients       
S03/117 70 F 6 C 4:30 3/3 
S03/162 72 F 6 C 3:45 4/3 
S05/307 85 F 6 C 5:00 3/3 
S05/236 91 F 6 C 4:35 4/3 
S05/072 68 M 6 C 4:15 4/4 
S04/188 73 M 6 C 5:00 4/3 
Case (NBB number), age at death (years), gender (F: female; M: male), Braak Stages according 
to neurofibrillary pathology [0-6] and senile plaques [A-C] [2], post-mortem time (in hours) 
and ApoE genotype of control and AD brains used in this study are shown. 
 
Table 2 
Primer sequences, product sizes and GeneBank accession numbers 
Gene Sense Antisense 
Product 
lenght 
(bp) 
GeneBank         
Accession 
number 
SST AACCCAACCAGACGGAGAA TAGCCGGGTTTGAGTTAGCA 111 BC032625 
CST CTCCAGTCAGCCCACAAGAT CAAGCGAGGAAAGTCAGGAG 173 NM_001302 
sst1 CACATTTCTCATGGGCTTCCT ACAAACACCATCACCACCATC 165 BC035618 
sst2 GGCATGTTTGACTTTGTGGTG GTCTCATTCAGCCGGGATTT 185 NM001050 
sst3 TGCCTTCTTTGGGCTCTACTT ATCCTCCTCCTCAGTCTTCTCC 190 NM001051 
sst4 CGTGGTCGTCTTTGTGCTCT AAGGATCGGCGGAAGTTGT 174 BC069063 
sst5 CTGGTGTTTGCGGGATGTT GAAGCTCTGGCGGAAGTTGT 183 NM001053 
Neprilysin GACCTCGTTGACTGGTGGACT CTGATAGGCTCTGTATGCTTGACC 186 NM000902 
drd1 GACCACCACAGGTAATGGAAAG AAGAAAGGTAGCCAACAGCACA 141 AF498961 
drd2T CGAGCATCCTGAACTTGTGTG GCGTTATTGAGTCCGAAGAGG 172 NM016574 
drd2L CTCCTCCATCGTCTCCTTCT CGGTGCAGAGTTTCATGTCC 188 NM000795 
drd3 GTACAGCCAGCATCCTTAATCTCT ACAGAAGAGGGCAGGACACA 168 U32499 
drd4 GACGCCCTTCTTCGTGGT GACAGTGTAGATGACGGGGTTG 130 L12398 
drd5 CTGGGCTAACTCCTCACTCAAC ATTGCTGATGTTCACCGTCTC 130 AY136750 
Cyclophilin TGGTCTTTGGGAAGGTGAAAG TGTCCACAGTCGGAAATGGT 109 AF022115 
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Table 3 
Absolute cDNA copy number/100ng of total RNA of each transcript in AD and 
controls patients as determined by quantitative real-time PCR 
 
Control mean 
(n=6) 
AD mean (n=6) 
Percentage of 
change 
p-value 
SST 365,572 ± 62,842 58,709 ± 13,490 -83,9 p≤0.0001 
CST 221,342 ± 29,919 136,216 ± 15,561 -38,5 p=0.016 
sst1 2,312 ± 483 992 ± 243 -57,1 p=0.015 
sst2 2,497 ± 617 1,400 ± 354 -43,9 p=0.148 
sst3 2,277 ± 613 886 ± 309 -61,1 p=0.016 
sst4 1,000 ± 170 486 ±160 -51,6 p=0.025 
sst5 14 ± 5 13 ± 4 -3,6 p=0.316 
Neprilysin 36 ± 17 26 ± 8 -29,6 p=0.907 
drd1 2,430 ± 389 1,203 ± 238 -50,5 p=0.030 
drd2T 995 ± 202 221 ± 45 -77,8 p=0.007 
drd2L 273 ± 51 43 ± 11 -84,4 p=0.007 
drd3 8 ± 2 4 ± 1 -55,7 p=0.047 
drd4 1,519 ± 225 819 ± 139 -46,1 p=0.031 
drd5 1,750 ± 348 1,212 ± 261 -30,8 p=0.083 
Values represent mean ± SEM 
 
 
Figure legends 
Figure. 1. mRNA levels of somatostatin (SST), cortistatin (CST) and neprilysin. Absolute 
mRNA copy number of SST, CST and neprilysin were measured using quantitative real 
time PCR in brain temporal lobe of normal (black columns; control) and Alzheimer disease 
(AD) (gray columns) subjects. Values indicate mean mRNA copy number ± SEM (adjusted 
by cyclophilin mRNA copy number) of these genes in the whole temporal lobe or in 
specific regions (inferior, medial and superior) of the temporal lobe. (*, p≤0.05; **, p≤0.01; 
***, p≤0.001). 
 
Figure. 2. mRNA levels of somatostatin receptors subtypes (sst1-5). Absolute mRNA copy 
number sst1-5 were specifically measured using quantitative real time PCR in brain 
temporal lobe of normal (black columns; control) and Alzheimer disease (AD) (gray 
columns) subjects. Values indicate mean mRNA copy number ± SEM (adjusted by 
cyclophilin mRNA copy number) of these genes in the whole temporal lobe or in specific 
regions (inferior, medial and superior) of the temporal lobe. (*, p≤0.05; **, p≤0.01). 
 
Figure. 3. mRNA levels of dopamine receptors (drd1-5). Absolute mRNA copy number of 
drd1-5 were specifically measured using quantitative real time PCR in brain temporal lobe 
of normal (black columns; control) and Alzheimer disease (AD) (gray columns) subjects. 
Values indicate mean mRNA copy number ± SEM (adjusted by cyclophilin mRNA copy 
number) of these genes in the whole temporal lobe or in specific regions (inferior, medial 
and superior) of the temporal lobe. (*, p≤0.05; **, p≤0.01). 
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Abstract 
The human ghrelin/obestatin gene contains 5 exons(Ex), with Ex2-Ex4 encoding a 117 
amino-acid(aa) preproprotein that is processed to yield a 28-aa(ghrelin) and/or a 25-
aa(obestatin) mature peptides which have biological activities in multiple tissues. 
However, the ghrelin/obestatin gene encodes several additional peptides, generated by 
alternative splicing or post-translational modifications. Our laboratory has recently 
identified a spliced mRNA ghrelin variant in the mouse containing Ex2, intron(In)2 and 
Ex3, but lacking Ex1,4 and 5 (named In2-ghrelin variant), which may be of biological 
relevance because its expression is regulated in a tissue-dependent manner in response to 
metabolic status. In the present work, we have identified a new ghrelin variant in humans 
which contains Ex0-1, In2, and Ex2 but lacks Ex3-4, which would encode a new 
prepropeptide that conserves the signal peptide and the first 12aa of native-ghrelin 
(including the Ser3-octanoylation) while having a different C-terminal tail. The expression 
of In2-variant was detected in 22 human tissues and its expression levels were positively 
correlated with ghrelin-O-acyltransferase (GOAT; R2=0,921) but not native-ghrelin (R2=-
0,025) expression, suggesting that In2-ghrelin could be a primary substrate for GOAT in 
human tissues. Interestingly, the level of In2-ghrelin variant expression in breast cancer 
samples was 8-times that of normal mammary tissue (P0.01), and correlated with GOAT 
(R2=0,655) and ghrelin receptor type 1b (GHSR-1b; R2=0,403), but not native-ghrelin or 
GHSR1a expression. These data together with the fact that In2-ghrelin variant 
overexpression increased the basal proliferation of MDA-MB-231 breast cancer cells, 
suggest that the In2-ghrelin may play a relevant role in breast cancer pathology. 
 
Introduction 
Ghrelin is a multifunctional 28-amino acids (aa) hormone mainly produced in the 
stomach (1), but it is also expressed by a wide variety of tissues where it can act as a 
paracrine or autocrine factor (2-4). Ghrelin can be acylated by the ghrelin O-
acyltransferase (GOAT) enzyme (5, 6), and this form of ghrelin has been recognized as the 
natural ligand of the type 1a growth hormone secretagogue receptor (GHSR1a) (1). To 
date, multiple physiological functions have been directly associated to the acyl-
ghrelin/GHSR1a system, many of them related to regulation of energy balance and 
metabolic function at the central and peripheral level (7, 8). In addition, ghrelin expression 
has been detected (at mRNA and protein levels) in many endocrine and non-endocrine 
tumor cell types (i.e. gastroenteropancreatic, pulmonary, pituitary, testicular, ovarian, 
prostate and breast tumors), as well as in their related cancer cell lines, where ghrelin has 
been shown to control neoplastic cell proliferation (9-17). Interestingly, a truncated 
isoform of GHSR1a, referred to as GHSR type 1b (GHSR1b), has also been found in the 
majority of the tumors and cancer cell lines cited above, however, the precise role that 
GHSR1b plays in tumor regulation remains unknown (15, 18-20). 
Human ghrelin is encoded in the GHRL gene, whose transcription originates a 117 
residues immature prepro-peptide (prepro-ghrelin) that can be acylated by the GOAT 
enzyme to be further processed by prohormone convertases (PC1, PC7, Furin), resulting in 
acyl-ghrelin or desacylated-ghrelin (DAG) (21, 22). Originally, human GHRL was thought to 
span 5kb on chromosome 3, with a 20 bp non-translated Exon (Ex; termed Ex0) and four 
coding Ex (Ex1-4). The prepro-ghrelin signal peptide is encoded by Ex1, and the coding 
sequence (CDS) of the mature ghrelin hormone is encoded by Ex2 and Ex3 (22). However, 
recent studies have demonstrated that prepro-ghrelin mRNA also encodes obestatin (23). 
The tissue- and cell-specific expression, as well as biological effects of obestatin, differs 
from that exhibited by ghrelin (24-26). In addition to ghrelin and obestatin, other peptides 
may also be encoded by the human GHRL, because  re-examination of the genomic 
structure revealed that this gene spans 7.2 kb  (27-29), with a novel upstream Ex-1 and 
extended exonic regions of Ex0 and Ex1 (27). Multiple tissue-specific, alternatively spliced 
 transcripts generated by the upstream exons have been recently identified, many lacking 
regions encoding ghrelin or obestatin and some encoding unique ghrelin/obestatin-
derived transcripts including ex1-proghrelin, ex1-2-proghrelin, ex1-3-proghrelin (29). 
Also an alternative splice site in the intron (In)-2 of the human and rodent ghrelin genes 
have been identified, which results in the translation of a biologically active peptide 
identical to mature ghrelin except for the loss of a single glutamine residue at position14 
(named des-Gln14-ghrelin) (30, 31). In addition, ghrelin transcript lacking the exon that 
encodes obestatin (named Ex3-deleted ghrelin in humans, and Ex4-deleted ghrelin in 
mice) was identified and found to be highly expressed in human breast and prostate 
cancer tissues and derived-cell lines (12, 17, 32). Therefore, it is now appreciated that the 
human ghrelin gene is regulated at multiple levels to yield transcripts and proteins of 
diverse function which can have their homologous counterparts in other mammalian 
species. 
Previously, our group has described a murine ghrelin transcript that retains In2, 
Ex2 and Ex3, but lacks Ex1, Ex4 and Ex5, and was named In2-ghrelin (33). Although 
translation of In2-ghrelin mRNA has not been demonstrated, the mRNA expression is 10- 
and 50-fold greater than that of the native-ghrelin in the pituitary and the hypothalamus, 
respectively. Importantly, In2-ghrelin mRNA levels where found to be regulated under 
extreme metabolic conditions (fasting and obesity) (33), and expression levels paralleled 
those of GOAT mRNA (34), suggesting that In2-ghrelin may be a primary substrate for 
GOAT. In that the sequence of In2 in the human and mouse ghrelin genes show high 
homology (29, 35), and the fact that intron 2 of human ghrelin possesses the typical 
hallmarks of retained introns (i.e., to be short introns flanked by weak splice sites) (36), 
the objective of the present work was to determine if In2 is also retained in the human 
ghrelin gene transcript and if so, to compare and contrast the tissue distribution of this 
putative transcript with that of native-ghrelin, and genes critical with ghrelin peptide 
modification (GOAT) and function (GHS-R1a and GHS-R1b). This manuscript demonstrates 
the existence of a new spliced mRNA variant of the human GHRL that retains In2 (named 
In2-ghrelin) which is present in a variety of human tissues and to be regulated in human 
breast cancer. 
 
Patients and methods 
Patients and samples 
A commercial panel of total RNA from various human tissues was obtained from 
Clontech (Human Total Master Panel II and human pituitary gland poly-A RNA; Palo Alto, 
CA). A group of 40 sporadic invasive ductal breast carcinomas and 4 normal breast 
samples were obtained from Tumour Bank-CNIO (Madrid). The mean patient age at 
surgery was 53 years (range, 27 to 87 years). This study was approved by the Ethics 
Committee of the University of Cordoba, and the Tumour Bank-CNIO (Madrid). Informed 
consent was obtained from each patient before study entry. 
Cell lines 
As previously reported (37), MDA-MB-231 cell line (ATCC, Manassas, VA) was 
maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS), 1% antibiotic-antimycotic and 2mM L-glutamine at 37º C and 5% 
CO2. For in vitro treatments, cells were cultured during 24h with DMEM complemented 
with charcoal-treated serum containing 10-7M of ghrelin, DAG, estradiol, tamoxifen, 
somatostatin (SST) or cortistatin (CST). 
RNA isolation and reverse transcription (RT) 
Nucleic acids were isolated with Trizol (Invitrogen, Barcelona, Spain) following the 
manufacturer’s instructions and treated with DNase as previously described (38, 39). The 
amount of RNA recovered was determined using the Ribogreen RNA quantification kit 
(Molecular Probes, Eugene, OR, USA). Total RNA (2µg) was reverse transcribed (RT) with 
the cDNA First-Strand Synthesis kit (Fermentas, Hanover, MD, USA). 
Primer selection and standard or quantitative real- time RT-PCR (qrtRT-PCR) 
 Primers used for standard PCR and qrtRT-PCR (Supplemental table 1 and 2) were 
selected using the human ghrelin gene sequence as template (GeneID: NM_016362) and 
primer3 software (http://frodo.wi.mit.edu). For standard PCR, 2X Master Mix PCR reagent 
(MRI-Fermentas) and brain cDNA were used following the manufacturer’s 
recommendations. The thermocycling profile consisted of one cycle of 94ºC for 4min, 
followed by 30-40 cycles of 94ºC (30sec), 58-62ºC (depending on the primer set; 30sec), 
and 72º (30-60s; depending on the product size), and a final cycle of 72ºC during 5min. 
Absolute expression levels of ghrelin, In2-ghrelin variant, GOAT, GHS-R1a and GHS-R1b 
was screened by qrtRT-PCR using specific primers (Supplemental table 2). Details 
regarding selection of primers, verification of primer specificity, confirmation of primer 
efficiency, construction of standard curves for each transcript as well as the details of the 
development, validation, and application of a qrtRT-PCR to measure expression levels of 
different human genes have been reported previously (40). The final volume of the PCR 
reaction was 25 µl including 100ng of sample and 12.5ml of IQ™ SYBR Green Supermix 
(Biorad). The thermocycling profile consisted of 40 cycles at 94º C (30s), 61º C (30s), and 
72º C (30s). To determine the starting copy number of cDNA, we used a specific standard 
curve of each transcript run in the same plate. Non-RT RNA samples and non-DNA 
controls were run on each plate to control for genomic DNA or exogenous contamination, 
respectively. Final PCR products were subjected to graded temperature-dependent 
dissociation to verify that only one product was amplified. PCR products were then run on 
2% agarose gel containing ethidium bromide to confirm that only one band, of the 
expected size, were amplified. All PCR products were then column-purified (Bioneer Inc., 
CA, USA) and sequenced to confirm target specificity. To control for variations in the 
amount of RNA used, the expression level of one housekeeping gene (beta-actin) was 
determined for each sample where beta-actin copy number was not altered between 
experimental groups (data not shown). 
Cloning of In2-ghrelin variant and transfection of breast cancer cell lines 
PCR amplification of the full coding sequence of In2-ghrelin variant was done using 
cDNA of MDA-MB-231 cells as template, Sn-520 and As-953 primers (Supplemental table 
1), and the high-fidelity-polymerase i-MAXII (iNtRON Biotechnology, Seongnam, Korea). 
The PCR product was directly cloned into pGEM-t vector (Promega, Madrid, Spain) to be 
further subcloned into the pCDNA3.1+ vector (Invitrogen) using an specific set of primers 
with the HindIII and BamHI restriction sites, respectively (In2-Hind-Up: 
TCTCAAGCTTATGCCCTCCCCAGGGAC and In2-Bam-Low: 
TGTGGGATCCCTAGAGCTCGGGGCTGCAG). MDA-MB-231 cells were transfected using 
Lipofectamine-2000TM (Gibco, Barcelona, Spain) as previously reported (38, 41). 
Transient transfected with empty pCDNA3.1+ (mock transfected) MDA-MB-231 cells were 
used as negative control. 
In Vitro Proliferation Assays 
Basal cell proliferation was evaluated in mock- or In2-ghrelin variant transient 
transfected MDA-MB-231 cells using Alamar-Blue reagent (Biosource International) as 
previously reported using other transcripts (38, 41). Briefly, after transfection, 2000 
mock- or In2-ghrelin variant transfected cells/well were seeded in a 96 well plate and 
cultured during 5 days. Then, cells were starved (serum-free media) during 24h and 
cellular proliferation rate was measured, every 24h, for the following 4 days. The day of 
measurement, cells were incubated for 3 hours in 10% alamar blue/ DMEM with 10% of 
FBS and then, alamar reduction was measured in a BioTek Synergy HT fluorescence plate 
reader (BioTek Instruments, Inc., Vermont, USA), exciting at 560 nm and reading at 590 
nm. Medium with alamar blue was replaced and washed twice with fresh medium 
immediately after each measurement. Kinetics curves were fitted to exponential growth 
curves with GraphPad Prism 4 (GraphPad Software, San Diego, CA). Doubling time and K 
growing constant were calculated from these exponential curves and the results obtained 
in the In2-ghrelin variant transient transfected MDA-MB-231 cells were expressed as 
 percentage of control (mock-transfected cells). In all instances, cells were seeded per 
quadruplicate and the assays were repeated three times. 
Statistical analysis 
Samples from all patients, tissues or cell cultures within the same experiment were 
processed at the same time and therefore correlations between expression of transcripts 
in different tissues (Fig. 2 and 3) were assessed by bilateral (two-tailed) Pearson´s 
correlation test while variations between normal vs. tumoral breast samples (Fig. 3) were 
assessed by Student´s t-test. Effect of pCDNA (mock) or In2-ghrelin variant transfection on 
in vitro proliferation assays was assessed by two-way ANOVA followed by a Newman-
Keuls test for multiple comparisons. P≤0.05 was considered significant. All values are 
expressed as means ± SEM.  
  
Results 
 
Identification of the human In2-ghrelin variant using standard RT-PCR 
As illustrated in Fig. 1A, the coding region of the human ghrelin gene (GHRL) 
consist of one noncoding (Ex0) and four coding (Ex1-Ex4) exons, where the 28-aa mature 
ghrelin is encoded by Ex1-Ex2, while the 25-aa mature obestatin is encoded by Ex3. In 
order to search for an In2-ghrelin variant in the human gene, we designed several sets of 
PCR primers located in Ex1 (sense) and Ex2 (antisense), thereby flanking In2 of the human 
GHRL gene (Figure 1B, sets 1-2). When brain cDNA was used as a template, two PCR bands 
were amplified by each primer set, one of the expected size for native-ghrelin (99bp and 
239bp, respectively) and one for the putative In2-ghrelin variant (293bp and 433bp, 
respectively) (Figure 1B-C). Sequencing of the PCR products confirmed the lower bands 
(99 and 293bp) corresponded to native-ghrelin, while the higher bands (239 and 433bp) 
corresponded to a variant that retains the entire In2. Additionally, we designed a pair of 
primers that would exclusively amplify the In2-variant using an antisense primer located 
entirely in the intronic region (Figure 1B, set 3), resulting in a single band of the expected 
size and sequence (215bp; Figure 1D), while no bands were amplified in non-
retrotranscribed and non-cDNA control, demonstrating that the band observed was not 
the consequence of genomic or external contamination, respectively. In order to study if 
other exons, different to Ex1-2, are present in the novel human In2-ghrelin mRNA variant, 
we selected primers located in Ex0, 3, and 4 (Figure 1B, sets 4-8 and Figure 1E-H) and 
combined these with primers in Ex1 and 2. PCR products obtained with these 
combinations of primers revealed that human In2-ghrelin variant comprises Ex0, Ex1, In2 
and Ex2, but lacks Ex3 and Ex4. This novel sequence of the In2-ghrelin variant was 
submitted to Genbank (accession #: GU942497).  
Since In2-variant and native-ghrelin share the Ex0 and 1, it is tempting to propose 
that the human In2-ghrelin variant shares the same start codon as native-ghrelin, located 
in the Ex1. If this were correct, translation of In2-ghrelin variant mRNA would encode a 
117aa protein (prepro-In2-ghrelin), sharing the first 36aa of native-prepro-ghrelin, 
including the signal peptide (24aa: MPSPGTVCSLLLLGMLWLDLAMA) and the first 12aa of 
the mature native-ghrelin, which include the putative acylation site at Ser3. However, as 
occurred with the mouse In2-ghrelin variant (33), the reading frame of the human In2-
ghrelin variant would be altered by the intron retention, thereby encoding a completely 
novel C-terminal tail where the obestatin would not be produced. Interestingly, in addition 
to human and mouse, we also identified the In2-ghrelin variant in a primate model 
(baboon, Papio Anubis) (Supplemental Fig. 1). Comparisons of human, baboon and mouse 
In2-ghrelin variants show the existence of a high inter-specific homology (at mRNA and 
protein level). 
Using a prepropeptide cleavage sites finder software (ProP 1.0 Server software), 
we have found various putative cleavage sites (i.e., Arg-42 and Lys-63) located in the 
human prepro-In2-ghrelin, which exhibit a similar cleavage score than the cleavage sites 
located in the prepro-ghrelin/obestatin precursor, whose processing would generate 
 ghrelin and obestatin. Although, it would be predicted that the first 12aa of native-ghrelin 
would be retained in a peptide encoded by In2-ghrelin transcript, use of two commercially 
available antibodies directed against this epitope [Rabbit Anti-Human Ghrelin, Alpha 
Diagnostic, San Antonio, TX (Cat. # GHS11-S) and Chicken Anti-Human Ghrelin, GeneTex, 
Inc., Irvine, CA (Cat. # GTX15861, USA)] failed to detect either native-ghrelin or In2 ghrelin 
(data not shown). 
 
mRNA expression levels of In2-ghrelin variant in human tissues 
In order to analyze the presence and abundance of In2-ghrelin variant in human 
tissues, we used the primer set 3 shown in Fig1B, and supplemental table 2 in qrtRT-PCR 
to exclusively amplify this transcript. Result of qrtRT-PCR using a variety of human tissues 
as templates showed that In2-ghrelin variant was expressed in the 22 tissues analyzed. 
However, the expression levels were quite variable (Figure 2A), where In2-ghrelin variant 
mRNA was abundantly expressed in thymus but also in several endocrine organs such as 
pituitary and stomach. We also measured the expression levels of native-ghrelin, GOAT, 
GHS-R1a and GHS-R1b, in the same human samples and the results are shown in Fig. 2B 
and table 1. Interestingly, we observed that expression levels of native-ghrelin and In2-
ghrelin variant did not share a tissue-specific expression pattern (Pearson´s coefficient= -
0,041) (Figure 2D-E). However, when comparing the expression levels of each ghrelin 
transcripts to GOAT, we found a strong correlation between In2-ghrelin variant and GOAT 
levels (Pearson´s coefficient= 0,921; Figure 2C and E) in all the tissues analyzed, while 
there was no significant correlation between native-ghrelin and GOAT (Pearson´s 
coefficient= -0,025; Figure 2E). Finally, our data showed that mRNA expression levels of 
both ghrelin receptors (GHS-R1a and R1b) did not correlate with native or In2-variant 
ghrelin in the human tissues analyzed (Figure 2E). 
 
In2-ghrelin variant is overexpressed in breast cancer samples. 
qrtRT-PCR results showed that In2-ghrelin variant is expressed in normal 
mammary gland (595 copies) and, surprisingly, the expression levels of In2-ghrelin 
variant were found to be 8-fold up-regulated in a battery of 40 sporadic invasive ductal 
breast carcinomas compared with their matched controls samples (p=0,0042) (Fig. 3A; 
Table 2). In contrast, expression levels of native-ghrelin did not differ between normal 
mammary and breast cancer samples (Fig 3A; Table 2); however, the mRNA levels of 
GOAT were up-regulated in breast cancer samples (Fig. 3A), and were significantly 
correlated with the expression levels of In2-ghrelin variant (Pearson´s coefficient= 0,655; 
p≤0,001; Figure 3B-C). mRNA levels of GHS-R1a were low (less than 10 copies) in both 
normal and tumoral breast samples (Fig. 3A; Table 2), and no significant differences were 
found between those experimental groups. Interestingly, the expression of GHS-R1b were 
not detected in normal mammary samples but were highly expressed in breast cancers 
samples (more than 350 copies) (Figure 3A; Table 2). Although GHS-R1a mRNA levels do 
not correlate with native-ghrelin or In2-ghrelin variant levels, we found that expression 
levels of GHS-R1b parallels with In2-ghrelin [two-tailed-Pearson´s coefficient=0,403; 
p=0.097 and one-tailed-Pearson´s coefficient=0,403; p=0.049] but not with native-ghrelin 
(Pearson´s coefficient= 0,122) mRNA levels (Figure 3B-C).  
 
In2-ghrelin variant increases the proliferation rate of MDA-MB-231 cells and its 
expression is regulated by ghrelin and tamoxifen. 
To study the in vitro action and regulation of In2-ghrelin transcript, we used a 
breast cancer cell line, MDA-MB-231, which expresses In2-ghrelin variant, GOAT and GHS-
R1b transcripts at high levels while the expression of native-ghrelin and GHS-R1a were 
almost undetectable (Table 2), a pattern that was similar to that observed in primary 
breast cancers. In vitro kinetic proliferation assays using MDA-MB-231 cells transfected 
with In2-ghrelin variant or empty vector (mock-control) indicated cells that over-express 
In2-ghrelin variant have a higher proliferative rate compared with mock-transfected cells 
 (Figure 4A). Specifically, cells that over-express In2-ghrelin variants exhibited a lower 
doubling time than mock-transfected cells (1,21 days vs. 1,43 days, respectively) being 
these differences statistically significant at 2, 3, and 4 days after serum starvation (p≤0,05, 
p≤0,01, and p≤0,001, respectively). Strikingly, expression levels of the native-ghrelin and 
In2-ghrelin variant transcripts were divergently regulated where treatment (24h) with 
acylated-ghrelin or DAG increased native-ghrelin mRNA levels, while In2-ghrelin variant 
levels were reduced, although the negative impact of DAG did not reach statistical 
significance (Figure 4B). Tamoxifen treatment tended to increase native-ghrelin 
expression but significantly reduced In2-ghrelin variant mRNA levels, while estradiol 
treatment did not alter the expression levels of native-ghrelin or In2-ghrelin variant 
(Figure 4B). It should be noted that expression levels of GOAT, GHS-R1a and GHS-R1b 
were not significantly altered in MDA-MB-231 with these treatments (Data not shown). 
 
Discussion 
The results of the current study indicated the human ghrelin gene, similar to that 
reported in the mouse gene (33), can retain In2, one type of alternative splicing likely 
associated with the failure of intron detection which occurs more frequently in short 
introns flanked by weak splice sites (36). Specifically, human In2-ghrelin variant contains 
Ex0, Ex1, In2 and Ex2 but lacks Ex3 and Ex4. Given the fact that the In2-variant and native-
ghrelin share the Ex0 and 1, we speculate that both share the same start codon, located in 
the Ex1. If this were the case, the first 36aa of the prepro-In2-ghrelin, including the signal 
peptide, and the first 12aa of the mature native-ghrelin, including the putative acylation 
site at Ser3, would be identical to that encoded by the native-prepro-ghrelin mRNA. 
However, as occurred with the mouse In2-ghrelin variant, the reading frame of the human 
In2-ghrelin variant would be altered by the intron retention, encoding a completely novel 
C-terminal tail where obestatin would not be produced. Specifically, the novel preproIn2-
ghrelin would possess a C-terminal tail with various putative cleavage sites which exhibit 
a similar cleavage score than the cleavage sites located in the prepro-ghrelin/obestatin 
precursor whose processing would generate ghrelin and obestatin, suggesting that 
different peptides could be processed from the In2-ghrelin variant. Interestingly, baboon 
ghrelin gene also undergoes processes of In2-retention which together with the fact that 
In2-ghrelin variants are highly conserved across species suggests that relevant functional 
parallels of this novel transcript may have occurred through mammal’s evolution.  
It is becoming recognized that the GHRL gene is very complex and can be regulated 
at multiple levels (27, 29, 42). In fact, several peptides are generated by alternative 
splicing of the ghrelin gene or by post-translational modifications (e.g. obestatin…) (21, 22, 
27-29). Our data demonstrate that a In2-ghrelin variant transcript is processed from the 
GHRL gene, similar to that previously reported in the mouse (33), and it is expressed in a 
wide variety of human tissues, suggesting this novel variant could be physiologically 
relevant and exert important biological actions in humans. Interestingly, expression levels 
of human native-ghrelin and In2-ghrelin variant were not correlated in the normal tissues 
studied, suggesting that the transcription of both variants could be differentially regulated 
in human tissues. Indeed, splice site recognition depends on several factors, such as mRNA 
regulatory elements or protein factors (43), which could modulate the expression of 
intron retaining and intron spliced isoform in a tissue-dependent manner (44-46). Of note, 
we clearly observed that expression levels of In2-ghrelin variant, but not of native-ghrelin, 
were strongly correlated with GOAT mRNA levels in human tissues. Given the possibility 
that translation of In2-ghrelin variant would produce a prepro-peptide having the first 
12aa similar to that of native-ghrelin, including the Serine-3 that is octanoylated by GOAT 
enzyme, it is reasonable to suggest that In2-ghrelin variant may be a primary substrate for 
GOAT in human tissues. This idea will be in keeping with a recent report showing that In2-
ghrelin variant may also be a primary substrate for GOAT in mice (34), since its expression 
clearly parallels changes in the expression level of GOAT in the pituitary of all mouse 
models analyzed (fasting, obesity and different knockout models), although it remains to 
 be determined if the putative novel protein of the human In2-ghrelin variant could be 
acylated by GOAT.  
Our data also indicate that In2-ghrelin variant could play relevant role in human 
breast cancer. Specifically, we observed that In2-ghrelin variant expression was strongly 
up-regulated in ductal breast cancer samples compared with normal breast tissue (8-fold 
increase). In accordance with our findings, a  previous high-throughput sequencing 
analysis using tissues samples obtained from excised human breast tumors samples (47) 
identified an ORF expressed sequence tags (EST) (GenBank: BF929001.1) that shares 99% 
nucleotide sequence homology with the human In2-ghrelin variant identify in the present 
report. Since the study of Dias-Neto focused on clone central portions of expressed coding 
regions by PCR amplifications, the clone homologous to In2-ghrelin variant (BF929001.1) 
contain the complete In2 of human ghrelin gene, but not the complete 5´- and 3´-regions. 
These results strongly suggest that the partial sequence obtained by Dias Neto 
corresponds to the novel human In2-ghrelin variant reported herein.  
This report is the first to show that the GOAT enzyme is present in breast cancer 
tissues where GOAT mRNA levels were found to be significantly increased compared with 
normal human mammary gland samples. Similar to that observed in the battery of normal 
tissues analyzed, the absolute copy number of In2-ghrelin variant, but not of native-
ghrelin, show a significant and positive strong correlation with GOAT expression in breast 
cancer, reinforcing the idea that In2-ghrelin variant could be the primary substrate for 
GOAT enzyme in these pathological circumstances. Our studies also demonstrate an 
upregulation of GHS-R1b which positively correlated with the expression of In2-ghrelin 
variant, while GHS-R1a and native-ghrelin were no significantly elevated in tumor 
samples. This latter finding is consistent with previous immunohistochemistry (IHC) 
results showing very low levels of native-ghrelin in the normal breast epithelium, with 
moderate elevation in breast cancer samples (12). It is interesting to mention that 
previous observations suggest GHS-R1b could have a dominant negative role, by binding 
and internalizing GHS-R1a (48), however the disproportionately high levels of GHS-R1b 
relative to GHS-R1a (60-fold) found in human breast cancer samples suggest this 
receptor may serves a different role in this pathology. Nonetheless, our data may be 
important for clinical purpose since this is the first report showing the presence of 
differential expression of the In2-ghrelin variant, GOAT and GHS-R1b in the breast cancer 
tissues which could represent potential novel markers as diagnostic/prognostic for breast 
pathogenesis. 
Intriguingly, we found that human breast cancer MDA-MB-231 cells were a good 
model to study the physiological relevance of the novel In2-ghrelin variant since the 
expression patterns of the ghrelin-axis in MDA-MB-231 cells were similar to that found in 
primary human breast cancer samples. Specifically, MDA-MB-231 cells expressed In2-
ghrelin variant, GOAT and GHS-R1b while the expression of native-ghrelin and GHS-R1a 
was very low. Interestingly, we found that the expression of native-ghrelin and In2-ghrelin 
variant can be oppositely regulated by acylated-ghrelin and DAG. To our knowledge, this is 
the first report showing that ghrelin (acyl-ghrelin and DAG) can regulate its own synthesis 
(native-ghrelin and In2-ghrelin transcripts). Specifically, although native-ghrelin mRNA is 
expressed at very low levels in MDA-MB-231, treatment with both endogenous peptides 
(acyl-ghrelin and DAG) significantly up-regulate the expression levels of native-ghrelin 
while decreasing the expression of In2-ghrelin variant, the dominant ghrelin form in 
breast cancer cells, suggesting the existence of an auto-regulatory loop in this cell type. In 
addition to this regulatory loop, we also found that tamoxifen significantly reduce In2-
ghrelin mRNA levels while trend to increase native-ghrelin mRNA levels in MDA-MB-231 
cells. This latter observation may have patho-physiological implications in breast cancer 
because tamoxifen is currently used for the treatment of estrogen receptors (ER) positive 
breast cancers and ghrelin axis have been reported to exert relevant actions in cancer cells 
(12). Indeed, although tamoxifen is an ER blocker and MDA-MB-231 is an estrogen-
independent breast cancer cell line, several studies have reported effects of tamoxifen and 
 other ER modulators such as raloxifene in ER-negative breast cancer cell lines via 
activation of several intracellular signaling pathways (PKC, PLD) through ER-independent 
mechanisms (49, 50). Finally, in support of a physiologically relevant role of In2-ghrelin 
variant in breast cancer, we demonstrated that overexpression of In2-ghrelin variant in 
MDA-MB-231 cells promote a robust increase in the proliferation rate as compared with 
mock-transfected cells suggesting that a blockade of the In2-ghrelin variant may have 
some therapeutic benefit. This results are also in keeping with previous reports showing 
that the ghrelin system is present in a wide range of cancer cell models where it can play a 
relevant role in controlling their proliferative rate in a paracrine/autocrine fashion (14, 
15), including breast cancer cell lines (12) where it precise role is still controversial. 
Therefore, the present results extend the pro-proliferative role of native-ghrelin to its 
splice In2-ghrelin variant, which seems to influence cell proliferation through an 
autocrine/paracrine pathway. 
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Figure legends  
 
Figure 1: Schematic representation of the human In2-ghrelin variant. (A) Classical organization of 
human ghrelin-obestatin gene consisting of 5 exons (Ex0-4) and 4 introns (In1-4). Structure of 
prepro-ghrelin/obestatin and prepro-In2-ghrelin mRNA precursors is also indicated. (B) Schematic 
diagram showing the primer position (indicated with arrows) used to detect, clone and/or 
quantitatively amplify the human In2-ghrelin. Exons are represented as boxes and introns as lines. 
(C-H) PCR products separated on agarose gel. (I) Nucleotide and aminoacid sequences of In2-
ghrelin. In-2 sequence and the putative start and stop codons are underlined. 
 
Figure 2: Tissue distribution of the human In2-ghrelin variant. (A) Quantitative expression levels 
on In2-ghrelin. (B) PCR bands of ghrelin-axis transcripts amplified from human tissues, where lane 
order corresponds to the order shown in panel A. Correlation between In2-ghrelin and GOAT (C) or 
native-ghrelin (D) expression in human tissues. (E) Correlations values between In2-ghrelin and/or 
native-ghrelin with GOAT and GHSR1a/1b expression in human tissues. 
 
Figure 3: In2-ghrelin variant in human breast samples. (A) Quantitative expression levels of the 
ghrelin-axis in normal and breast cancer samples. Values are shown as the mean ± S.E.M (* P<0.05, 
** P<0.01; indicate differences from controls). (B) Correlations between In2-ghrelin and ghrelin, 
GOAT, GHSR1a/1b expression in breast cancer samples. (C) Correlations values between In2-
ghrelin and/or native-ghrelin with GOAT, GHSR1a/1b expression in breast cancer samples. 
 
Figure 4: Effect and expression regulation of In2-ghrelin variant in MDA-MB-231 cells in vitro. (A) 
Proliferation kinetics of MDA-MB-231 transfected with In2-ghrelin or control-mock. (B) Regulation 
of native-ghrelin and In2-ghrelin expression in MDA-MB-231. The data represent the means ± SEM. 
Asterisks (* P<0.05, ** P<0.01, *** P<0.001; indicate differences from controls).  
 
 
  
 
 
 
  
  
 
  
 
 
 
  
 
 
 
 
 
 
 
 Table 1 Absolute mRNA copy number of ghrelin axis components in human tissues 
Tissue Ghrelin 
In2-
ghrelin 
GOAT GHSR1a GHSR1b B-actin 
Bone Marrow 4750 720 1150 n.d. 2 1880000 
Brain 1783 1140 1170 13 1 2680000 
Fetal Brain 879 1740 2500 259 23 5470000 
Fetal Liver 1287 84 1360 n.d. n.d. 1010000 
Heart 1689 365 1400 n.d. 2 677000 
Kidney 6235 1140 972 n.d. 1 2430000 
Liver 788 295 658 n.d. n.d. 837000 
Lung 3427 778 2360 12 3 5330000 
Placenta 928 512 1680 3 19 2150000 
Prostate 1434 969 953 n.d. 4 1370000 
Skeletal Muscle 433 361 154 n.d. 2 243000 
Spleen 4498 615 2580 n.d. 1 2440000 
Testis 2341 2490 1270 186 19 2900000 
Thymus 3618 6520 17200 2 3 6690000 
Trachea 2100 510 421 5 3 1730000 
Uterus 1218 975 1510 n.d. 2 5730000 
Colon 980 641 1080 11 3 3460000 
Small Intestine 18516 985 1040 11 2 3350000 
Spinal Cord 2756 1050 907 292 11 3570000 
Stomach 44229 680 1630 15 8 2360000 
Pituitary 634 129 732 3060 554 313000 
       
 
Table 2 Expression level of ghrelin axis in breast tissues and cell lines 
  In2-ghrelin Ghrelin GOAT GHSR1a GHSR1b 
Normal breast 595 442 202 3 n.d. 
Tumoral breast 5155 664 991 6 373 
MDA-MB-231 5783 3 552 3 193 
Values represent mean copy number of each transcript per 100ng of total mRNA 
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samples and increases the malignancy of breast MCF-7 cells. 
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Summary 
The activation of somatostatin receptors, ssts, leads to the inhibition of cellular processes 
including proliferation and invasion. ssts are expressed in normal tissues and highly 
expressed in tumors, including breast cancers. In this work, we show how a newly 
discovered sst, sst5TMD4, conversely increases the malignancy of MCF-7 breast cancer 
cells. Cells expressing the endogenous or transfected sst5TMD4, have increased P-ERK1/2 
and P-Akt levels, and also an elevated expression of cyclin D1 and Arp2/3 complex, which 
leads to the acquisition of a mesenchymal-like phenotype, and to their enhanced invasion 
and proliferation abilities. In breast cancer samples, sst5TMD4 was found in aggressive 
tumors, were it is co-expressed with the sst2. sst5TMD4 interacts with sst2 and may 
promote this phenotypic and functional alteration by disrupting sst2 functioning, 
eliminating an inhibitory somatostatin feedback. 
Significance 
The high expression of somatostatin receptors, ssts, in tumor cells, added to their 
antiproliferative effects after activation make them a suitable target for diagnose 
purposes, but also for the treatment of these pathologies with somatostatin and its 
analogues. Indeed, the use of sst2 preferring compounds as octreotide or lanreotide has 
been extensively used for fighting against the secretory/proliferative aspects of multiple 
kinds of neuroendocrine tumors, being a notably successful strategy. Thus, sst2 is 
considered a good prognosis factor. However, the use of somatostatin and its analogues in 
the treatment of breast cancer has not been as thriving as expected, even though sst2 is 
overexpressed in these tumors. In this paper, we describe the presence of a new player in 
the scene of ssts and breast cancer, sst5TMD4, which expression overlaps to that of sst2, 
and confers the cell more aggressive features. 
 
 
INTRODUCTION 
Breast cancer is the most frequent type of cancer in women (27%) (Pollan et al., 2007) and 
the second most frequent neoplasia overall (Parkin et al., 2005), having an approximate 
30% mortality rate (Orlando et al., 2004; Parkin et al., 2005). Far away from eradicating, 
its incidence is estimated to increase in a 10% in industrialized world in the next 7 years 
(Parkin et al., 2005), which is fortunately counteracted by a better prognosis and 
treatment, due to the effort at identifying new and earlier prognosis factors and specific 
molecular signatures (Dowsett et al., 2007). Among these molecular signatures 
somatostatin (SST) receptors or ssts stand out. 
Ssts receptors family is composed by five non-allelic intronless genes, encoding five seven 
transmembrane receptors, sst1-5, which are widely distributed in normal and tumor 
tissues (Moller et al., 2003). In addition, two new truncated variants of the sst5, originated 
by non classical splicing, have been recently discovered in human pituitary tumors 
(Duran-Prado et al., 2009). ssts, are densely expressed in breast cancer cells as well as in 
many other neuroendocrine tumors compared to their normal tissues (Weckbecker et al., 
2003). More in detail, 50-70% of breast tumors are positive for at least one of the five ssts 
(Fekete et al., 1989; Reubi, 2003; Reubi et al., 1990; van Eijck et al., 1994) being sst2, 
overall, the most qualitative and quantitatively abundant in tumor cells (Orlando et al., 
2004; Pilichowska et al., 2000; Pinzani et al., 2001; Reubi, 2003; Reubi et al., 2001; Schulz 
et al., 1998; Xu et al., 1996). Likewise, sst2 is considered a good prognosis factor, due to its 
association with low proliferative and invasive breast cancers (Orlando et al., 2004). 
ssts inhibit deregulated proliferation and invasion (Barresi et al., 2008; Kahan et al., 1999; 
Keri et al., 1996; Pola et al., 2003; Sun et al., 2007a). Inhibitory responses triggered by ssts 
after activation by their natural or synthetic ligands rely on their ability to turn on 
inhibitory cascades, by mechanisms dependent and independent of Gi/o proteins (Moller 
et al., 2003; Weckbecker et al., 2003). This includes the modulation of ERK/1/2 and Akt 
phosphorilation (Lahlou et al., 2003; Moller et al., 2003) which are the two major signal 
transduction pathways involved the transformation and enhanced proliferation and 
migration of cancer cells (Liu et al., 2007b; Santen et al., 2002; Shen and Brown, 2003). 
The antiproliferative effect of somatostatin in breast cancer cells, in vitro, is so long known 
(Setyono-Han et al., 1987). Similarly, sst appears effective at inhibiting proliferation and 
migration of prostate cancer cells and neuroblastoma cells through downregulation of Akt, 
or Akt and ERK cascades, respectively (Pola et al., 2003; Sun et al., 2007a). These effects 
are not restricted to in vitro cancer models. sst and their analogues also result effective, in 
vivo, inhibiting the growth of induced xenografts and animal tumors (Kahan et al., 1999; 
Keri et al., 1996) as well as combating the growth of neuroendocrine tumors, where it has 
been demonstrated that its efficiency is due to a downregulation of the ERK cascade 
(Hubina et al., 2006). 
The lost of sst2 expression in certain cancer cells is translated in the elimination of an 
autocrine inhibitory loop that lead to phenotypical and functioning alterations (Benali et 
al., 2000; Leu et al., 2008). In some instances, the elimination of the negative sst feedback 
mediated by sst2 resulted in epithelial to mesenchymal transition, EMT, and in increased 
cell proliferation (Leu et al., 2008). Similarly, in pancreatic cancer cells, the loss of the sst2 
mediated autocrine sst-induced inhibition increases the proliferation and metastasis of 
these cells, in vivo and in vitro (Benali et al., 2000). 
In the present work, we propose that a new player in the system SST/ssts, the truncated 
isoform of sst5, sst5TMD4, is present in breast cancer and breaks the inhibitory SST 
signaling mediated by sst2 in these cells. We show that sst5TMD4 is qualitative and 
quantitatively positively correlated with sst2 expression in primary breast cancer 
samples, which pathological characteristics fit to the most aggressive/metastatic tumors 
analyzed. We have demonstrated by fluorescence resonance energy transfer, FRET, that 
these two receptors, sst2 and sst5TMD4, are interacting and form heterodimers. 
Moreover, their physical interaction is translated to an inhibition of sst2 function and 
functioning in both, CHO-K1 and MCF-7 cells, resulting in a blockade of calcium signaling 
and increased basal P-ERK and P-Akt levels. As consequence, sst5TMD4 expressing cells 
alter their morphology, showing increased invasion ability and proliferative rates, in vitro 
and in vivo in xenograft models. 
 
RESULTS 
 
Real time quantitative PCR and IHC analysis of breast cancer samples 
sst5TMD4 and sst2 expression levels were evaluated by real time PCR in 40 ductal breast 
carcinomas and 4 normal tissues. sst5TMD4 mRNA was detected in 28% of breast cancer 
samples and was expressed under the detection limit of real time PCR or not detected in 
the other samples, including negative controls. The pathological stage of each tumor was 
evaluated by immunohistochemical techniques, based in the presence of ER, p53 and 
Her2neu. The criterion to assess invasiveness was the metastases of cancer cells to lymph 
nodes. Comparison of sst5TMD4 expression with the pathological classification of each 
tumor, revealed that presence of sst5TMD4 was correlated with lower levels of ER 
(p=0.053), p53 (p=0.037) and Her2neu (p=0.038) (Figure 1). Additionally, the expression 
of sst5TMD4 was positively correlated with the most invasive/metastatic tumors 
(p≤0.001) (Figure 1). 
Accordingly with previous results, we detected that sst2 was ubiquitously expressed in 
both normal and tumor samples (supplemental Figure 1). Interestingly, in tumors 
expressing sst2 and sst5TMD4, the expression level of both receptors was positively 
correlated (R2=0.715) (Figure 2.A). 
 
Interaction between sst5TMD4 and sst2 
Due to the high correlation of sst5TMD4 and sst2 expression in the same tumors, we used 
a heterologous cell model, CHO-K1 cells, to ascertain the possible relevance of the 
interaction between sst2 and sst5TMD4 or between native sst5 and the truncated 
sst5TMD4. Confocal microscopy studies using recombinant forms of these receptors 
tagged with fluorescent proteins revealed that presence of sst5TMD4 is able to modify the 
subcellular localization of sst2 (Figure 2.B). Plasma membrane localization is mainly 
observed when sst2 is expressed alone in CHO-K1 cells, while sst5TMD4 exhibit a 
predominant intracellular distribution as previously reported (Duran-Prado et al., 2009). 
However, coexpression of both receptors in the same cell altered the localization of sst2 at 
the plasma membrane being mainly retained intracellularly (Figure 2.B). Similar results 
were obtained, by immnunocytochemistry, for the sst2 and sst5TMD4 endogenous 
receptors in the breast cancer cell model MCF-7 (Figure 2.C). We reproduced the same 
experiments with the wild type sst5 and sst5TMD4. The results indicate that sst5TMD4 is 
also capable to modify the subcelullar localization of sst5 when both receptors, transfected 
or endogenous, are coexpressed in CHO-K1 or MCF-7 cells, respectively (Figure 2.F and G). 
FRET technique was lately used to determine if sst5TMD4 and sst2 tagged with 
fluorescent proteins were able to interact. This approach revealed that the recombinant 
sst2 forms constitutive multimeric structures as shown by a FRET efficiency value of 67%, 
and recombinant sst5TMD4 also homodimerizes although with a lower FRET efficiency 
value (43%; supplemental Figure 2). To determine the ability of sst5TMD4 to modify sst2 
homodimerization, competitive FRET assays were performed using CHO-K1 cells, 
transfected with a constant amount of tagged sst2 and increasing quantities of untagged 
sst5TMD4 (Figure 2.D). We observed that transfection with equimolecular concentrations 
of untagged sst5TMD4 reduced sst2 FRET efficiency in 35%, whereas a quantity 5-fold 
higher reduced this value in 63% (Figure 2.D). 
Furthermore, coexpresion and physical interaction of sst5TMD4 and sst2 was translated 
in a functional interaction. Specifically, application of a Ca2+ imaging approach by 
microflurimetry demonstrated that the capability of sst2 transfected CHO-K1 cells to 
increase the free cytosolic calcium concentration, [Ca2+]i, in response to SST-14 is 
reduced when cells also expressed sst5TMD4 (Figure 2.E).  
In contrast, sst5TMD4 failed to alter sst5 homodimerization and neither its capability to 
respond to SST-14 (Figure 2.H and I), thus, reinforcing the selectivity of the truncated 
receptor to regulate, specifically, the functioning of sst2. 
 
Characterization of MCF-7 ssts expression profile 
To explore the role and functionality of sst5TMD4 in a homologous model, we used the 
breast cancer cell line MCF-7, which expresses sst2, sst5 and sst5TMD4. Interestingly, the 
expression pattern of truncated somatostatin receptor 5 was modified during culturing 
(Figure 3A). Specifically, we checked by PCR that the mRNA corresponding to sst5TMD4 
completely disappeared after 10 passages (Figure 3.B), which was accompanied by an 
absence of protein (Figure 3C). On the other hand, sst2 and the wild type sst5 mRNA were 
not altered during culturing (Figure 3A). This feature allowed studying the role of 
endogenous sst5TMD4 in MCF-7 cell line, and studying the functioning of MCF-7 with or 
lacking sst5TMD4, without the needed of silencing its expression. Therefore, MCF-7 cells 
that endogenously expressed sst5TMD4 (“Initial passages”) and MCF-7 cells that lack its 
expression (“Final passages”) were compared to analyze the role of the endogenous 
sst5TMD4. 
 
Measurement of [Ca2+]i in single MCF-7 cells 
Application of a Ca2+ imaging approach demonstrated that the presence or absence of 
sst5TMD4 in MCF-7 can modify the cellular response to somatostatin (SST). 
Administration of SST to cells that endogenously express sst5TMD4 (Initial passages) did 
not alter [Ca2+]i (Figure 3.D). However, caused a 20% reduction in the [Ca2+]i in more 
than 70% of cells that lacks sst5TMD4 (final passages, Figure 3.D). In order to check if this 
response was due to culturing, we also analyzed [Ca2+]i dynamics in MCF-7 cells stably 
transfected with sst5TMD4 or with the empty expression vector (mock). Accordingly, 
almost 80% of mock transfected MCF-7 cells reduced [Ca2+]i upon SST treatment but only 
25% the cells transfected with sst5TMD4 inhibited [Ca2+]I after challenge with SST 
(Figure 3.E). These results suggest that the presence of sst5TMD4 in MCF-7 cells alters 
calcium signaling in response to SST-14. 
 
MCF-7 cells phenotype 
MCF-7 stably transfected cells with or without sst5TMD4 where used to study if the 
presence of this receptor modified the typical epithelial cell phenotype of this breast 
cancer cell model. More than 20% of sst5TMD4-transfected MCF-7 cells exhibited a 
mesenchymal-like phenotype in contrast to the 5% of mock-transfected MCF-7 (Figure 
3.F). Specifically, we observed that the expression of the epithelial marker E-cadherin was 
decreased in cells expressing sst5TMD4 (Figure 3.G). More in detail, we observed a 75% 
reduction of E-cadherin mRNA level in sst5TMD4-transfected MCF-7 compared with mock 
controls (P=0,0051; Figure 3.G, left panel). Accordingly, we also observed a significant 
reduction of E-cadherin protein in this cells (P=0,0086; Figure 3.G, right panel). 
 
MAPKs and Akt fosforilation assays in MCF-7 cells with or without sst5TMD4 
Inmunoblotting assays were performed to determine basal level of both, 
active/phosporilated ERK1/2 (P-ERK) and Akt (P-Akt) in MCF-7 cells expressing or 
lacking sst5TMD5. Western-blotting results showed that MCF-7 cells of “initial passages”, 
which express sst5TMD5, have higher levels of p-ERKs/ERKs (P=0.040) and p-Akt/Akt 
(P=0.002) compared to MCF-7 cells of “final passages” which lack sst5TMD4 (Figure 4.A 
and C, left panels). Similarly, sst5TMD4 stably transfected MCF-7 cells also exhibited 
higher levels of phosphorilation of both kinases compared with MCF-7 cells stably 
transfected with the empty vector, mock, (P=0.006 and P=0.003, respectively, Figure 4.C 
and D, left panels).  
Time-course experiments also showed differences in the regulation of these two kinase 
cascades between sst5TMD4-expressing and sst5TMD4-lacking cells in response to SST. 
Indeed, SST treatment leads to a decrease of basally elevated p-ERKs levels in MCF-7 cells 
of initial passages or in sst5TMD4-stably transfected cells, reaching the low levels 
observed in MCF-7 cells of final passages (40% reduction, P=0.021) or in MCF-7 cells 
stably transfected with empty vector (mock, 55% reduction, P=0.021), respectively. In 
contrast, SST treatment did not alter basal P-ERK levels of MCF-7 cells of final passages or 
stably transfected with empty vector (Figure 4A and B, right panels).  
Oppositely, PI3K-Akt pathway was inversely regulated by SST in MCF-7 cells. Specifically 
SST treatment leads to a 42 and 48% increase in p-Akt levels in cells expressing the 
endogenous or the transfected sst5TMD4, respectively (P=0.015 and P=0.042) while p-Akt 
levels were neither altered in sst5TMD4-lacking cells (Figure 4C and D, right panels). 
 
Migration and invasion assays 
Invasion assays carried out in matrigel and collagen IV polycarbotate treated filters, 
showed that sst5TMD4-trasfected MCF-7, but not mock transfected cells cells, were able to 
invade (Figure 5.A). Specifically, mock trasfected MCF-7 cells were not able to invade, 
neither in matrigel nor in collagen coated filters (Figure 5.A), whereas invasion of 
sst5TMD4 expressing MCF-7 cells was enhanced by 48 and 35% compared to control in 
matrigel (P=0.032) and collagen (P=0.029) coated filters, respectively (Figure 5.A). 
Consistent with these results, wound healing assays carried out with the same MCF-7 cells 
showed that the ability to migrate after 24h was also higher in cells expressing sst5TMD4 
than in mock transfected cells (P<0.001), indicating that the presence of sst5TMD4 
increases the basal migration ability of MCF-7 cells (Figure 5.B, left graph). Treatment with 
SST did not modify the wound recovery ability of mock transfected cells. However, SST 
completely restored the migratory ability of MCF-7 cells expressing sst5TMD4 to the levels 
observed in mock transfected cells (Figure 5.B, right graph). 
We also measured the expression level of genes involved in cellular migration and 
invasion. Specifically, we quantified the expression of the actin-related protein (Arp) 2/3 
complex, which enables the formation of new branched actin filament networks at the cell 
surface of migrating cells (Yamaguchi et al., 2005). Our results indicated that mRNA levels 
of three transcripts corresponding to the heptameric Arp2/3 complex, Arp2, Arp3 and 
p16, were overexpressed in sst5TMD4 expressing MCF-7 cells compared mock transfected 
cells (Figure 5.C). In particular, Arp2 expression was increased in 228% (P=0.007), Arp3 in 
223% (P=0.017) and p16 in 357% (P=0.044). We also analyzed the expression of the 
metalloproteases MMP-2 and MMP-9. MMP-2 was downregulated in a 50% (P=0.0118) in 
cells lacking sst5TMD4 expression (MCF-7 cells in final passages, Figure 5.D, left) and its 
expression was three fold increased (Figure 5.D, right, P=0.0354) after the reintroduction 
of the recombinant receptor. The same tendency was observed for MMP-9 expression 
levels, though did not reach statistical significance (Figure 5.E, P=0.0778 and P=0.1806). 
 
MCF-7 proliferation 
The evaluation of cell proliferation and viability, measured with Alamar Blue, revealed 
that the ability of MCF-7 cells lacking sst5TMD4 (“Final passages”) to proliferate (24h 
incubation) was 30% lower (P<0.0001) than that observed in MCF-7 cells expressing 
sst5TMD4 (“Initial passages”) (Figure 6.A, top panel). Consistent with these results, MCF-7 
cells transfected with sst5TMD4 showed a higher basal proliferation rate (P<0.0001) 
compared to mock transfected cells (Figure 6.A, lower panel). Furthermore, kinetic 
proliferation assays using stably transfected MCF-7 cells (Figure 6.B), showed that cells 
transfected with sst5TMD4 proliferated more than mock transfected MCF-7 cells, 
exhibiting a lower doubling time (P=0.037). Similarly, sst5TMD4 expressing cells showed 
an increased exponential growing constant, K, compared to mock transfected cells 
(P=0.041) (Figure 6.B). Consistent with these results, mRNA levels of the positive cell cycle 
regulator cyclin D3 were increased in a 175% (P=0.005) in sst5TMD4 transfected cells vs. 
mock-transfected cells (Figure 6.B). 
 
Growing of subcutaneous xenografts 
The effect of the presence of sst5TMD4 on cell proliferation was evaluated in an in vivo 
model of induced subcutaneous xenograft in nude mice (Figure 6.C). Consistent with in 
vitro data, the results obtained in vivo indicate that subcutaneous tumors induced with 
sst5TMD4 transfected cells, grew more than the induced with mock MCF-7 cells, being this 
difference significant after the fourth week of injection (76 vs. 50 mm2, respectively, 
P=0.01, Figure 6.C, left panel). This difference between the tumor growth of sst5TMD4- 
and mock-transfected cells induced xenografts was maintained until the ninth week, when 
the experiment was ended (131 vs. 102 mm2, respectively, P=0.03). In addition, the 
xenograft induced with mock transfected cells exhibit the ultrastructure of a typical well 
differentiated breast tumor (Figure 6.C, middle panel), while sst5TMD4 transfected cells 
produced unorganized structures, characteristic of a undifferentiated tumor (Figure 6.C, 
right panel). 
 
DISCUSSION 
Ssts are expressed in breast tumors (Schulz et al., 1998), being the sst2 the most expressed 
one (Orlando et al., 2004). In support with this notion, our results indicate that sst2 and 
sst5, but not other receptors, are expressed in the breast tumor samples analyzed, being 
sst2 the most expressed, both by number of positive tumors and by expression level. In 
addition, we show for the first time, the presence of the new truncated isoform sst5TMD4 
in breast cancer cells. Specifically, expression of sst5TMD4 was roughly in one third of the 
samples analyzed which was rather unexpected since we recently have shown that the 
expression of this variant is restricted to lung, kidney, liver, brain, and some kind of 
pituitary tumors (Duran-Prado et al., 2009). Nonetheless, to our knowledge, there are two 
indirect references in which the presence of sst5TMD4 could have been detected in breast 
tumors. Specifically, almost two decades ago, Prévost et al., detected by cross-linking with 
lanreotide, the presence or a reactive band of 27 KDa in protein extracts obtained from 
breast cancer samples (Prevost et al., 1993) which molecular weight was much smaller 
than the obtained for the known ssts to that date, but that matches with that of sst5TMD4 
shown herein. In addition, a few years later, Xu et al., demonstrated by RNAse protection 
assays the presence of a band corresponding to a putative sst5 mRNA in the cell line MCF-
7 (Xu et al., 1996). However, they failed to detect the protein because the antibody used 
was raised against the C terminal domain, which does not recognize the sst5TMD4. 
As shown previously, when both receptors, sst2 and sst5TMD4 are coexpressed in the 
same cell (CHO-K1 or MCF-7 cells), they show a preferential intracellular localization, 
comparable to the described for the sst5TMD4 alone (Duran-Prado et al., 2009) and 
parallel to reported recently by Watt et al., for the endogenous ssts expressed in MCF-7 
(Watt and Kumar, 2006). Our results shown herein confirm that the colocalization 
between sst5TMD4 and sst2 and their intracellular localization is not a mere spatial 
overlapping of their signals but involve physical interaction. sst5TMD4 recruit a high 
proportion of sst2 intracellularly by physical interaction, acting as dominant negative to 
sst2 in terms of localization, which is extended to its function. In recent times, it has been 
described the expression of sst2 in high grade meningiomas, were, interestingly, the 
receptor show a preferential cytoplasmatic localization in most of the tumors (Barresi et 
al., 2008), as it was reported for pancreatic cells (Papotti et al., 2002) and for the 
endogenous ssts expressed in the hepatic cell line HepG2 (Notas et al., 2004). We have to 
remember that the availability of ssts at the plasma membrane is essential and 
determinant for an effective treatment of these tumor pathologies using sst and analogues 
as well as with labeled derivates (Huang et al., 2000; Krenning et al., 2004; Sun et al., 
2007b; Weckbecker et al., 2003). Moreover, the alteration of sst2 membrane localization 
could lead to the elimination of an inhibitory sst2-mediated autocrine loop, which derives 
to EMT, and enhanced proliferation and invasion (Benali et al., 2000; Leu et al., 2008). To 
date, there are many cases of truncated GPCRs that function as dominant negative to their 
wild type (Bakker et al., 2006; Blanpain et al., 2000; Chelli and Alizon, 2001; Grosse et al., 
1997; Lee et al., 2000; Neill et al., 2004; Pawson et al., 2005; Sarmiento et al., 2004; Seck et 
al., 2005) and it has been suggested that the presence of these truncated variants could act 
as a new regulatory mechanism to finely tune the response to a ligand, by altering the 
availability, affinity and functionality of the wild type receptor (Bakker et al., 2006). We 
show in this report that the sst5TMD4 is one of these receptors since the presence of 
sst5TMD4 in breast cancer cells modify the cellular responses of these cells to its 
endogenous ligand SST. In addition, there are many other evidences of natural or 
“laboratory mutant” truncated receptors that posses their own function that usually 
differs from their wild type (Perron et al., 2005; Seck et al., 2005) or sometimes have 
constitutive activity (Hasegawa et al., 1996). For instance, as described recently, the 
ghrelin receptor isoform B, GHSR-B, (Petersenn, 2002), is highly expressed in lung cancer 
cells, where it heterodimerizes with neurotensin receptor 1, originating a new 
heteroreceptor that promotes cell proliferation and migration in response to neuromedin 
U (Takahashi et al., 2006).  
The new sst5 variant reported herein, sst5TMD4, also seems to play its own function in 
MCF-7 tumor cells. First of all, the stably expression of sst5TMD4 in MCF-7 cells leads to a 
mesenchymal-like or fibroblastoid appearance as shown for MDCK cells transfected with 
Snail (Cano et al., 2000) or HMLE cells treated with TGFβ (Mani et al., 2008), instead of the 
usual epithelial morphology signature of this cell type. Moreover, these sst5TMD4 stably 
transfected cells, showed increased migratory and proliferative basal abilities which 
correlates to the observed phenotype (Cano et al., 2000) and which, at last instance, could 
be determinant in tumor progression and metastases. Overall, as we found that sst5TMD4 
expression correlated to the most aggressive of a series of breast tumor samples, it is 
tempting to speculate that their increased malignancy could be due, at least in part, to the 
presence of the truncated receptor. 
In order to ascertain the molecular basis of the transformation of MCF-7 cells by 
transfection with sst5TMD4, we studied two major signal transduction pathways involved 
in proliferation, migration and phenotype transformation in cancer cells, Akt and ERK (Liu 
et al., 2007b; Santen et al., 2002; Shen and Brown, 2003). Our results indicate, for the first 
time, that the basal phosphorilation levels of Akt and ERK are different in MCF-7 cells on 
initial and final passages. Specifically, cells of initial passages which express endogenously 
the sst5TMD4 variant, show a higher level of both, P-Akt and P-ERK levels than cells of 
final passages which do not express sst5TMD4. Moreover, the re-insertion of sst5TMD4 
variant in MCF-7 cells of final passages increased both P-Akt and P-ERK levels to that 
observed in initial passages, which is ultimately translated to higher proliferation and 
migration rates.  
Akt phosphorilated level is increased in 30-40% of breast cancers vs. control samples, and 
promotes epithelial-mesenchymal transition, which derives in tumor progression to an 
invasive and metastatic carcinoma (Liu et al., 2007b). Other studies have correlated 
activation of Akt with a decrease in disease free survival and, consequently, it may have 
prognostic relevance in breast cancer (Liu et al., 2007a; Perez-Tenorio and Stal, 2002; 
Schmitz et al., 2004). It is known that the PI3K/Akt pathway can be activated by several 
factors: estrogens, epidermal growth factor (EGF), insulin-like growth factor (IGF), and the 
HER2/neu network. Actually, several studies have tried to explain high levels of p-Akt due 
to the presence of specific receptors, such as estrogen receptor (ERs) or HER2/neu, since 
in vivo studies have shown that Akt is frequently activated in patients with HER2/neu-
overexpressing breast tumors (Tokunaga et al., 2006b; Tokunaga et al., 2006c) and with 
(ER)-positive tumors (Kirkegaard et al., 2005; Tokunaga et al., 2006a). However, 
additional data suggest that other factors able to stimulate Akt network in breast cancer 
might exist. Specifically, triple-negative breast cancers, although lacking ERs, PgRs and 
HER2/neu are also characterized by increased phosphorylation of Akt kinase (Umemura 
et al., 2007). Moreover, in cancer cells, the Akt is overexpressed and its expression 
correlates to ER negative tumors. Interestingly, we have found an inverse correlation 
between presence of both ERs and HER2/neu and expression of sst5TMD4. To our 
knowledge, though Akt regulation, stimulation and inhibition, by ssts is not novel 
(Charland et al., 2001; Grozinsky-Glasberg et al., 2008; Sellers et al., 2000), this is the first 
time that there is a direct link between expression of an sst, Akt and breast cancer, and 
moreover, that the solely presence of a specific sst leads to increased Akt phosphorilated 
levels in a breast cancer cell line. However, more studies are needed to determine if 
sst5TMD4 can also increase basal levels of p-Akt in human primary breast tumors. 
Our results presented herein, also show that cells expressing sst5TMD4 exhibit increased 
P-ERK levels. In breast cancer, it has been shown that MAPK cascades are even more 
important than Akt. Specifically, ERK1 and ERK2 are the most relevant MAP kinases in 
breast cancer and are usually over-expressed and over-phosphorilated in certain type of 
mammary tumors, especially, node positive primary tumors (Santen et al., 2002). This 
increased P-ERK level is associated to poor survival in triple negative cancers and is 
considered a poor prognosis factor (Eralp et al., 2008). Furthermore, the constitutive 
activation of ERK signaling could derive to antiestrogen resistance (Donovan et al., 2001). 
Somatostatin receptors are coupled to ERK signaling (Florio et al., 1999; Lahlou et al., 
2003; Pola et al., 2003; Sellers et al., 1999). However, somatostatin is not only an inhibitor 
and exerts a dual stimulatory/inhibitory effect on P-ERK and also on cell proliferation. 
More in detail, sst1 and sst2 increase P-ERK which is accompanied by a decrease in cell 
proliferation (Florio et al., 1999; Lahlou et al., 2003). On the other hand, sst4 also 
stimulates P-ERK but this time, resulting in increased proliferation (Sellers et al., 1999). It 
has also been reported that somatostatin inhibits P-ERK and cell proliferation in human 
neuroblastoma cells that express the endogenous sst2 receptor (Pola et al., 2003). In 
addition, there is evidence appointing to a constitutive inhibitory effect of endogenous 
murine ssts expressed in AtT20 to P-ERK (Ben-Shlomo et al., 2007). Specifically, the 
selective silencing of sst2, sst5 and sst3 receptors expressed in these cells resulted in 
increased both cAMP and P-ERK levels (Ben-Shlomo et al., 2007). Taking in account that 
the novel sst5TMD4 has a role of dominant negative to sst2 signaling, it is tempting to 
propose that these increased p-ERK levels could be derived of a blockade of the 
constitutive inhibitory action of sst2. 
Our data show that stimulation of sst5TMD4-expressing MCF-7 with SST lead to a negative 
cross-talk between Akt and ERK signaling pathways. Specifically, addition of SST to MCF-7 
cells expressing sst5TMD4 provoked a slight but significant increase in Akt 
phosphorilation and a decrease in ERKs phosphorilation. Crosstalk between the PI3K-Akt 
and the Raf/MEK/ERK pathways has been reported at multiple levels, though the results 
are rather opposing. Some studies suggest that the PI3K-Akt pathway enhances 
Raf/MEK/ERK (Germack et al., 2004; Jaquet et al., 2005; la Sala et al., 2005; Sebolt-Leopold 
and Herrera, 2004; Vivanco and Sawyers, 2002). However, PI3K-Akt and Ras-Raf-MEK-
ERK signaling pathways have also been reported be inversely regulated (Guan et al., 2000; 
Moelling et al., 2002; Reusch et al., 2001; Rommel et al., 1999). Interestingly, first 
evidences showing inhibition of ERK pathway by maintained high levels of Akt were 
reported in MCF-7 cells, suggesting that this cross-talk might switch the biological 
response to some compounds from growth arrest to proliferation (Zimmermann and 
Moelling, 1999). Our results and previous data reported in MCF-7 cells suggest that SST 
treatment of cells expressing sst5TMD4 leads to an increase in Akt phosphorilation that 
could provoke the concomitant inhibition of Raf-MEK-ERK pathway. In addition, we have 
observed that SST can inhibit the capacity of invasion of sst5TMD4-MCF-7 cells; therefore, 
in presence of SST, p-ERK levels and invasiveness of sst5TMD4-expressing- and 
sst5TMD4-lacking cells are related. These data are consistent with latest reports showing 
that Raf-MEK-ERK signaling pathway is directly involved in cell invasion through 
activation of Focal Adhesion Kinase (FAK) (Behmoaram et al., 2008; Sawai et al., 2005). 
Results shown herein indicate that the presence of sst5TMD4 in the breast cancer cell line 
MCF-7 increased Arp2/3 expression, which it is involved with the increased ability of 
these cells to invade. Increased and sustained basal P-ERK level, as we observe in 
sst5TMD4-MCF-7 expressing cells, derives in an activation of the Arp2/3 complex 
(Martinez-Quiles et al., 2004; Nakanishi et al., 2007) which can be reinforced by increased 
P-Akt (Lee et al., 2006). Arp2/3 complex, as other scaffolding proteins that link migratory 
signals to the actin cytoskeleton, are upregulated in invasive and metastatic breast cancer 
cells (Sahai, 2005; Wang et al., 2005; Yamaguchi and Condeelis, 2007). The heptameric 
Arp2/3 complex is an activator of actin filament nucleation and branching, and is essential 
in the formation of invadopodia in other cancer types (Wang et al., 2005; Yamaguchi and 
Condeelis, 2007). Knocking down its expression or expressing a dominant negative 
isoform results in a complete blockade of carcinoma cell invasiveness (Yamaguchi et al., 
2005). 
In sum, our results describe the presence of a new player, sst5TMD4, in the scene of 
SST/ssts and breast cancer. Specifically, we show for the first time, the presence of the 
truncated isoform sst5TMD4 in sporadic ductal invasive breast cancer samples and MCF-7 
cells and how this receptor alters the phenotype of epithelial breast cancer cells, 
enhancing their ability of growing and invading. sst5TMD4 is able to interact physically 
and modify sst2, but not sst5, mediated SST-14 signaling, resulting in an impaired calcium 
response and increased basal ERK and Akt phosphorilation levels. The role of this receptor 
in aggressive breast cancers could be disrupting an sst2 mediated SST-14 negative 
feedback. Sst5TMD4 could be considered as a bad prognosis factor for certain breast 
cancers. 
 
EXPERIMENTAL PROCEDURES 
 
Breast samples  
We analyzed a group of 40 sporadic invasive ductal breast carcinomas and 4 normal 
breast samples obtained from Tumour Bank-CNIO (Madrid). The mean patient age at 
surgery was 53 years (range, 27 to 87 years). This study was approved by the ethic 
committee of the institution.  
 
Cell Lines 
MCF-7 cell line (ATCC, Manassas, VA) was maintained in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% antibiotic-
antimycotic and 2 mM L-glutamine. CHO-K1 cells (ATCC) were cultured using F12 medium 
and the same supplements as above. Both cell lines were maintained at 37º C and 5% CO2. 
 
Plasmids and transfection 
sst5TMD4 sequence (DQ448304) was modified by PCR to include HindIII and BamHI 
restriction sites that were used clone it into the pCDNA3.1+ vector (Invitrogen, Barcelona, 
Spain). sst2A (AY236542) and sst5 (NM_001053) receptors inserted into pCDNA3.1+ 
vector (clones SST200000 and SST500000 respectively) were obtained from Missouri S&T 
cDNA Resource Center (http://www.cdna.org/). sst5TMD4 and sst2 were inserted into the 
HindIII and BamHI sites of E-YFP-N1 and E-CFP-N1 vectors (Clontech, NJ, USA) removing 
the TGA sequence from the antisense primer. For sst5, the antisense primer incorporated 
an EcoRI restriction site. Both MCF-7 and CHO-K1 cell lines were transfected using 
Lipofectamine 2000TM (Gibco, Barcelona, Spain) according to the manufacturer’s 
protocol. pCDNA3.1+ and derived vectors were used for stable transfection. To select 
stable transfectants, geneticin (G418; Gibco) was added to the culture media at 1mg/mL. 
Cells were maintained for one month, replacing the medium every week. Clones were 
characterized by immunolabeling and PCR. Stable clones of MCF-7 cells transfected with 
empty pCDNA3.1+ (mock transfected) were used as negative control. 
 
Antibodies 
Immunostaining of human sst5TMD4 was carried out using a rabbit polyclonal antiserum, 
generated through a commercial source (Genosphere Biotechnologies, Paris, France) 
which was generated against the sequence CRERLSGHKSWQEKG, which is unique for the 
sst5TMD4 isoform, and only identified this receptor variant. Antibodies against sst2 (goat 
anti-SST2 (A-20)) and sst5 (goat anti-SST5 (D-15)) were purchased from Santa Cruz 
Biotechnology, Inc. (CA, USA). The corresponding secondary antibodies were Alexa Fluor 
488 donkey anti-goat and Alexa Fluor 594 chicken anti-rabbit (Invitrogen). Antibody 
against total ERKs (ERK 2(C-14) were purchased from Santa Cruz Biotechnology, Inc. and 
antibodies against phospho-ERKs (Phospho-p44/42 MAPK (thr202/Tyr204)), Akt and 
phosphor-Akt (Phospho-Akt (Ser473)) were purchased from Cell Signaling Technology, 
Inc. (MA, USA). The secondary antibody used in western blotting was horseradish 
peroxidase (HRP) goat anti-rabbit IgG (Sigma, Barcelona, Spain). The rat anti-E-cadherin 
antibody and the corresponding horseradish peroxidase (HRP) goat anti-rat IgG were 
kindly provided by A. Cano.In E-Cadherin experiments, we use mouse anti-β-actin 
antibody (Sigma) as loading control; the corresponding secondary antibody was 
horseradish peroxidase (HRP) goat anti-mouse IgG (Sigma). 
 
PCR and quantitative real time PCR 
An amount of 100 ng of cDNA was used for each PCR. Qualitative PCR was used to detect 
the presence of ssts in MCF-7 cells. Quantitative PCR was used to quantify sst2, sst5, 
sst5TMD4, Arp2, Arp3, p16, cyclin D3, E-cadherin, MMP-2 and MMP-9. 18S was used as 
internal standard. Primer pairs were sst2_S 5`-TCAAGTCGGCCAAGTGGAGGAG-3`, sst2_AS 
5`-CATGATGGGCAAGATGACCAGC-3`, sst5A_S 5`-CCGCCAGAGCTTCCAGAAGGTT-3`, sst5A 
_AS 5`-GCTGGTCTGCATAAGCCCGTTG-3`, sst5TMD4_5`-GTCCTGTCTCTGTGCATGTCGCT-3`, 
sst5TMD4_AS 5`-CAGGATTTGTGCCCACTCAGCC-3´, arp2_S 5`-
ACAACTTTTGGATGACCCGACAA-3`, arp2_AS 5`-ACCTTTCCAGTCAAAGGGCAGAG-3`, arp3_S 
5`-CCAATCCGCCATGGTATAGTTGA-3`, arp3_AS 5`-CACAGCAATGTACAAGCCTGGAA-3`, 
p16_S 5`-TGGGTGAATACCACTGCCAAGTT-3´, p16_AS 5`-GATGTTCATGCCCAACAAGCTCT-
3`, hECAD_S 5`- AACACATTTGCCCAATTCCA-3`, hECAD_AS 5`- CACTACCCCCTACCCCTCAA-
3`, hMMP2_S 5`- CTACGATGGAGGCGCTAATG-3`, hMMP2_AS 5`- 
ACTCTTTGTCCGTTTTGGGG-3`, hMMP9_S 5`- CAGTGCCATGTAAATCCCCA-3`, hMMP9_AS 
5`- CACCTCCACTCCTCCCTTTC-3`, 18s_S 5`-CCCATTCGAACGTCTGCCCTATC-3` and 18s_AS 
5`-TGCTGCCTTCCTTGGATGTGGTA-3`.  
For qualitative PCR, we used EcoTaq polymerase (Ecogen, Barcelona, Spain). For real time 
quantitative PCR, we used a 2x master mix from BioRad (BioRad, Madrid, Spain) with the 
SYBR chemistry. The reactions were supplemented with 5 µl of 1.5 M betaine (Sigma) to 
amplify sst5TMD4. All PCR reactions were carried out in an iCycler IQ™ termal cycler 
(BioRad). 
 
Confocal imaging 
CHO-K1 cells growing onto glass coverslips were transiently cotransfected with sst2-YFP 
and sst5TMD4-CFP or sst5-CFP and sst5TMD4-YFP. Twenty four hours after transfection, 
cells were rinsed in PBS, fixed for 5 min in 4% paraformaldehyde, rinsed twice in PBS and 
mounted onto a slide using Fluoromount (Molecular Probes, Eugene, OR). Images were 
acquired with a Leica Espectral TCS-SP2-AOBS confocal scanning microscope (Leica Corp, 
Heidelberg, Germany) with the CFP and YFP channels. Images of CFP and YFP channels 
were analyzed and merged with ImageJ (NIH, Bethesda, MD). 
 
FRET measurements 
The interaction among the truncated sst5TMD4 isoform and sst2 and sst5A was evaluated 
by competitive FRET, in which sst2 and sst5A homodimerization is evaluated in the 
presence of increasing amounts of untagged sst5TMD4. Images of CHO-K1 transfected 
cells were acquired with an inverted Nikon Eclipse TE2000 E scope equipped with a 400 
DCLP dichroic filter (Chroma, Rockingham) and recorded with an ORCA II BT digital 
camera, both controlled with MetaMorph software (Imaging Corporation, West Chester, 
PA). Net FRET was calculated using the three filters method with the methodology 
developed previously (Duran-Prado et al., 2007). FRET efficiency was calculated in 
relation to the positive control consisting in a vector with E-CFP and E-YFP coupled in 
frame, which provided the upper FRET efficiency limit (100%). Images were acquired with 
the MetaMorph software and analyzed with ImageJ and Microsoft Excel 2007. For image 
analysis and coefficient calculation, background was always subtracted in each picture. A 
1:1 E-YFP/E-CFP ratio and equal E-YFP and E-CFP intensities between all samples were 
use for FRET measurements. 
 
Measurement of free cytosolic calcium concentration ([Ca2+]i) in single cells 
MCF-7 or CHO-K1 cells were plated onto poly L-lysine treated 25mm-coverslips. For MCF-
7 cells, 24h before the experiment the medium was replaced by charcoal-stripped 
medium. The day of the measurement MCF-7 and CHO-K1 cells were incubated for 30 min 
at 37º C with 2.5 µM of the Ca2+ indicator dye Fura-2 AM (Molecular Probes, Eugene, OR) 
in phenol red-free DMEM containing 20 mM NaHCO3, pH 7.4. Coverslips were washed 
with phenol red-free DMEM and mounted on the stage of a Nikon Eclipse TE2000 E 
microscope (Nikon, Tokyo, Japan) with attached back thinned-CCD cooled digital camera 
(ORCA II BT; Hamamatsu Photonics, Hamamatsu, Japan). Cells were examined under a 40X 
oil immersion objective during exposure to alternating 340- and 380-nm light beams, and 
the intensity of light emission at 505 nm was measured every 5s. Changes in [Ca2+]i after 
10-7 SST administration were recorded as background subtracted ratios of the 
corresponding excitation wavelengths (340/F380) using MetaFluor Sofware (Imaging 
Corporation). In the case of cells cotransfected with the receptor pairs sst2-
YFP/sst5TMD4-CFP and sst5-YFP/sst5TMD4-CFP, only cells with the same quantity of YFP 
and CFP, namely receptor, were selected for analysis. 
 
Western blotting 
Cells were cultured to subconfluence in 6-well plates, assayed for the indicated time, and 
immediately lysed in pre-warmed SDS-DTT sample buffer (62,5mM Tris-HCl, 2% SDS, 
20% glicerol, 100mM DTT and 0,005% bromophenol blue) followed by sonication for 10 
sec and boiling for 5 min at 95º C. To detect sst5TMD4 truncated receptor, cells cultured in 
50 cm2 culture flasks were detached with a cells scraper in PBS solution (containing 5 mM 
EDTA, 0.02 % sodium azide, 15 U/ml DNase1 and protease inhibitors). Then, cells were 
lysated with a 25-G gauge, incubated for 30 minutes at 4º C and centrifuged at 13.000g for 
10 min. Pellet was resuspended in warm SDS-DTT sample buffer and lysates were 
sonicated for 10 sec and boiled for 5 min at 95º C. In both instances, proteins were 
separated by SDS-PAGE and transferred to nitrocellulose membranes (Millipore). 
Membranes were blocked with 5% non fat dry milk in Tris-buffered saline/0.05% Tween 
20 and incubated with the primary antibodies for ERK1/2, p-ERK1/2, p-Akt, Akt, E-
Cadherin, β-actin or anti-sst5TMD4 and the appropriate secondary antibodies. Proteins 
were developed using an enhanced chemiluminescence detection system (GE Healthcare, 
UK) with dyed molecular weight markers. Where corresponding, a densitometric analysis 
of the bands was carried out with ImageJ software. The relative p-ERK and p-Akt values 
were obtained from normalization of p-ERK1/2 or p-Akt values against the total ERK1/2 
or β-Akt values, respectively, or normalization of E-Cadherin against β-actin values. 
 
In Vitro Proliferation Assays 
Basal cell proliferation was evaluated in cells coming from “initial” and “final” passages, 
and in transiently and stably transfected MCF-7 cells, in all instances using Alamar-Blue 
reagent (Biosource International). Briefly, the day of measurement, cells were incubated 
for 3 hours in 10% alamar blue/ serum free-DMEM and then, alamar reduction was 
measured in a BioTek Synergy HT fluorescence plate reader (BioTek Instruments, Inc., 
Vermont, USA), exciting at 560 nm and reading at 590 nm. Results are expressed as RFU or 
percentage vs. control (mock transfected cells). For initial and final passages cells, 5000 
cells/well were counted and seeded in a 96 well plate and basal proliferation was 
evaluated 24h after seeding. For transiently transfected cells, 5000 cells/well were plated 
and transfected 24h after seeding. Proliferation was evaluated 48h after transfection. For 
kinetics proliferation experiments in mock and sst5TMD4 stably transfected cells, 1500 
cells were seeded and cultured during 5 days, measuring proliferation in days 3, 4 and 5. 
Medium was replaced by fresh medium immediately after each measurement. Kinetics 
curves were fitted to exponential growth curves with GraphPad Prism 4 (GraphPad 
Software, San Diego, CA). Doubling time and K growing constant were calculated from 
these exponential curves. In all instances, cells were seeded per quadruplicate and all 
assays were repeated a minimum of three times. 
 
Migration and Invasion Assays 
The ability of mock and sst5TMD4 stably transfected cells to migrate was evaluated by 
wound healing technique. Briefly, MCF-7 stable cells were plated at sub-confluence in 12 
well plates. Confluent cells were serum-starved for 24h and after synchronization the 
wound was made using a 10 µl sterile pipette tip. Wells were rinsed in PBS and then cells 
were incubated for 24h in FBS supplemented medium. Wound healing was calculated as 
the area of a 400 pixels rectangle centered in the picture 24h after the wound vs. the area 
of the rectangle just after doing the wound. Three experiments were performed in 
independent days, in which four random pictures along the wound were acquired per well. 
Invasion of mock and sst5TMD4 stably transfected cells was evaluated by a modified 
Boyden chamber method, using a 48 well chemotaxis chamber (NeuroProbe, 
Gaithersburg, MD). Briefly, 10000 cells per well were seeded onto a 8µM pore PDVF 
membrane (NeuroProbe) previously treated with collagen type IV (BD Biosciences, San 
Jose, CA) or matrigel (BD Biosciencies). Cells were placed on the upper chamber onto the 
membrane. The lower well was filled with FBS-free media (negative control) and 10% 
FBS, including three replicates per condition. After 6h incubation, non migrated cells were 
removed and migrated cells fixed in methanol and stained with DAPI. Images were taken 
with a standard fluorescence microscope and a 20X objective. Three random fields per 
well were imaged for further analysis with ImageJ. 
 
Xenografts 
Animal maintenance and experiments were carried out following the European 
Regulations for Animal Care and the ethics committee of the University of Cordoba. Six-
week-old female athymic Swiss nude mice (Charles River Laboratories) were 
subcutaneously grafted in the ﬂank with 2x106 mock or sst5TMD4 stably transfected MCF-
7 cells. Tumor growth was monitored once a week with a digital caliper, at the site of 
injection. Tumors were allowed to grow during three months, at which point animals were 
euthanized. The tumor volume was calculated using the formula: (length x width)/(4 x π). 
Each tumor was dissected, ﬁxed in formaldehyde and sectioned at 8 µM histopathologic 
examination after hematoxylin and eosin staining. 
 
Statistics 
Statistical analysis was performed with SPSS 15 (Chicago, Illinois, USA) and GraphPad 
Prism 4. Data are expressed as mean ± SEM obtained from, at least, three separate, 
independent experiments carried out in different days and with different cell preparations 
(n=3). Statistical analysis was carried out using Student´s t-test followed by a Mann-
Whitney statistical test or one-way ANOVA (Kruskal-Wallis test) followed by a statistical 
test for multiple comparisons (Dunn’s test). Differences were considered to be significant 
at P=0.05 or lower. 
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FIGURE LEGENDS 
 
Figure 1. Correlation of sst5TMD4 and tumor markers in 40 sporadic ductal breast cancer 
samples. Graphs show statistical analysis correlating presence of sst5TMD4 to diverse 
tumor parameters. sst5TMD4 expression is inversely correlated with levels of ER 
(P=0.053), p53 (P=0.037) and Her2neu (P=0.038) and directly correlated with tumor 
invasiveness (P≤0.001), measured as the presence of tumor cells in lymph nodes. 
 
Figure 2. Coexpression of sst2 and sst5TMD4 in primary breast cancers; physical and 
functional interaction of sst2 and sst5TMD4 in homologous and heterologous cell models. 
(A) Correlation between expression levels, by quantitative RT-PCR, of sst5TMD4 and sst2 
in ductal breast cancer samples possitive for sst5TMD4 (R2=0,715, n=40).  
(B, F) Representative images of CHO-K1 cells transiently transfected with sst2-YFP and 
sst5TMD4-CFP (B) or sst5-YFP and sst5TMD4-CFP (F). Colocalization of each pair of 
receptors is shown in yellow.  
(C, G) Representative images of confocal colocalization of the endogenous sst2 or sst5 with 
sst5TMD4 in MCF-7 obtained by immunocytochemistry. Pictures show MCF-7 cells 
immunolabelled with sst2 or sst5 (green) and sst5TMD4 (red) specific antibodies. 
Colocalization of each pair of receptors is shown in yellow. 
(D, H) Measurements of competitive FRET assays using CHO-K1 cells transfected with 
tagged sst2 (D) or tagged sst5 (H) and increasing amounts of untagged sst5TMD4. The 
data represent the means ± SEM of three independent experiments (more than 30 cells in 
three independent experiments).  
(E, I) Measurements of free cytosolic calcium ([Ca2+]i) in CHO-K1 cells transiently 
transfected with sst2 alone or with sst2 and sst5TMD4 (E) and with sst5 alone or with sst5 
and sst5TMD4 (I) in response to SST-14. The data represent the means ± SEM of more 
than 15 cells. 
 
Figure 3. Molecular, functional and morphological analysis of the MCF-7 cell line. 
(A) RT-PCR analysis of somatostatin receptors (sst2, sst5, and sst5TMD4) and 18s during 
the culturing of MCF-7 cells.  
(B) RT-PCR quantification of sst5TMD4 in MCF-7 cells of initial and final passages and in 
stably transfected mock- and sst5TMD4-MCF-7.  
(C) Western blotting analysis of sst5TMD4 in MCF-7 cells of initial and final passages and 
in stably transfected mock- and sst5TMD4-MCF-7.  
(D) Representative profiles of changes in the concentration of free cytosolic calcium 
([Ca2+]i) in MCF-7 cells of initial and final passages in response to 10-7 M SST-14 
administration and percentage of responsive cells of each passage. The data represent the 
means ± SEM of more than 150 cells measured in three separate experiments. 
(E) Representative profiles of changes in the concentration of free cytosolic calcium 
([Ca2+]i) in MCF-7 cells transiently transfected with sst5TMD4 in response to 10-7 M SST-
14. Inset indicates the percentage of responsive cells of each passage. The data represent 
the means ± SEM of more than 150 cells measured in three separate experiments. 
(F) Morphological analysis of MCF-7 cells stably transfected with or without sst5TMD4. 
Pictures shows representative images of MCF-7 cells transfected with the mock vector and 
sst5TMD4 construct. Total and mesenchymal-like cells were counted in mock- and 
sst5TMD4-MCF-7 cultures. Results are represented as percentage of cells with 
mesenchymal-like morphology versus total cells. The data represent the means ± SEM of 
more than 450 cells per group. Black arrows indicate cells with mesenchymal-like 
morphology. 
(G) Expression of E-cadherin in stably transfected MCF-7. Quantitative real time PCR 
quantification of E-cadherin mRNA in transfected MCF-7 cells (left chart; P=0.0051). 
Western blot analysis of E-cadherin protein from stably transfected MCF-7. The actin blot 
is serving as a loading control. Representative immunoblots are shown. Densitometric 
readings are given as mean ± SD values and normalized to actin expression (right chart; 
P=0,0086). 
 
Figure 4. Basal and induced phosphorilation of mitogen-activated protein kinases 
(MAPKs) and Akt kinase in MCF-7 cells. Lysates from MCF-7 cells were subjected to 
western blotting with anti-ERKs, anti-phospho-ERKs (p-ERKs), anti-Akt and anti-phospho-
Akt (p-Akt) antibodies. Densytometric analysis of the bands was done with ImageJ 
software. Quantitative data from the immunoreactive bands were normalized against the 
corresponding control values (total ERK and Akt). 
(A) Representative western-blotting and quantification of basal levels of phosphorilated 
ERKs in MCF-7 of initial and final passages.  
(B) Representative western-blotting and quantification of basal p-ERKs levels in 
transfected MCF-7 (mock or sst5TMD4).  
 (C) Representative western-blotting and quantification of basal levels of phosphorilated 
Akt in MCF-7 of initial and final passages.  
(D) Representative western-blotting and quantification of basal p-Akt levels in transfected 
MCF-7 (mock or sst5TMD4).  
Regulation of phosphorilation of ERK and Akt by 10-7M of SST was determined by time-
course experiments. In all instances, the data represent the means ± SEM of three 
independent experiments.  
 
Figure 5. Invasion and migration of MCF-7 cells, in vitro.  
(A) Representative pictures of invasion assays of mock- and sst5TMD4-transfected MCF-7 
cells plated onto Matrigel or collagen IV treated filters in response to a 10% FBS gradient. 
Charts represent percentage of migrated cells after 6h versus control in collagen and 
matrigel treated filters. The data represent the means ± SEM of three independent 
experiments. 
(B) Representative pictures of wound healing assays carried out with stably transfected 
mock- and sst5TMD4-MCF-7 cells. Panels show pictures at time 0 and 24h under basal 
conditions or treated for 24h with 10-7 M SST. Lower charts show percentage of wound 
area vs. time 0. The data represent the mean ± SEM of three independent experiments. 
(C) Quantification of mRNA levels of Arp complex components in mock- and sst5TMD4-
MCF-7 cells. Quantitative PCR was used to detect the presence of components of the actin-
related protein (Arp) 2/3 complex in stably transfected MCF-7 cells. The data represent 
the means ± SEM of four independent experiments. 
(D and E) Quantitative real time PCR quantification of MMP-2 (D) and MMP-9 (E) in 
different passages (left) or transfected MCF-7 cells (right), respectively. The data 
represent the means ± SEM of four independent experiments. 
 
Figure 6. Proliferation of sst5TMD4 expressing MCF-7 cells is increased both, in vitro and 
in vivo.  
(A) Percentage of basal proliferation after 24h in initial and final cultures of MCF-7 (top) 
and in transient transfected MCF-7 cells (bottom). The data represent the means ± SEM of, 
at least, three independent experiments. 
(B) Proliferation kinetics of stably transfected MCF-7 (mock and sst5TMD4) cultured for 5 
days (top panel). Doubling time, growth constant (K) and mRNA levels of cyclin D3 of each 
cell clone (lower panel). The data represent the means ± SEM of three independent 
experiments. 
(C) Growing of mock- and sst5TMD4-MCF-7 xenografts subcutaneously inoculated into 
nude mice. Left chart show growth curves of induced tumors up to 9 weeks. A 
representative picture of hematoxylin-eosin staining for each group is shown in right 
pictures. 
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Abstract 
Ghrelin and neurotensin (NTS) are two neuroendocrine peptides with opposite roles in 
food intake and energy homeostasis, albeit exert similar actions improving memory and 
learning processes. Their actions are mediated by two-ghrelin GPCRs (GHSR1a/1b) and 
three-NTS receptors, two GPCRs (NTSR1/2) and one non-GPCR (NTSR3). Noteworthy, 
GHSRs and NTSRs display a high evolutionary identity and compose the so-called ghrelin-
receptor-like family. Since, ghrelin and NTS systems are clearly involved in energy balance 
regulation and cognitive processes, both have been proposed to be altered in Alzheimer 
disease (AD), a dementia syndrome clearly influenced by the metabolic state. Although it 
has been demonstrated that ghrelin and NTS can attenuate AD-related cognitive 
impairment, a comprehensive analysis of these systems in AD has been not yet underwent. 
Therefore, we have analyzed by quantitative-real time PCR the ghrelin/NTS axis in one of 
the most affected cortical regions in AD, the temporal gyrus. Specifically, we observed a 
marked reduction of ghrelin, In2-ghrelin variant (a recently discovered variant), GOAT 
(the enzyme responsible to its acylation), and GHSR1a expression, whereas the mRNA 
levels of the dominant-negative GHSR1b was increased. Similarly, we observed a profound 
decrease in the mRNA copy number of NTSR1 and NTSR2, and a slight reduction in NTS 
expression. In contrast, expression of NTSR3, a receptor involved in neuronal apoptosis, 
did not vary. Collectively, our results represent the first quantitative evidence showing 
that ghrelin/NTS systems are altered in the brain of AD patients which could help to 
explain, in part, the severe cognitive deficit observed in this pathology. 
 
Introduction 
The endogenous brain-gut peptides ghrelin and neurotensin (NTS) are the most 
studied members of two complex peptides-receptors families. Ghrelin gene encodes a 
family of related-peptides which can be generated by alternative splicing and/or post-
translational modifications (Seim, 2009). Ghrelin and likely In2-ghrelin variant (a splicing 
isoform recently identified by our group, can be acylated by the Ghrelin-O-acyltransferase 
(GOAT) enzyme (Gutierrez, 2008; Yang, 2008). Although desacyl-ghrelin (DAG) is the most 
abundant form in the circulation, only acyl-ghrelin binds to G-protein coupled receptor 
type 1a (GHSR1a), which is encoded by a gene that also originates an alternative spliced 
variant (GHSR1b) whose precise role is still known. Conversely, three neurotensin 
receptor, two GPCRs (NTSR1/2) and one non-GPCR [NTSR3, also known as sortilin (SORT-
1)], encoded by independent genes have been hitherto described (Vincent, 1999). 
Interestingly, ghrelin and NTS GPCRs share a high evolutionary identity and compose the 
so-called ghrelin receptor family (Holst, 2004). Indeed, NTSR1 and GHSR1b have also been 
reported to functionally interact in lung cancer cells to mediate the proliferative effect of 
the NTS-related peptide neuromedin-U (NMU) (Takahashi, 2006). 
Because ghrelin and NTS are involved in food intake, body weight gain, energy 
homeostasis, and adiposity, it has been suggested that the dys-regulation of ghrelin and/or 
NTS systems could be directly associated with obesity and metabolic syndrome (Williams, 
1991; Chollet, 2009). In addition, ghrelin and NTS systems are also involved in 
inflammatory processes (Bossard, 2007; Koon, 2009), and neuromodulation acting as 
positive stimulus in memory and learning processes (Ohinata, 2007; Yamauchi, 2007; 
Toth, 2009a; Toth, 2009b). Therefore, since Alzheimer´s disease (AD) is a 
neurodegenerative disorder characterized by severe cognitive deficit, and is clearly 
influenced by metabolic syndrome, obesity, energy impairment and inflammation 
(Giordano, 2007; Erol, 2008), the question of whether modulation of ghrelin and NTS 
systems is relevant in this pathology has recently emerged (Giordano, 2007). Indeed, 
evidences supporting a close relationship between ghrelin or NTS systems and AD have 
been recently demonstrated. For instance, DAG can act as a “neuroprotective” molecule 
through binding to CD36, which interferes in the initiation of signaling cascades that lead 
to neuronal dysfunction and death (Bulgarelli, 2009). In addition, NTSR3 has been shown 
to be involved in neurodegeneration since can interact with two protein up-regulated in 
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AD, the pro-neural growth factor (NGF) and p75, forming a heterotrimer capable of induce 
neuronal apoptosis (Clewes, 2008).  
In spite of AD is also characterized by the impairment of several 
neuropeptides/neurotransmitter systems (Golomb, 2000), few studies have been 
addressed to understand the precise regulation of ghrelin and NTS systems in AD 
pathology. Since the temporal lobe is one of the most important cortical structures in 
memory and cognition, and one the most affected region in AD (Braak and Braak, 1991), in 
the present study, we carried out a detailed quantification of mRNA levels of ghrelin and 
NTS systems (ghrelin, In2-ghrelin variant, GOAT, GHSR1a/b, NTS, and NTSRs) using 
quantitative real-time PCR (qrt-PCR) in three different regions of the temporal lobe 
(inferior, medial and superior) of control and AD human brains. 
 
Material and methods 
Tissue samples.  
Human brain tissues were obtained from the Netherlands Brain Bank (Netherlands 
Institute for Neuroscience, Amsterdam) which supplies post-mortem specimens from 
clinically well documented and neuropathologically confirmed cases and controls as 
recently reported (Gahete, 2010). The Netherlands Brain Bank abides to all local ethical 
legislation. Frozen samples used in this study were from three different regions of the 
temporal lobe (inferior, medial and superior) of six patients (four males and two females, 
68-91 years) with the clinical diagnosis of AD and six non-demented controls (four males 
and two females, 73-93 years). Tissue samples were taken at death and during 3-5h post-
mortem intervals. Available clinicopathological details of each patient are shown in Table 
1. 
Nucleic acids isolation and reverse transcription (RT). 
Total RNA from frozen samples was isolated with the RNA Miniprep Kit 
(Stratagene, Texas, USA) following manufacturer’s instructions and the amount was 
quantified using the Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, DE, 
USA). For RT-PCR studies, 1 µg of total RNA were reverse transcribed using the AMV kit 
(Roche diagnostics, Mannheim, Germany).  
Quantitative real-time PCR (qrt-PCR) measurements.  
Expression of ghrelin, In2-ghrelin variant, GOAT, GHSR1a, and GHSR1b, as well as 
NTS, NMU, NTSR1, NTSR2, and NTSR3 was screened by qrt-PCR using specific primers for 
each transcript (Table 2). Details of primer selection, verification of primer specificity, 
confirmation of PCR efficiency, construction of standard curves as well as confirmation of 
target specificity (verification of graded temperature dependent dissociation curves and 
sequence analysis) have been previously reported in detail (Taboada, 2007; Neto, 2009). 
Amplifications were performed using the iCycler IQ™ system (Biorad, CA, USA) as 
previously described (Gahete, 2010). A non-DNA control was always run on each plate to 
monitor potential exogenous contamination. To control for variations in the amount of 
RNA used in the RT reaction and the efficiency of the RT reaction, the expression level 
(copy number) of one housekeeping gene (cyclophilin-A) was determined for each sample 
where cyclophilin A copy number was not altered between experimental groups. To 
determine the starting copy number of cDNA, RT samples were PCR amplified, and the 
signal was compared with that of a specific standard curve for each transcript run on the 
same plate (1, 101, 102, 103, 104, 105 , 106 copies). It should be noted that the slope of a 
standard curve for each template examined was between -3,31 and -3,35 (R2 of the 
standard curve between 0,997 and 1,002) indicating that the efficiency of amplification 
was close to a 100%, meaning that all templates in each cycle were copied. 
Statistical analysis.  
Kolmogorov-Smirnov test was used to assess the normality of the distribution of 
all variables. Student's t-test analysis was used for normally distributed variables, while 
Mann-Whitney U-test was used for nonparametric variables. P values less than 0.05 were 
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considered significant. All statistical analyses were performed using the GraphPad Prism 
and SPSS 13.0 software packages. 
 
Results 
Expression of ghrelin axis in the brain of control subjects and AD patients. 
Absolute quantification of mRNA copy number in the temporal cortex showed that 
ghrelin and In2-ghrelin variant, as well as GOAT, were highly expressed in the brain of 
both control and AD subjects (Table 3). Specifically, we observed a clear reduction of 
ghrelin expression (48,8%) in the whole temporal gyrus of AD patients as compared with 
controls (Table 3 and Figure 1A). In contrast, when each lobe was analyzed separately, we 
observed that ghrelin expression was statistically decreased only in the inferior temporal 
region and not in the medial and superior gyrus. In addition, although the expression 
levels of In2-ghrelin variant tended to decrease in the whole temporal gyrus (41%), this 
difference did not reach statistical significance (Figure 1B). Interestingly, In2-ghrelin 
variant mRNA expression was not detected in the inferior lobe, did not change in the 
medial lobe but it was severely decreased in the superior lobe. GOAT mRNA levels did not 
change in the whole temporal gyrus of AD patients as compared with matched controls 
(Figure 1C); however, when each region was considered separately, we unexpectedly 
observed a significant reduction of GOAT expression in the inferior lobe of AD patients 
compared with control subject, whereas no variations were observed in the medial and 
superior lobes (Figure 1C). It should be noted that no differences between genders were 
observed in ghrelin, In2-ghrelin variant and GOAT expression differences between AD and 
control subjects (data not shown). As internal standard, we used cyclophilin, a 
housekeeping gene whose mRNA expression has been reported to remain consistently 
unaltered in brains from AD patients (Mousavi, 2003; Merali, 2004; Hellstrom-Lindahl, 
2008). In fact, consistent with that data, the mean mRNA copy number measured in this 
study for cyclophilin in non-demented control was 3,412 ± 1,080 copies/100ng of RNA 
and, in AD patients 3,158 ± 1,227 (p=0.72).  
We also analyzed the expression levels of ghrelin receptor gene (GHSR) 
transcripts, GHSR1a and GHSR1b, in the temporal lobe of AD and control subjects. Both 
receptors were present in control subjects, being GHSR1a more expressed than GHSR1b; 
however, their regulation were absolutely opposite in the temporal region of AD patients 
(Table 3). Specifically, mRNA levels of GHSR1a were markedly reduced (54%) in the whole 
temporal lobe of AD patients compared with normal controls (Figure 1D). When each 
region was considered separately, we observed that GHSR1a expression was also 
significantly reduced in the inferior and superior regions; however, it was not altered in 
the medial region of AD patients compared with controls. On the other hand, GHSR1b 
mRNA levels were 3-fold increased (P≤0,001) in the whole temporal lobe of AD patients as 
compared with controls (Figure 1E), and this difference was consistently observed across 
cortical regions (inferior, medial and superior) of AD patients. As a result, we found that 
the GHSR1a/GHSR1b ratio is completely altered in AD pathology. Indeed, while the 
majority of the control subjects present a GHSR1a/GHSR1b ratio higher than 1 (5 of 6 
controls), meaning a higher amount of GHSR1a than GHSR1b mRNA, AD patients have a 
GHSR1a/GHSR1b ratio ≤ than 1 (5 of 6 patients  1 and one patient with a ratio of 1; 
Figure 1F). No differences between genders were observed in GHSR1a or GHSR1b mRNA 
levels between AD and control subjects (data not shown). 
 
Expression of NTS axis in the brain of control subjects and AD patients. 
Quantification of NTS and NMU mRNA copy numbers revealed that the expression 
levels of these genes were, by and large, considerably lower than that of ghrelin or In2-
ghrelin (Table 3). In whole temporal lobe, expression levels of NTS and NMU tend to be 
lower in AD patients compared to control subjects, although this difference did not reach 
statistical significance (Table 3). Similarly, no significant differences in NTS expression 
level were found within the three temporal regions (inferior, medial and superior) of AD 
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patients compared with controls (Figure 2A). Interestingly, a significant reduction in NMU 
mRNA levels was observed in the superior lobe of AD patients compared with controls 
while no differences were found in the inferior or medial cortical regions (Figure 2B). 
We also analyzed the expression levels of NTS receptors (NTSR) transcripts, 
NTSR1-3, in the temporal lobe of AD and control subjects. We found that all three NTSRs 
were expressed in temporal cortex of control brains, although at very different levels 
(NTSR2 >> NTSR3 >>> NTSR1) (Table 3). Interestingly, an overall reduction of 50% in the 
number of NTSRs mRNA copies was observed in AD temporal cortex compared with 
controls. Specifically, expression level of NTSR1 and NTSR2 were significantly reduced 
while NTSR3 mRNA levels did not change in the whole temporal region of AD patients 
compared with controls samples (Fig. 2D-E). When each region was considered separately, 
we observed a consistent reduction of NTSR1 and NTSR2 in the three areas analyzed of AD 
patients (Figure 2C and D, respectively), while NTSR3 expression was not significantly 
altered in any of the regions (Figure 2E). Again, gender comparison did not reveal any 
differences in the expression of NTS axis between female and male patients (Data not 
shown). 
 
Discussion 
Alzheimer disease (AD) is a progressive disorder characterized by severe cognitive 
deficit, augmented accumulation of amyloid-β (Aβ), hyperphosphorylated tau proteins, 
and impairment of several neuropeptides/neurotransmitter systems (Golomb, 2000; 
Selkoe, 2001). Similar to that occurred in other neurodegenerative disorders, AD is 
profoundly affected by the metabolic and inflammatory status (Giordano, 2007; Erol, 
2008). However, although ghrelin and NTS peptides are well-known key players in the 
regulation of energy balance (Remaury, 2002; Cui, 2005; De Vriese and Delporte, 2007; 
2008) and some inflammatory processes (Bossard, 2007; Koon, 2009), their systems have 
not yet been comprehensively studied in AD. To our knowledge, this is the first report 
quantitatively analyzing the ghrelin and NTS axis in brains of AD patients. Specifically, we 
have focused our studies in the temporal lobe of AD patients since the most severe 
cognitive deficit in AD is the impairment of episodic memory, and this cortical structure, 
the temporal lobe, is the most important area associated with episodic memory functions 
(Braak and Braak, 1991). Our results demonstrate that ghrelin and its recently discover 
splice variant, In2-ghrelin, are highly expressed in the temporal lobe of control subjects. 
Interestingly, the expression of ghrelin and In2-ghrelin variant were found to be down-
regulated in a region-specific manner in AD patients compared with controls (inferior 
region for ghrelin and superior region for In2-ghrelin variant), suggesting the existence of 
a divergent regulation of the ghrelin gene to generate a specific ghrelin transcript isoform 
in the temporal lobe of AD patients. Although it has been demonstrated that ghrelin 
plasma levels decrease with age in normal subjects (Rigamonti, 2002), this is the first 
report showing that AD patients have further reduction in brain ghrelin mRNA production 
compared with age-matched controls. Surprisingly, the mRNA levels of the enzyme 
responsible to acylate ghrelin, and likely In2-ghrelin variant, were not notably altered in 
the whole temporal lobe. However, when each lobe was analyzed separately, we found 
that changes in GOAT expression parallel those of ghrelin (down-regulation exclusively in 
the inferior gyrus) which could suggest that native ghrelin could be a primary substrate 
for GOAT in that specific cortical region. Since it has been found that ghrelin levels do not 
vary in the cerebrospinal fluid of AD patients compared with age-matched controls (Proto, 
2006), our findings suggest that the locally-produced acylated/non-acylated ghrelin and 
In2-ghrelin variant could exert autocrine and/or paracrine function in the temporal lobe, 
similar to that observed in astrocytoma cell lines (Dixit, 2006), where ghrelin and GHSR1a 
constitute a autocrine pathway controlling astrocytoma motility. Indeed, it is commonly 
accepted that ghrelin exert the majority of its actions through binding to GHSR-1a 
(Castaneda, 2009), a GPCR widely distributed in human tissues, including brain (Guan, 
1997). Even more, a significant proportion of these actions have been reported to be 
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mediated by an autocrine loop (Jeffery, 2003; Dixit, 2006). Our results demonstrate that 
mRNA levels of GHSR1a were more abundant than GHSR1b in normal subjects; however, 
the relative expression of these receptors were completely opposite in AD patients since 
expression levels of GHSR1a were drastically reduced in a region-specific manner while 
GHSR1b mRNA levels were potently up-regulated in all temporal lobe regions of AD 
patient. These results are in keeping with previous reports showing that GHSR1b is more 
expressed in some pathologies, such as colorectal cancer (Waseem, 2008), adrenocortical 
tumors (Barzon, 2005), and breast cancer. Interestingly, it has been recently 
demonstrated that GHSR1b can heterodimerize with GHSR1a, promoting their 
translocation to the nucleus and thereby, GHSR1b could act as a dominant-negative 
receptor, partially blocking GHSR1a functionality (Chu, 2007; Leung, 2007). In 
consequence, since ghrelin has been demonstrated to act as a positive stimulus in learning 
a memory processes, we could hypothesized that overexpression of GHSR1b could be, at 
least, partially responsible of the severe cognitive impairment that occurs in AD. In 
addition, the data presented in this manuscript may be important for clinical purpose 
since this is the first report showing the existence of differential expression of the ghrelin 
axis in the brain of AD patients compared with normal controls which could represent 
potential novel markers as diagnostic/prognostic for this pathology. 
Although NTS has been also found to be involved in memory consolidation 
(Ohinata, 2007; Yamauchi, 2007), and in learning processes (Tirado-Santiago, 2006), its 
role in AD pathogenesis has not been yet comprehensible analyzed. In the present work, 
we have quantitatively analyze the mRNA levels of NTS system (NTS, NTSR1, NTSR2, and 
NTSR3) in AD patients, as well as, a highly-related peptide, NMU, since it has been 
reported that this peptide is able to bind to heterodimers of GHSR1b/NTSR1 (Takahashi, 
2006). Specifically, we have observed that both peptides, NTS and NMU, are expressed, 
although at very low levels, in the human temporal lobe. In AD patients, NTS and NMU 
expression tend to be decreased; however, this differences were only significant for NMU 
expression in the superior temporal lobe of AD patients which suggest the existence of a 
region-dependent regulation of NMU expression in the brain of AD patients compared 
with controls subjects. In accordance with our data, the results obtained in early studies 
indicate no change (Biggins, 1983; Yates, 1985) or a tendency to decrease (Ferrier, 1983; 
Nemeroff, 1989; Benzing, 1990; Benzing, 1992) in the NTS-immunoreactivity in different 
cortical regions of AD patients. However, to our knowledge, no previous data have been 
reported concerning NMU expression in brains of AD patients.  
Since 90´s, it has been extensively demonstrated that NTSRs are widely distributed 
in mammalian brains (Quirion, 1992). Accordingly, we have detected significant mRNA 
levels of all three NTSRs in the brain of control subjects. However, the absolute mRNA 
copy number differed considerably, being NTSR2>>NTSR3>>>NTSR1. We found that 
NTSR1 and NTSR2 mRNA levels were abruptly reduced in the temporal lobe of AD 
patients compared with controls. These results are consistent with a report showing a 
57% reduction in the NTS- binding sites in the hippocampus of AD patients compared with 
controls by radioligand binding assays (Jansen, 1990). In contrast, we found that 
expression levels of NTSR3 were not significantly altered in AD samples which would also 
be consistent with previous observations showing that sortilin/NTSR3 
immunohistochemistry levels do not vary in basal forebrains of AD patients (Allen, 1990; 
Clewes, 2008). Nonetheless, our data showing an significant overall (50%) reduction in 
NTSR1 and NTSR2 in the temporal lobe of AD patients could be patho-physiologically 
relevant because:  1) the temporal lobe is the major cortical structure involved in episodic 
memory functions, 2) it has been demonstrated that NTS can act as a positive stimulus in 
learning and memory processes, and 3) it has been shown that NTSR2 is the major 
receptor involved in NTS-mediated memory actions (Yamauchi, 2007). Therefore, a 
reduction in NTSR in the temporal lobe of AD patients, including the most abundant 
NTSR2, could also help to explain the impairment in the cognitive function observed in 
this pathology.  
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In summary, the results presented in this work suggest a noteworthy 
dysregulation of ghrelin and NTS system in the temporal lobe of AD patients, not only 
originated by a reduction of ghrelin, In2-ghrelin variant, GOAT, GHSR1a, NTSR1 and 
NTSR2 mRNA levels but also by a strong increase in the GHSR1b mRNA expression. This 
data may be important for clinicians dealing with AD patients because we shown that 
some components of the ghrelin and NTS axis are finely regulated in the brain of AD 
patients compared with normal subjects and therefore, they could represent potential 
novel markers as diagnostic/prognostic for this pathology. In addition, since ghrelin and 
NTS have been demonstrated to directly influence memory and learning processes 
(Carlini, 2002; Carlini, 2004; Diano, 2006; Tirado-Santiago, 2006; Carlini, 2007; Ohinata, 
2007; Yamauchi, 2007; Carlini, 2008; Carvajal, 2009), the breakdown of the ghrelin and 
NTS systems reported herein in the temporal lobe of AD patients could help to explain, at 
least in part, the impairment of cognitive processes observed in AD. However, future 
studies should be addressed to evaluate the precise role of each component of these 
regulatory systems in this pathology and on their potential value as specific therapeutic 
target and diagnostic/prognostic markers in AD. 
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Table 1 
Case details of control subjects and AD patients 
Case (NBB number) Age Gender Tangles Senile plaques PM time (h) ApoE Genotype 
Controls       
S00/183 73 F 0 B 4:00 3/2 
S00/318 83 F 1 B 5:30 3/2 
S94/068 85 F 1 B 5:00  
S96/204 93 F 1 A 4:25  
S95/181 74 M 3 C 5:00 4/3 
S01/206 85 M 1 B 4:15 4/4 
AD patients       
S03/117 70 F 6 C 4:30 3/3 
S03/162 72 F 6 C 3:45 4/3 
S05/307 85 F 6 C 5:00 3/3 
S05/236 91 F 6 C 4:35 4/3 
S05/072 68 M 6 C 4:15 4/4 
S04/188 73 M 6 C 5:00 4/3 
Case (NBB number), age at death (years), gender (F: female; M: male), Braak Stages according 
to neurofibrillary pathology [0-6] and senile plaques [A-C] (Braak and Braak, 1991), post-
mortem time (in hours) and ApoE genotype of control and AD brains used in this study are 
shown. 
 
Table 2 
Primer sequences, product sizes and Genebank accession numbers 
Gene Sense Antisense 
Product 
lenght 
(bp) 
GeneBank         
Accession 
number 
Ghrelin TCAGGGGTTCAGTACCAGCA CAAGCGAAAAGCCAGATGAC 158 NM_016362.3 
In2-ghrelin TCTGGGCTTCAGTCTTCTCC GTTCATCCTCTGCCCCTTCT 215 XXX 
GOAT TTGCTCTTTTTCCCTGCTCTC ACTGCCACGTTTAGGCATTCT 161 NM_001100916 
GHSR1a TGAAAATGCTGGCTGTAGTGG AGGACAAAGGACACGAGGTTG 168 NM_198407 
GHSR1b GGACCAGAACCACAAGCAAA AGAGAGAAGGGAGAAGGCACA 107 NM_004122 
NTS GGCTTTTCAACACTGGGAGTTA AGGGTCTTCTGGGTTTATTCTCA 140 NM_006183 
NMU CACAGAAGTTGGGCAAGTCAA CATTCCGTGGCCTGAATAAAA 168 NM_006681 
NTSR1 AGCAGTGGACTCCGTTCCTC AAGTTGGCAGAGACGAGGTTG 118 NM_002531 
NTSR2 CCAGGTGAATGTGCTGGTGT TCCATACGATGAAGCTGAGGAG 185 NM_012344 
NTSR3 GCCAAATGGGGATCAGACA CAGCCATCACAGAGGCAAAA 184 NM_002959 
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Table 3 
Absolute cDNA copy number/100ng of total RNA of each transcript in AD and controls 
patients as determined by quantitative real-time PCR 
 
Control mean (n=6) AD mean (n=6) 
Percentage of 
change 
p-value 
Ghrelin 153.564 ± 22.961 78.650 ± 7.751 -48,8 p=0.027 
In2-ghrelin 61.768 ± 12.853 35.912 ± 5.573 -41,9 p=0.101 
GOAT 128.506 ± 18.749 124.705 ± 32.045 -3,0 p=0.392 
GHSR1a 10.725 ± 1.812 4.920 ± 462 -54,1 p=0.029 
GHSR1b 6.641 ± 903 27.951 ± 1.492 320,9 p≤0.001 
NTS 66 ± 9 54 ± 6 -17,6 p=0.730 
NMU 64 ± 18 59 ± 14 -7,3 p=0.375 
NTSR1 1.838 ± 229 321 ±87 -82,5 p=0.002 
NTSR2 266.514 ± 41.775 109.158 ± 31.643 -59,0 p=0.019 
NTSR3 77.768 ± 14.326 66.055 ± 11.223 -15,1 p=0.445 
Values represent mean ± SEM 
 
 
Figure legends 
Figure. 1. Absolute mRNA copy number of ghrelin (A), In2-ghrelin variant (B), GOAT (C), 
GHSR1a (D), GHSR1b (E), and GHSR1a/GHSR1b ratio (F) measured by quantitative real 
time PCR in brain temporal lobe of normal (black columns or dots; control) and Alzheimer 
disease (AD) (gray columns or dots) subjects. Values indicate mean mRNA copy number ± 
SEM of each transcript (adjusted by cyclophilin mRNA copy number) in the whole 
temporal lobe or in specific regions (inferior, medial and superior) of the temporal lobe. 
Asterisks (*p≤0.05; **, p≤0.01; ***, p≤0.001) indicate values that differ from controls.  
Figure. 2. Absolute mRNA copy number of NTS (A), NMU (B), NTSR1 (C), NTSR2 (D), and 
NTSR3 (E) measured by quantitative real time PCR in brain temporal lobe of normal 
(black columns; control) and Alzheimer disease (AD) (gray columns) subjects. Values 
indicate mean mRNA copy number ± SEM of each transcript (adjusted by cyclophilin 
mRNA copy number) in the whole temporal lobe or in specific regions (inferior, medial 
and superior) of the temporal lobe. Asterisks (*, p≤0.05; **, p≤0.01) indicate values that 
differ from controls. 
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